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Abstract 
Familial Amyloidotic Polyneuropathy (FAP) is a neurodegenerative disorder, characterized 
by the extracellular deposition of transthyretin (TTR) aggregates and amyloid fibrils, 
particularly at the peripheral and autonomic nervous systems (PNS and ANS, 
respectively). TTR is a homotetrameric protein synthesized mainly by the liver, choroid 
plexuses of the brain and retinal epithelium, acting as a physiological carrier of thyroxine 
and retinol. Over 100 single point mutations have been identified in the TTR gene being 
the most common associated with FAP the substitution of a methionine for a valine at 
position 30 of the polypeptide chain (V30M). The molecular mechanisms related to 
neurodegeneration in FAP are still poorly understood; however, evidence suggests that 
non-fibrillar aggregates are the major neurotoxic culprits in the pathological process. Thus, 
signs of endoplasmic reticulum (ER) stress, extracellular matrix (ECM) remodeling, heat 
shock response, inflammation and oxidative stress are present since the earlier stages of 
disease. Synthesis of interleukin-1β (IL-1β) by axons of the peripheral nerve from FAP 
patients has been associated with nerve fiber degeneration, which consequently creates a 
feed-forward mechanism aggravating the disease phenotype. Thus, a balanced cytokine 
environment is fundamental, as uncontrolled pro-inflammatory responses culminate in 
tissue damage and cell death. 
In this work, we studied the role of ECM remodeling and inflammation in the progress of 
FAP to open new avenues for novel therapeutic approaches. We demonstrated in vivo 
that upregulation of heparan sulfate proteoglycans promote TTR polymerization. Given 
the relationship between inflammation and ECM remodeling, we next investigated whether 
a pro-inflammatory stimulus might influence TTR deposition. Using a nerve injury model 
we found for the first time that neuroinflammation triggers TTR expression and non-fibrillar 
deposition in the peripheral nerve and that FAP mice are impaired in their ability to recruit 
innate immune cells and regenerate after damage. These findings prompt us to test in 
vivo the effect of the anti-inflammatory drug Anakinra on pathology progression. Our 
results revealed that Anakinra efficiently impairs TTR non-fibrillar deposition in the sciatic 
nerve, inhibits production of intermediate molecules of the IL-1 signaling pathway and 
lowers the levels of apoptotic, oxidative and ER stress associated biomarkers. Moreover, 
by treating FAP transgenic mice with Anakinra, 48 hours before sciatic nerve ligation, we 
were able to prevent nerve TTR non-fibrillar deposition and expression, rescuing the 
observed phenotype. In addition, activation of apoptotic cascades was diminished and 
accompanied by an improved regenerative response.  
The multi-target properties of Anakinra together with its low toxicity in humans, prompt us 
to propose anti-inflammatory therapy in the treatment of TTR-related amyloidosis. Future 
Abstract 
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therapies for FAP will probably encompass for a combinatorial approach targeting multiple 
pathways of the disease. 
Previous studies demonstrate soluble non-mutated TTR internalization by a variety of cell 
types, for instance through the megalin receptor. Here we evaluate internalization of TTR 
by glial cells of the PNS and ANS. We found that TTR was internalized in vivo by 
Schwann cells and satellite cells of both nervous systems, through an endocytic process. 
Partially colocalization between TTR and early endosome antigen 1 (EEA1) or lysosome-
associated membrane glycoprotein 1 (Lamp-1) suggests TTR translocation along the 
endosomal compartment to lysosomes for degradation. Additional studies will be 
imperative to uncover the underlying molecular mechanisms.  
Taken together, this work contributed to disclose new disease platforms important for 
modulation of TTR amyloidosis, which might be key targets for future therapy.  
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Resumo 
A Polineuropatia Amiloidótica Familiar (PAF) é uma doença neurodegenerativa 
caracterizada pela deposição extracelular de agregados de transtirretina (TTR) e fibras de 
amilóide, especialmente nos sistemas nervoso periférico e autonómico (SNP e SNA, 
respetivamente). A TTR é uma proteína homotetramérica produzida sobretudo pelo 
fígado, pelo plexo coróide no cérebro e pelo epitélio da retina, cuja principal função é o 
transporte de tiroxina e retinol. Mais de 100 mutações no gene da TTR foram já 
identificadas sendo a mutação principal associada à PAF a substituição de uma 
metionina por uma valina na posição 30 da cadeia polipeptídica (V30M). Os mecanismos 
moleculares relacionados com a neurodegenerescência na PAF são pouco conhecidos, 
no entanto há evidência de que os agregados não-fibrilares de TTR serão as espécies 
mais tóxicas para o desenrolar desta patologia. Deste modo, stress do retículo 
endoplasmático (RE), remodelação da matriz extracelular (ME), resposta associada a 
choque térmico, inflamação e stress oxidativo estão presentes desde o estadio inicial da 
doença. A síntese de interleucina-1β (IL-1β) pelos axónios dos nervos periféricos de 
doentes PAF tem sido associada com a degenerescência das fibras nervosas, 
consequentemente criando um mecanismo de feedback positivo, agravando o fenótipo da 
doença. Assim sendo, um perfil de produção de citocinas equilibrado é fundamental, uma 
vez que respostas pro-inflamatórias descontroladas culminam em dano tecidular e morte 
celular.  
Neste trabalho, propusemo-nos a estudar o papel da remodelação da ME e da 
inflamação na progressão e desenvolvimento da PAF de forma a abrir novos caminhos 
na procura de estratégias terapêuticas. Demonstramos in vivo que um aumento de 
proteoglicanos de heparano sulfato contribuí para a polimerização da TTR. Dada a 
relação entre remodelação da ME e inflamação, de seguida fomos investigar de que 
forma é que um estímulo inflamatório pode influenciar a deposição de TTR. Através de 
um modelo de lesão de nervo periférico observamos in vivo que a inflamação pode de 
facto levar à deposição não-fibrilar de TTR e aumentar a sua síntese local no nervo. Mais 
ainda, os murganhos transgénicos para a PAF recrutam menos células do sistema imune 
inato e têm uma regeneração nervosa também comprometida. Estes dados levaram-nos 
a testar o efeito in vivo de uma terapia anti-inflamatória com Anacinra na patologia da 
PAF. Os nossos resultados revelaram que o tratamento com Anacinra inibiu com 
eficiência a deposição não-fibrilar de TTR no nervo ciático, reduziu a síntese de 
moléculas da via de sinalização da IL-1 e diminuiu os níveis de biomarcadores 
relacionados com a apoptose e stress oxidativo ou do RE. Mais ainda, o tratamento de 
animais transgénicos para a PAF com Anacinra, 48 horas antes de realizar a ligação do 
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nervo ciático, preveniu a deposição não-fibrilar e a expressão local de TTR, permitindo 
reverter o fenótipo observado em resposta a um estímulo inflamatório. Além disso, com 
este tratamento foi prevenida a ativação de cascatas apoptóticas, acompanhada por uma 
melhoria na resposta regenerativa do nervo. 
As propriedades multifatoriais do Anacinra juntamente com a baixa toxicidade em 
humanos levam-nos a propôr esta terapia anti-inflamatória para o tratamento de 
amiloidoses de TTR. Terapias futuras para a PAF vão sem dúvida passar por uma 
abordagem combinatória, tendo como alvo múltiplas vias da doença. 
Estudos anteriores demonstram que a TTR nativa é internalizada por diversos tipos de 
células, por exemplo através do recetor da megalina. Com este trabalho nós avaliamos a 
internalização de TTR pelas células da glia dos SNP e SNA. Vimos que a TTR é 
internalizada pelas células de Schwann e pelas células satélite de ambos os sistemas 
nervosos, por um processo endocítico. A colocalização parcial entre a TTR e um 
marcador de endossomas precoces (EEA1) ou com uma glicoproteína da membrana dos 
lisossomas (Lamp-1) sugere translocação de alguma TTR ao longo do compartimento 
endosomal para degradação nos lisossomas. Estudos adicionais serão essenciais de 
forma a esclarecer os mecanismos que operam por detrás destas observações. Em 
conclusão, este trabalho contribuiu para a descoberta de novos fatores importantes para 
a modulação das amiloidoses de TTR, que podem ser alvos principais para futuras 
terapias. 
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General Introduction 
Transthyretin 
In 1942 a protein travelling faster than albumin on an electrical field was named 
prealbumin. It circulates as a tetramer composed of identical 127 amino acid monomers in 
cerebrospinal fluid (CSF) (Kabat et al., 1942) and plasma (Seibert and Nelson, 1942). 
Knowledge regarding physiological roles of this protein in the transport of thyroxine (T4) 
and retinol (Raz and Goodman, 1969), lead to a change of its name to transthyretin (TTR) 
in 1981 by the International Union of Biochemists.  
In a phylogenetic context, TTR is a highly conserved protein found in several vertebrate 
species. More recently, TTR-like proteins have been found in prokaryotes, nematodes and 
plants, eventually without the ability to bind T4 or similar ligands (Hennebry et al., 2006). 
Mutations in the human TTR gene are associated with amyloidoses, a group of disorders 
characterized by the extracellular accumulation of amyloid deposits (Westermark, 1998), 
clinically termed Familial Amyloidotic Polyneuropathy (FAP) or Cardiomiopathy (FAC) 
when point mutations result in protein deposition in the peripheral and autonomic nervous 
systems (PNS and ANS) or heart, respectively. 
 
 
Transthyretin gene structure and dynamics 
The single gene encoding TTR is found on chromosome 18, more precisely in the 
18q11.2-q12.1 region (Whitehead et al., 1984), spans about 7 kilobases and has four 
exons and three introns (Sasaki et al., 1985; Tsuzuki et al., 1985). The first exon, with 95 
base pairs (bp) long, encodes a leader peptide of 20 amino acids and the first three amino 
acid residues of the mature protein, while exons 2 (131 bp), 3 (136 bp) and 4 (253 bp) 
hold the coding sequences for residues 4-47, 48-92 and 93-127 of the mature protein, 
respectively. Introns 1 and 3 have two independent open reading frames (Tsuzuki et al., 
1985) with unclear functions since these are not transcribed to be expressed as 
independent polypeptides in vivo neither as part of functional transcripts (Soares et al., 
2003). In the 5'-flanking region, a TATA box, a CAAT box and two overlapping sequences 
homologous to glucocorticoid responsive elements were identified. Additionally, in the 3'-
untranslated region, downstream from the coding sequence, a polyadenylation signal 
(AATAAA) is present (Sasaki et al., 1985). 
The TTR gene is highly conserved through evolution; mouse and rat Ttr genes share 82% 
and 90% homology, respectively, with the human TTR sequence (Costa et al., 1986). A 
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proximal promoter and a distal enhancer are the two major regulatory domains present in 
the 5’ flanking region of the TTR gene. The TTR promoter is bound by nuclear 
transcription enhancing factors, namely hepatocyte nuclear factors 1, 3, 4 and 6, 
CCAAT/enhancer binding proteins (c/EBP) and the the activator protein 1 (AP-1) (Costa et 
al., 1990). 
TTR is mainly synthesized by liver hepatocytes and the choroid plexuses of the brain, 
secreting the protein into plasma and CSF, respectively (Soprano et al., 1985; Dickson et 
al., 1986). Moreover, in vivo studies noticed that synthesis and secretion of TTR are 
regulated independently in the liver and choroid plexus (Dickson et al., 1986) suggesting 
the presence of different regulation factors between tissues. The choroid plexus consists 
of modified ependymal cells that secrete 10 times more TTR mRNA than the liver, when 
expressed as tissue/weight, representing TTR 20% of the total ventricular proteins in the 
CSF (concentration levels range from 5 to 20 μg/mL) (Vatassery et al., 1991). More than 
90% of plasma circulating TTR arises from liver production. Plasma TTR levels are age 
dependent since they increase gradually after birth until reach the adult concentration of 
200-400 μg/mL (Goldsmith and Munson, 1987), beginning to decline at age 50. 
Importantly, TTR plasma levels have been useful for the control of nutritional and 
inflammatory status in several conditions (Dickson et al., 1982; Potter and Luxton, 1999). 
Low amounts of the TTR gene have been also detected in stomach, namely in gastric 
ghrelin cells (Walker et al., 2013), heart, skeletal muscle, spleen (Soprano et al., 1985), 
human placenta (McKinnon et al., 2005), pancreas, retinal pigment epithelium in the eye 
(Westermark and Westermark, 2008) and Schwann cells of the peripheral nerve 
(Murakami et al., 2010). Recently, TTR expression in hippocampal and cortical neuron 
cultures has also been suggested (Li et al., 2011). This system highlights a prominent 
example for the differential regulation of TTR in different cell types, since the heat shock 
factor 1 (Hsf-1) was found as a regulator for TTR transcription in primary hippocampal 
neurons but not in hepatocytes (Wang et al., 2014). 
TTR is expressed during embryonic development and throughout life; nevertheless it does 
not seem to be essential since TTR knockout (KO) mice shows normal fetal development, 
fertility and life span (Episkopou et al., 1993).  
TTR has a fast turnover rate with a biological half-life of approximately 2 days in humans 
(Socolow et al., 1965) and 29 h in Buffalo rats (Dickson et al., 1982). The mechanism for 
TTR cellular uptake is not fully understood, however liver and kidney are thought to be the 
two major active organs for TTR degradation, with 15% of TTR being excreted in urine 
(Makover et al., 1988). Additionally, some studies revealed that TTR internalization by the 
liver and kidney is receptor-mediated. One endocytic receptor has been described based 
on cell culture studies, which is megalin, a multi-ligand binding receptor found in the 
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plasma membrane of many epithelial cells, mediating TTR internalization by the kidney 
and dorsal root ganglia (DRG) (Sousa et al., 2000a; Fleming et al., 2009). A yet 
unidentified receptor member of low-density lipoprotein (LDL) family sensitive to receptor-
associated protein (RAP) seems to be involved in TTR uptake by the liver (Sousa and 
Saraiva, 2001). Additionally, TTR interacts with the receptor for advanced glycation end 
products (RAGE) with a Kd of 120 nM (Sousa et al., 2000b; Monteiro et al., 2006a). 
 
 
Transthyretin structure 
The TTR cDNA codes for a mature polypeptide chain of 127 amino acids being the protein 
secreted in the form of a tetramer, with 55 KDa, of identical subunits (Blake et al., 1974). 
Each monomer is composed of 8 β-sheet strands (denoted A-H), organized into 4-
stranded β-sheets (DAGH and CBEF), and a short α-helix, located between E and F. 
Strands F and H of each monomer can join edge-to-edge to form a dimer through 
hydrogen bonding (Blake et al., 1978) (Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1 – Ribbon diagram of the wild-type TTR dimer. A TTR dimer is originated when two 
TTR monomers join side-by-side. Adapted from Protein Data Bank 1ETB. 
 
The association of two dimers, through hydrophobic contacts, form the native TTR 
tetrameric structure (Figure 2). The dimer-dimer contact is mediated by only eight 
backbone hydrogen bonds and these associations are substantially weaker than those 
between the two monomers in a dimer. Non-covalent assembly of the tetramer creates a 
50 Å long central hydrophobic channel comprising two symmetrical binding sites for 
thyroxine with distinct binding constants. As these binding sites exhibit negative 
cooperativity, due to an allosteric communication between them, only one molecule of T4 
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bounds to TTR tetramer (Irace and Edelhoch, 1978). The position of T4 in the spacious 
channel is defined by charged amino acids Lys15 and Glu54. Another TTR ligand – retinol 
binding protein (RBP) has four binding sites located at the surface of the TTR molecule 
(Monaco et al., 1995).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 – Diagram denoting TTR quaternary structure. Front view along the bivalent T4 binding 
channel (A) and side view perpendicular to the binding channel (B). The four identical monomers 
are represented in different colors. The concave shaped β-sheet saddle constitutes the dimer-
dimer interface, leaving a central channel (adapted from Haupt et al., 2014). 
 
 
From a structural point of view, TTR is a very stable protein; however the existence of 
genetic point mutations may alter the structural stability of the molecule. For instance, the 
substitution of a methionine for a valine at position 30 of the polypeptide chain (V30M) 
results in distortion of the T4 binding cavity leading to a lower binding affinity and TTR 
destabilization (Hamilton et al., 1993). 
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Transthyretin physiological functions 
TTR homotetramer acts as a transport protein for about 15% of circulating plasma 
thyroxine and almost all retinol (vitamin A, 95%), through the formation of a complex with 
RBP (Kanai et al., 1968). However, during the last years, several other functions have 
been associated with this molecule.  
 
Transthyretin as a transporter protein 
Thyroid hormones are primarily responsible for regulation of metabolism and for normal 
mammalian development. The major form of thyroid hormone in the blood is thyroxine 
(T4), which has a longer half-life than triiodothyronine (T3), the active hormone derived 
from T4 deiodination (Palha, 2002). Thyroxine is a tyrosine-based hormone synthesized by 
the follicular cells of the thyroid gland and its production is regulated by the thyroid 
stimulating hormone released from the pituitary gland. In humans, most of the T4 
circulating in the bloodstream is transported by thyroxine binding globulin, 20% is 
transported by albumin and 15% bounds TTR (Bartalena, 1990). In contrast, TTR is the 
major T4 carrier in plasma rodents and in the CSF of both rodents and humans (Bartalena 
and Robbins, 1993). Thus, the stoichiometry of T4 binding to TTR is higher in the CSF as 
compared to that in serum (Palha, 2002). However, the role of TTR in the physiology of 
thyroid hormones is not yet fully understood. Studies with TTR KO mice suggested that 
TTR is not required for normal T4 metabolism since regardless of a two-fold decrease in 
total circulating T4 levels, these animals were still euthyroid without major phenotypic 
abnormalities or altered thyroid gland morphology (Episkopou et al., 1993; Palha et al., 
1994). In addition, Palha and colleagues (Palha et al., 1997) showed that T4 levels in CSF 
of TTR null mice were 30% decreased, but with no differences in brain T4 content. 
Moreover, it was previously described that T4 distribution from the CSF into the brain was 
TTR-dependent and mediated by receptor endocytosis (Kassem et al., 2006). In addition, 
an important role for TTR on T4 transport across the placenta was recently described 
(Landers et al., 2009). All together these results point towards a preferential relevance for 
the TTR-T4 interaction in the brain; however, further studies need to be performed to 
elucidate TTR role in thyroid hormone homeostasis. 
TTR is also involved in the transport of retinol (vitamin A), an essential molecule for 
several biological functions, namely embryonic development, growth, cellular 
differentiation, reproduction and vision (Gudas, 2012). RBP is formed in the endoplasmic 
reticulum (ER) of hepatocytes and associates with TTR, before being secreted to the 
bloodstream (Kanai et al., 1968). The formation of the complex TTR-RBP-retinol, usually 
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in a 1:1:1 stoichiometry, prevents loss of RBP through the renal glomeruli (Kanai et al., 
1968; Monaco et al., 1995). Retinol-RBP complex binds on the exterior of TTR tetramer 
utilizing four symmetric-related RBP binding sites; however steric hindrance prevents the 
binding of more than two RBP molecules. Nevertheless, due to the limiting RBP 
concentration in plasma, only one RBP molecule is transported by TTR under 
physiological conditions (Monaco et al., 1995). Consequently, RBP binding to TTR leads 
to a 70% decrease in its internalization, suggesting that the TTR tetramer is taken up 
without RBP (Sousa and Saraiva, 2001). 
Despite presenting significant lower plasma levels of retinol and RBP, due to increased 
renal filtration, TTR null mice show normal retinol concentration in tissues and no signs of 
vitamin A deficiency (van Bennekum et al., 2001). These findings suggest that TTR 
probably acts as a retinol reservoir, preventing its loss via kidneys. Kawaguchi and 
coworkers reported a specific receptor for cellular uptake of RBP-retinol, the 
transmembrane protein “stimulated by retinoic acid 6” (STRA6) that is mostly expressed in 
brain, eye, kidney, spleen and reproductive tract (Kawaguchi et al., 2007). Circulating 
retinol may be recycled by liver multiple times before degradation. Recently, a novel RBP 
transporter regulating retinol homeostasis in liver, intestine and adipose tissue was 
identified, the RBP receptor-2 (Alapatt et al., 2013). 
It has been shown that other molecules can interact with TTR such as noradrenaline 
oxidation products, retinoic acid, pterin, perlecan, lysosomal-associated membrane 
protein 1 (Lamp-1) and metallothionein 2 (Liz et al., 2010). However, little is known about 
the functions assigned by these interactions. Additionally, several compounds sharing 
molecular structural similarities with T4 can bind TTR in the T4 channel; among them are 
non-steroid anti-inflammatory drugs like flufenamic acid or diflunisal, natural isoflavones 
(genistein) and polyphenols (resveratrol and curcumin) (Almeida et al., 2004; Sekijima et 
al., 2008). Recently, in vitro studies highlight the binding of epigallocatechin gallate 
(EGCG) to the surface of the TTR tetramer, which were further corroborated with the 
complex crystal structure (Ferreira et al., 2009; Miyata et al., 2010). Discovery and 
characterization of the interaction between these small molecules and TTR is of major 
importance due to their effect on TTR stabilization with possible therapeutic actions for 
TTR amyloidosis.  
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Transthyretin as a novel protease 
A small fraction of plasma TTR is associated with high density lipoproteins (HDL) through 
binding to apolipoprotein A-I (apoA-I) (Sousa et al., 2000c). Further investigation revealed 
the proteolytic activity of TTR. Thus, in vitro studies showed that TTR is a non-canonical 
serine protease able to cleave apoA-I in its C-terminus (Liz et al., 2004). This phenomena 
lead to a reduced ability of apoA-I in cholesterol efflux, which can increase development of 
atherosclerosis (Liz et al., 2007). Yet, the in vivo role of TTR in HDL biology requires 
further evaluation. Although the catalytic machinery of TTR remains unclear it was 
recently described that a small fraction of TTR is active as a metallopeptidase since metal 
chelators abolished its activity (Liz et al., 2012).  
It was reported that neuropeptide Y (NPY), acting as a neurotransmitter in the brain and in 
the ANS, can be also cleaved in vitro by TTR thus promoting neurite outgrowth (Liz et al., 
2009). 
Evidence suggests a protective role of TTR in Alzheimer’s disease. Costa and colleagues 
showed that TTR cleaves amyloid β (Aβ) originating smaller and less amyloidogenic 
peptides than the full length counterpart. Furthermore, TTR species suppress Aβ 
aggregation in vitro suggesting Aβ proteolysis by TTR (Costa et al., 2008a; Costa et al., 
2008b; Li et al., 2013). 
 
Transthyretin in the nervous system 
Recent studies have been implicating TTR as an important molecule in the nervous 
system physiology. To clearly understand the role of this protein in neurobiology, 
characterization of TTR null mice is being fundamental.  
Concerning the central nervous system (CNS), it was shown that TTR KO animals 
presented lower signs of depressive-like behavior and increased exploratory activity, 
suggesting a link between TTR and behavior (Sousa et al., 2004). Later, these 
observations were ascribed to the increased levels of norepinephrine in the limbic 
forebrain and NPY, which among others holds anti-depressant properties (Nunes et al., 
2006). Further supporting a role for TTR in cognition, it was shown that TTR null mice 
presented memory impairment (Buxbaum et al., 2008). Moreover, recent data, using RBP 
KO animals, revealed that the phenotype of TTR KO mice is not related to TTR function 
as an RBP carrier since both strains display memory and motor deficits, cortical and 
hippocampal neuronal loss, some degree of gliosis and reduction in proliferating 
neuroblasts in the subventricular zone (Buxbaum et al., 2014). 
Evidence supports a role for TTR in neuroprotection after cerebral ischemia. Using a 
model of permanent middle cerebral artery occlusion in TTR KO mice, deficient for the 
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heat shock response, Santos and colleagues found increased infarct area, cerebral 
edema and increased microglial response in these animals as compared with the wild-
type (WT) situation (Santos et al., 2010a). Still, the mechanisms behind these 
observations require further investigation. 
TTR has been suggested to play a key role in the modulation of Aβ aggregation, a major 
feature of Alzheimer’s disease. It was shown that TTR binds to Aβ preventing amyloid 
fibril formation and cellular toxicity (Schwarzman et al., 1994). Moreover, several studies 
reported decreased levels of TTR in CSF (Serot et al., 1997) and plasma (Han et al., 
2011; Ribeiro et al., 2012) in patients with Alzheimer’s disease, turning TTR to a potential 
biomarker in the neurochemical differential diagnosis of this disorder. In addition, a 
neuroprotective role for TTR in Alzheimer’s disease has been suggested by inhibition of 
Aβ fibril formation and consequent protection of neurons from oligomer-induced toxicity 
and amelioration of cognitive functions (Ribeiro et al., 2012; Cascella et al., 2013; Li et al., 
2013; Ribeiro et al., 2014). However, this phenomenon needs further investigation. 
Differential TTR levels have also being found in diverse neurological conditions. For 
instance TTR has been proposed as an early biomarker for frontotemporal dementia, 
Guillain-Barré syndrome and Parkinson’s disease since its levels are upregulated in 
plasma or CSF from patients (Vieira and Saraiva, 2014). 
Very recently, a role for TTR in 14-3-3ζ metabolism was suggested as the hippocampus of 
TTR KO mice presented lower levels of this protein due to increased lysosomal 
degradation (Vieira et al., 2013). In addition, in vitro and in vivo studies suggest that TTR 
regulates insulin-like growth factor receptor I at the transcriptional and translational levels, 
triggering receptor nuclear translocation (Vieira et al., 2014). Taken together, these results 
unravel a new function for naïve TTR in neuroprotection.  
Regarding TTR roles in the PNS, Fleming and coworkers, showed that mouse TTR WT 
plays an important role in nerve regeneration, since TTR KO animals presented slower 
nerve conduction velocity, impaired sensorimotor recovery and lower fiber density after 
nerve crush (Fleming et al., 2007). A few years later, the underlying mechanism behind 
TTR neuritogenic activity was proven to be its internalization by a megalin mediated 
clathrin-dependent pathway in sensory neurons (Fleming et al., 2009). Very recently, 
studies with Caenorhabditis elegans show that a TTR-like protein (TTR-52) is critical for 
successful axonal regenerative fusion (Neumann et al., 2015), further reinforcing the 
importance of this protein for proper axonal growth. 
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Other functions of transthyretin 
TTR tetramer has been considered a functional protein in pancreatic β-cells, promoting 
insulin release and protecting against β-cell apoptosis (Refai et al., 2005). In addition, it 
was demonstrated that TTR may bind glucose-regulated proteins at the plasma 
membrane being thus internalized into the β-cell via a clathrin-dependent pathway (Dekki 
et al., 2012). Furthermore, TTR KO mice evidenced impaired recovery of blood glucose 
and lower levels of glucagon in the islets of Langerhans, suggesting that TTR expressed 
in pancreatic α-cells might play an important role in glucose homeostasis (Su et al., 2012). 
 
 
Transthyretin molecular variants 
More than 100 TTR mutations have been identified, resulting from point substitutions in 
the polypeptide chain. The only exception is the mutation V122 consequent to one amino 
acid deletion at position 122. From all TTR mutations (an updated list can be found at 
http://amyloidosismutations.com/mut-attr.php), 98 are associated with amyloidoses 
(Benson and Kincaid, 2007). Amyloidoses are rare diseases caused by extracellular 
deposition of insoluble misfolded proteins, disrupting normal tissue function (Westermark, 
1998). TTR-related amyloidosis are phenotypic heterogeneous and although the major 
clinical feature is sensorimotor polyneuropathy, cardiomyopathy, carpal tunnel syndrome, 
vitreopathy or leptomeningeal involvement occur as well. Most affected individuals are 
heterozygous for the pathological mutation, expressing both WT and mutant TTR (Benson 
and Kincaid, 2007). The most common TTR mutation associated with peripheral 
neuropathy is V30M (Saraiva et al., 1984). This TTR variant is present worldwide with 
major endemic areas in northern Portugal, northern Sweden and Japan (Andrade, 1952; 
Saraiva et al., 1984; Benson and Kincaid, 2007). The penetrance rate of V30M induced 
disease varies and sometimes cases of early-onset (≤ 35 years) and late-onset (≥ 50 
years) coexists in the same family. Indeed, younger generations are usually associated 
with more severe phenotypes and disease anticipation (Lemos et al., 2014), correlating 
with differences in clinical findings (Koike et al., 2004). The most amyloidogenic variant 
often leading to an early-onset with both cardiac and neurologic involvement is the 
replacement of a leucine by a proline at position 55 (L55P) (Jacobson et al., 1992). 
Several heterozygous individuals, carriers of two different TTR mutations, usually in 
different alleles, have been reported. For instance, patients with T119M or the R104H 
non-pathogenic variants, in addition to the V30M mutation, present milder phenotypes and 
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slower disease progression, due to increased stabilization of the protein tetrameric 
structure (Longo Alves et al., 1997).  
The most prevalent mutation in the United States is V122I affecting 3-4% of African 
Americans and leading to a late-onset restrictive cardiomyopathy (Jacobson et al., 1996).  
TTR WT protein has a tendency to aggregate with ageing, depositing primarily in the 
heart, but also in the gut and carpal tunnel, condition denominated senile systemic 
amyloidosis (SSA). It is thus not associated with any TTR variant but affects 10-25% of 
the elderly population over 80 years of age (Pitkänen et al., 1984; Westermark, 2005). 
Furthermore, 9% of TTR mutations give rise to leptomeningeal amyloidosis, including 
those derived from the TTR mutation L12P, considered as one of the most aggressive 
variants (Brett et al., 1999). 
The study of TTR variants is of major importance for deeply characterization of TTR-
related amyloidosis and to provide novel insights regarding therapeutic strategies.  
 
 
Familial Amyloidotic Polyneuropathy  
Familial Amyloidotic Polyneuropathy (FAP) was first described by Corino de Andrade 
in northern Portugal in 1952 (Andrade, 1952). Over the next two decades, Japan and 
Sweden were found as other large foci (Araki et al., 1968; Andersson, 1976). This 
type of hereditary amyloidosis was characterized histologically by generalized atypical 
amyloid, affecting particularly the peripheral nerves. Amyloid is a heterogeneous 
material with distinctive β-sheet fibrils identified by green birefringence under 
polarized light, after staining with alkaline alcoholic Congo red (Puchtler and Sweat, 
1965). TTR was identified as the precursor of amyloid in this setting (Costa et al., 
1978) and later the most common mutation, V30M, was recognized (Saraiva et al., 
1984), becoming a biochemical marker for FAP (Saraiva et al., 1985). Deep 
ultrastructural characterization of amyloid deposits show that fibrils are typically 
straight nonbranching filaments, with several lenghs and with approximately 10 nm 
diameter (Coimbra and Andrade, 1971a; Inoue et al., 1998). 
Until 20 years ago, FAP was believed to be a disease restricted to endemic areas; 
however, with progress in technology, nowadays it is known that this disorder, despite 
being rare, is distributed worldwide with cases diagnosed in Spain, France, Italy, 
Greece, United States of America and Brasil (Ando et al., 2005). In Portugal the 
prevalence of FAP is estimated to be 1 in 538 individuals while in Europe the 
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incidence of this genetic disorder is estimated to be less than 1 in 100,000 individuals 
(Ando et al., 2013). 
 
Pathological features of Familial Amyloidotic Polyneuropathy 
FAP is an autosomal dominant neurodegenerative disorder characterized by the 
deposition of TTR aggregates and amyloid fibrils in the connective tissue of several 
organs, with exception of the CNS and liver parenchyma, affecting particularly the PNS 
(Coimbra and Andrade, 1971 a, b). The onset of clinical symptoms generally occurs 
between the third and fourth decade of life but with great variations across different 
populations (Ando et al., 2013). Patients with early-onset presentation deteriorate quickly 
while in carriers with the late-onset, the polyneuropathy progresses slowly with different 
pathological presentations (Koike et al., 2004; Planté-Bordeneuve and Said, 2011). This 
peculiar form of nerve length-dependent polyneuropathy is fatal in about 10 years on 
average, varying accordingly to endemic region, genotype and clinical symptoms (Ando et 
al., 2013). Symptoms start with sensory involvement in the lower limbs, particularly 
impaired thermal sensibility and neuropathic pain. The sensory deficit gradually 
progresses relentlessly to the upper limbs and motor deficit appears in the distal lower 
limbs with walking becoming increasingly difficult also caused by loss of balance, weight 
loss and muscle wasting. Due to the random distribution of TTR amyloid in the peripheral 
nerves, carpal tunnel syndrome might be an early non-specific manifestation of FAP. Life-
threatening autonomic dysfunction is generally present in FAP patients with early-onset 
since the first stage of disease including orthostatic hypotension, erectile dysfunction, 
postprandial diarrhea, constipation or both alternately, nausea, vomiting, dysuria and 
urinary retention. Cardiac involvement occurs in about 50-80% of FAP patients leading to 
amyloid restrictive cardiomyopathy with episodes of arrhythmias, syncope or even sudden 
death. Additional symptoms often found include vitreous opacity, dry eye, glaucoma, 
nephritic syndrome, renal failure and anemia due to low levels of erythropoietin (Sousa 
and Saraiva, 2003; Ando et al., 2005; Planté-Bordeneuve and Said, 2011; Ando et al., 
2013; Ando et al., 2014). Despite being a multi-symptom disease, CNS manifestations in 
FAP are rare, regardless of leptomeningeal amyloid deposition (Said and Planté-
Bordeneuve, 2009). 
At post-mortem examination, amyloid deposits are found in almost every tissue. In 
peripheral nerve specimens, TTR deposits as amyloid are characteristically found in the 
endoneurium in close contact with Schwann cells and collagen fibrils (Figure 3). With 
disease progress, axonal fiber degeneration begins in the unmyelinated and small 
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diameter myelinated fibers together with invasion and destruction of endoneurial blood 
vessels. In advanced cases, electroneurophysiological studies demonstrate loss of larger 
myelinated fibers with demyelination in points of contact with endoneurial clumps of 
amyloid. Very recently, novel neurophysiological markers of early TTR induced 
neuropathy were established and proposed as novel tests for FAP diagnosis (Conceição 
et al., 2014). 
 
 
 
 
 
 
 
 
 
 
Figure 3 – TTR amyloid deposits in the endoneurium highlighted by Congo red staining. 
Longitudinal section of a paraffin-embedded nerve biopsy specimen from a 30-year-old man 
carrying the V30M mutation. Scale bar 10 µm (from Planté-Bordeneuve and Said, 2011). 
 
Amyloid fibrils might occasionally invade the cytoplasm of degenerating Schwann cells 
due to disruption of the basal lamina (Coimbra and Andrade, 1971b; Thomas and King, 
1974), thus impairing nutritional support to several unmyelinated fibers and accounting for 
early unmyelinated axonal loss. Consequently, abundant groups of flat sheets of Schwann 
cells processes without axons (bands of Büngner) and Wallerian degeneration are often 
found in FAP nerve biopsies. In ganglia, amyloid deposition occurs in the stroma in close 
contact with satellite cells leading to neuron chromatolysis and progressive cell death 
(Sobue et al., 1990); therefore, these neuronal lesions might produce a distally 
symmetrical polyneuropathy characterized by the loss of small caliber fibers (Thomas and 
King, 1974). The deleterious effect of endoneurial amyloid deposits might also be due to a 
mechanical and toxic effect to the tissue. Moreover, in severely affected cases, vessel 
walls may be destructed or occluded by amyloid, leading to vascular permeability, 
interstitial edema and ischemia, thus contributing to the progressive polyneuropathy. 
Recently, Congo red positive material was detected in circulation, suggesting the 
presence of TTR aggregates in blood (Liu et al., 2014).  
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Mechanisms for transthyretin amyloidogenesis 
Although remarkable progress has been made regarding TTR amyloidogenesis, the 
precise molecular mechanisms underlying amyloid fibril formation are not completely 
understood. It is now accepted that several factors might be involved in the pathogenesis 
of TTR amyloidosis. First among them is the structure of the native precursor protein, as 
amino acid substitutions usually destabilize the primary protein, dictating the inheritance of 
the disease (Benson and Kincaid, 2007). Biophysical studies demonstrate that under acid 
conditions or increased temperature, WT and mutant TTR tetramers can dissociate into 
non-native monomers with low conformational stability, originating high molecular mass 
soluble aggregates that self-assemble leading to the formation of unsoluble fibrils in an 
infinitely propagating fashion (Figure 4) (Colon and Kelly, 1992; Lai et al., 1996; Quintas et 
al., 2001). Indeed, X-ray diffraction studies have suggested that TTR monomers or dimers 
are the intermediate moiety and the building blocks for the pathway of amyloid fibril 
formation (Blake and Serpell, 1996). In addition, stability of the TTR tetramer has been 
pointed out as the most important factor for amyloid fibril initiation. In fact, there is a 
correlation between the thermodynamic stability of TTR variants and their potential to form 
modified monomers and soluble aggregates. For instance, crystallographic studies have 
shown that the mutation V30M forces the two β-sheets of each monomer to become more 
apart, resulting in a distortion of the T4-binding pocket, associated with reduced affinity for 
T4 and lower protein stability (Hamilton et al., 1993).  
 
 
 
Figure 4 – Hypothetical model for TTR amyloid cascade. Tetramer dissociation into non-native 
monomers is the first and rate-limiting step for amyloid fibril formation. This unfolded monomer is 
prone to aggregation, leading to the formation of intermediate species such as 
oligomers/aggregates finally ending in insoluble amyloid fibrils (adapted from Azevedo et al., 2013). 
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The rate of amyloid formation and growth is dependent on TTR concentration, thus the 
quality control system of the cell, such as ER retention or protein degradation by the 
proteasome (ERAD), might be an important factor determining amyloidogenesis (Sekijima 
et al., 2005). The presence of an N-glycosylated circulating TTR secreted from FAP liver 
that is able to escape from ERAD, was recently described (Teixeira and Saraiva, 2013). 
However, its implication for the etiopathogenesis of the disease needs further clarification.  
Although the conformational hypothesis having oligomeric TTR as the nucleus of the 
polymerization is currently the most accepted theory, proteolytic cleavage may well be a 
determinant factor in FAP pathogenesis. This theory is supported by findings of the 
presence of C-terminal TTR fragments in amyloid deposits extracted from FAP patients, 
raising the hypothesis that proteolytic processing might prompt amyloid fibril formation 
(Bergström et al., 2005). Moreover, fibril type has been associated with the clinical and 
pathological phenotypes since patients with truncated TTR in the amyloid deposits 
present a late-onset form of disease and packed/short fibrils as compared with patients 
with early-onset disease, who did not exhibit TTR fragments in amyloid deposits (Ihse et 
al., 2008). Gaining more insight into this issue, recent data demonstrate that the main 
component of the ex vivo fibrils derived from the TTR variant S52P was the fragment 
corresponding to residues 49-127, thus supporting the important role of proteolytic 
cleavage for TTR amyloid fibrillogenesis (Mangione et al., 2014). However, the referred 
proteolytic fragments are not always detected in TTR fibrils (Tawara et al. 1983), therefore 
despite the release of small peptides might contribute to the initiation or progression of 
FAP pathology, the role of proteolysis in TTR amyloidogenesis seems to be not an 
essential mechanism behind amyloid formation, further needing deeply investigation.    
 
 
Composition of transthyretin amyloid deposits 
Amyloids from different disorders might share a common rich cross-β structure and similar 
pathways for fibril formation; however, they have different compositions. In TTR 
amyloidosis, all deposits contain a set of accessory molecules, regardless of the fibril 
precursor. Indeed, affinity between TTR and glycosaminoglycans (GAGs) was previously 
demonstrated, with evidence that GAGs may be involved in TTR deposition (Inoue et al., 
1998; Noborn et al., 2011; Bourgault et al., 2011). GAGs are a heterogeneous group of 
highly sulfated polysaccharides regulating several physiological processes, such as 
development or cell adhesion. The common sulfated GAGs are dermatan sulfate, 
chondroitin sulfate and heparan sulfate, which differ in the structure of the carbohydrate 
backbone and in sulfate groups. GAGs are usually found in the ECM attached to a core 
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protein, as proteoglycans (Häcker et al., 2005). Heparan sulfate proteoglycans might be 
present extracellularly or at cell surface and have been frequently associated with TTR 
amyloid deposits (Noborn et al., 2011). In fact, Noborn and colleagues showed that 
heparan sulfate or heparin are able to prompt TTR aggregation and fibrillogenesis both in 
vitro and in a transgenic Drosophila melanogaster model of amyloidosis. The mechanism 
behind this interaction was dependent on the size of heparin, extent of sulfation, pH, TTR 
concentration and conformation (Noborn et al., 2011). Additional in vitro studies 
demonstrate that larger GAGs are able to interact with multiple TTR aggregates at the 
same time and that they preferentially bind to pre-formed aggregate species, enhancing 
its self-assembly, changing TTR quaternary structure, thus increasing the formation of 
amyloid fibrils (Bourgault et al., 2011). These studies represent an important piece of the 
puzzle to better understand how GAGs accelerate the amyloidogenic process. For 
instance, endoneurium is rich in proteoglycans, which might contribute for the tissue 
selectivity of TTR deposition. Also, the sulfation degree of heparan sulfate increases with 
age, which may explain the deposition of naïve TTR in the elderly population, giving rise 
to SSA.  
Besides proteoglycans, amyloid fibrils also contain other ubiquitous components, like 
serum amyloid P component (SAP) and several basement membrane constituents, such 
as fibronectin, laminin or collagen type IV (Pepys, 2001; Misumi et al., 2009). SAP is a 
plasma glycoprotein and an important molecule favoring fibrillogenesis since it is 
estimated that 14% of the dry mass of amyloid deposits is formed by SAP. It is postulated 
that SAP is non-covalently linked to amyloid deposits, preventing proteolytic breakdown, 
thus retarding their clearance (Pepys, 2001). Hence, this molecule has been very useful 
for the clinical diagnosis of amyloidosis through scintigraphy analysis, where radio-labelled 
protein locate areas of amyloid deposition (Hawkins and Pepys, 1995). Recently, SAP 
protection against the cytotoxicity of amyloidogenic aggregates was also suggested 
(Andersson et al., 2013). 
Ultrastructural analysis of cardiomyocytes and vascular smooth muscle cells from FAP 
patients provide evidence that TTR amyloid fibrils formed first at the basement membrane 
with simultaneous increase in the biosynthesis of membrane components, like laminin, 
collagen type IV and fibronectin. These micro-environmental changes function as a 
scaffold for the amyloid fibril growth and this chain reaction could affect in vivo fibril 
turnover and dynamics, contributing for FAP pathogenesis (Misumi et al., 2009). 
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Animal models of human amyloidoses 
TTR amyloidoses are the prototypic protein folding disorders, with protein deposition 
occurring extracellularly, frequently taking place distant from the site of synthesis. The 
development of recombinant molecular techniques made possible to analyse folding and 
misfolding mechanisms, for instance by adding small molecules or peptides able to 
accelerate or inhibit fibril formation. Despite the first insights into protein aggregation 
provided by the in vitro studies or autopsy analyses, more precise notions of pathogenesis 
and protein roles are awaited. Thus, several animal models have been generated to allow 
disease modeling, deeply knowledge regarding pathophysiological mechanisms or 
development of new therapeutic strategies. 
Experimental models based on transgenic expression of normal or mutant forms of TTR in 
Drosophila melanogaster have been generated. TTR V30M flies presented reduced 
lifespan and neurological impairment, while flies with human TTR WT showed a mild 
phenotype, similar to that of SSA patients (Berg et al., 2009). In addition, a double mutant 
form overexpressing either the clinically relevant mutant TTR L55P, or the highly 
destabilized engineered mutant TTR-A was constructed (Pokrzywa et al., 2007), denoting 
intracellular aggregates and amyloid filaments in fat body cells (Pokrzywa et al., 2010). 
The introduction of amyloid precursors in flies compresses the time necessary to obtain a 
disease phenotype; however, the comparison of a highly mitotic model to mammals might 
be problematic as cellular and molecular phenotypes could have major differences. Thus, 
a mammalian model rather than flies would seem to be favored. Several mouse models 
for TTR amyloidosis have been created but until this moment none of the murine 
transgenic models exhibit perfect characteristics. Regarding FAP, the first mouse model 
utilized cDNA's encoding the amyloidogenic allele TTR V30M driven by the 
metallothionein promoter (Sasaki et al., 1986; Sasaki et al., 1989). Zinc induced the 
expression of TTR but circulating levels were too small and no amyloid deposition was 
detected, suggesting that such a construct would not generate a useful disease model. 
Subsequently, transgenic mice with the intact human TTR V30M gene, with a 6.0 kb of 
sequence upstream to the initiation site, were generated. These animals showed similar 
TTR levels in plasma as found in humans and presented appropriate tissue specific TTR 
expression and deposition (gut, heart, skin, kidney) beginning at about 9 months of age. 
Nevertheless, the PNS and ANS were spared (Nagata et al., 1995; Takaoka et al., 1997).  
Gene depletion (KO) technology allows for gene silencing, generating animals with a 
totally different phenotype. In 1993, Episkopou and colleagues developed a Ttr KO mouse 
to investigate the TTR roles, namely in embryonic development (Episkopou et al., 1993). 
Since then, this strain has been widely used to address several aspects of TTR biology. In 
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a collaborative work, Ttr KO mice were crossed with the 6.0-TTR V30M transgenic mice, 
creating animals with the human TTR V30M variant but lacking the endogenous mouse 
Ttr gene. These mice contained 30-60 copies of the human gene and at 24 months of 
age, TTR deposition resembled that of human FAP patients, but still without deposition in 
PNS or ANS, not displaying peripheral or autonomic neuropathy (Kohno et al., 1997). 
Although they were considered moderately successful, these animals still provide means 
to define new disease biomarkers, to find novel factors modeling disease progression or 
to evaluate potential therapeutic agents.  
Transgenic animals carrying the highly amyloidogenic TTR variant L55P were first 
developed by Teng and coworkers (Teng et al., 1995); however, this strain showed no 
deposition phenotype even at 2 years of age. Later on, mice with TTR L55P construct 
were crossed onto the murine Ttr null background. Non-fibrillar TTR deposition was found 
earlier in both gastrointestinal tract and skin, while amyloid deposits started to accumulate 
in these organs approximately at 8 months of age (Sousa et al., 2002). These findings 
suggested that murine Ttr inhibited aggregation and deposition of the highly unstable 
human TTR L55P variant. However, since TTR deposits were not found involving the 
nervous system, a new attempt to generate a more accurate model was tried. In 2010, a 
new mouse model emerged by crossing animals with the V30M mutation, in a Ttr null 
background, with mice KO or heterozygous for the Hsf-1. The impaired chaperone 
response led to relatively early TTR gastrointestinal deposits and, for the first time, protein 
deposition in the PNS and ANS (Santos et al., 2010b). Moreover, this novel model 
displayed signs of inflammatory and oxidative stress replicating nerve pathology of 
asymptomatic carriers of FAP. Overall, this study pointed out the involvement of genes 
related to the unfolded protein response (UPR) in the neuroprotection against tissue 
damage elicited by TTR aggregates. 
Very recently, through liver specific adeno-associated virus (AAV) gene transfer, a new 
somatic transgenic mouse line was settled. Viral shocks with TTR L12P (a very 
aggressive mutant) were administered to TTR KO mice which, after 3 months treatment, 
presented TTR L12P aggregates inside hepatocytes, found to be degraded by the 
lysosomal proteolytic system (Batista et al., 2013). This novel model replicates the 
pathological features displayed by patients with the TTR L12P mutation, namely the 
severe protein deposition in liver, opening new windows of action for the establishment of 
innovative models based on gene therapy.     
The effect of genetic factors, with manipulation of genome, can be easily assessed in 
transgenic mouse models; however, their small size makes difficult certain types of 
manipulation. A Japanese group chose to develop a transgenic rat model expressing the 
human TTR V30M, under the action of mouse albumin promoter, favoring studies on liver 
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transplantation. Nevertheless, this model only showed non-fibrillar TTR deposits in colon 
at very late ages (Ueda et al., 2007).  
In addition to the mouse models above described for FAP, an additional mouse model for 
SSA, overexpressing human TTR WT is also available. Non-fibrillar TTR deposits are 
present earlier and over age 18 months and amyloid deposits are frequently found in heart 
and kidney, similar to lesions characterizing age-related fibrillogenesis in humans (Teng et 
al., 2001).  
In summary, it is unquestionable that murine transgenic models for TTR amyloidoses 
have provided interesting insights into the pathogenesis of these disorders. Although they 
might raise mechanistic questions that probably are ultimately answered only in more 
reductionist experimental systems, moving a drug to the clinical practice will certainly 
require extensive animal testing. Despite all the recent efforts, the perfect animal model 
for FAP was still not established since none of the referred above models develop 
peripheral neuropathy. 
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Mechanisms for cytotoxicity in Familial Amyloidotic Polyneuropathy 
While most attention has been focused on amyloid fibrils, different studies evidence that 
low molecular mass aggregated species are the most cytotoxic culprits. The observation 
of aggregated non-fibrillar forms of TTR, negative for Congo red staining, in nerve 
biopsies from asymptomatic FAP carriers dates back to 2001 (Sousa et al., 2001a). Using 
microscopic and cell viability assays, Sousa and colleagues also demonstrated that these 
are the most toxic species, in contrast to the fibril counterpart, and that in advanced 
stages of disease, non-fibrillar TTR aggregates coexist with fibrillar forms in nerve tissue 
(Figure 5). Based on these results and on the density of nerve fibers, a scoring system 
was developed for the classification of patient material and stage of disease. Patients 
classified as FAP 0 have no reduction in the number of fibers, presenting only non-fibrillar 
TTR aggregates deposition; FAP 1 patients present a discrete decrease in fiber density 
and fibrillar TTR deposition starts to appear; FAP 2 and 3 have evident or severe fiber 
reduction, respectively, with extensive amyloid deposition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Photomicrograph of TTR electron immunocytochemistry in an FAP nerve. Arrows 
pointed out fibrillar TTR deposition while arrowheads denote TTR non-fibrillar aggregates. Scale 
bar: 100 nm (from Sousa and Saraiva, 2003). 
 
Later on, it was shown in vitro that monomeric or relatively small, rapidly formed TTR 
aggregates, of a maximum size of six subunits, were the major cytotoxic intermediates 
(Reixach et al., 2004). Further studies characterized these aggregated forms of TTR using 
dynamic light scattering (DLS) and the presence of smaller intermediate species was 
found to be correlated with calcium influx (Hou et al., 2007). Altogether, these data 
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indicates that cellular toxicity starts at early stages of FAP disease, predominantly 
consequent to the presence of non-fibrillar TTR aggregates. Although the precise 
molecular mechanisms mediating cytotoxicity in FAP are not yet fully understood, several 
pathways, including ER stress, apoptosis, ECM remodeling, oxidative stress and 
inflammation have been implicated. 
 
Endoplasmic reticulum stress and the unfolded protein response 
It seems increasingly probable that dysregulation of intracellular calcium homeostasis may 
represent the common primary mechanism of pathogenesis of amyloid related 
neurodegenerative disorders. Calcium is critical to normal cell physiology and the function 
of excitable cells. The calcium ion gradient across cells is maintained by plasma 
membrane calcium-ATPase pump and the sodium/calcium exchanger that are able to 
actively release it into the extracellular space. In addition, calcium might also be 
sequestered into intracellular organelle stores by the ER ATPase pump (Surmeier and 
Schumacker, 2013). Recently, it has become apparent that calcium regulation also affects 
ER function and the unfolded protein response (UPR) (Mattson, 2012). ER dysfunction 
and stress leads to inappropriate protein folding with consequent accumulation of 
misfolded molecules and UPR activation. This adaptive response is dependent on three 
basic transmembrane signaling sensors like inositol-requiring enzyme 1 (IRE1), activating 
transcription factor 6 (ATF-6) and pancreatic ER kinase (PKR)-like ER kinase (PERK). All 
the main transducers are activated in a process dependent on the ER-resident chaperone 
binding immunoglobulin protein (BiP/Grp78). In non-stressed conditions, BiP binds to the 
ER luminal domain of these transmembrane protein receptors, repressing the UPR. When 
overwhelming load of misfolded proteins or overexpression of proteins occurs, higher 
levels of BiP are required to bind them, leading to its dissociation from IRE1, ATF-6 and 
PERK, which in turn become active. Thus, upon BiP release, IRE1 and PERK 
oligomerize, inducing autophosphorylation and allowing for the activation of transcription 
factors involved in the UPR, such as X-box-binding protein (XBP1) and phosphorylated 
eukaryotic translation initiation factor 2α (eIF2α), able to reduce protein burden in the ER 
by decreasing initial protein translation. On the other hand, ATF-6 translocates to the 
Golgi apparatus, where it is cleaved for migration to the nucleus, initiating transcription of 
genes related to the UPR (Xu et al., 2005; Szegezdi et al., 2006). In summary, most of the 
adaptive measures involve activation of transcription factors and upregulation of ER 
chaperones to enhance the folding capacity of ER, promote ER-associated degradation 
(ERAD) and inhibit general translation, aiming at restoring the normal ER function (Xu et 
al., 2005; Szegezdi et al., 2006; Colgan et al., 2011).  
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A connection between ER stress and FAP was previously demonstrated. Indeed, 
increased levels of the ER-resident chaperone BiP were found both in tissues from FAP 
patients and from an FAP mouse model, in close relation with TTR deposition; effect that 
seems to be dependent on calcium mobilization from the ER to the cytosol (Teixeira et al., 
2006). Additional results demonstrate proteolysis of ATF-6 and phosphorylation of eIF2α. 
These mechanisms that initially might be protective, switches from pro-survival to pro-
apoptotic if protein aggregation persists and the stress cannot be resolved. During 
prolonged ER stress, all the upstream mentioned signals ultimately result in caspase 
activation, with ordered and sequential dismantling of the cell. Caspase-12 has been 
proposed as a key mediator in ER stress-related apoptosis (Nakagawa et al., 2000). The 
mechanism involved in its activation is not yet fully clear but evidence suggests cleavage 
of caspase-12 through calpain activation, secondary to calcium release during the ER 
stress response (Nakagawa and Yuan, 2000). Involvement of caspase-12 mediated ER-
specific apoptosis was demonstrated for FAP. In vitro studies disclose activation and 
cleavage of the pro-caspase-12 into an activated fragment when neuroblastoma cells 
were incubated with TTR aggregates, hence reinforcing the role of these intermediary 
species for cytotoxicity in FAP (Macedo et al., 2010). 
Traditional BiP-mediated ERAD, retrogradely transport the misfolded proteins from the ER 
to cytosol towards further degradation by the ubiquitin proteasome system. Protein 
ubiquitination is the major pathway of non-lysosomal proteolysis of intracellular proteins, 
which are then recognized by the 26S proteasome. Aberration of this system leads to the 
dysregulation of cellular homeostasis with accumulation of damaged, oxidized or 
misfolded proteins (Wang and Maldonado, 2006). It is the case of FAP disease, where 
ubiquitin expression is increased in tissues from human patients and transgenic mouse 
lines presenting TTR deposition, but accompanied by a significant decrease in 
proteasome activity, indicating proteasome impairment triggered by TTR aggregates 
(Santos et al., 2007). 
It has been proposed that membrane permeabilization triggered by TTR aggregates may 
be a key event in the pathophysiology of amyloidosis. Supporting this idea, Cecchi and 
coworkers proposed that membrane fluidity and disruption, raised by TTR aggregates, 
correlate with disturbances in calcium homeostasis, representing an important mechanism 
for TTR amyloid pathogenesis (Cecchi et al., 2005). In addition, calcium release from ER 
stores can modulate cell death and toxicity. In this regard, in vitro studies denote that 
increased levels of the chaperone BiP, following cell stimulation with TTR aggregates, 
involves calcium mobilization from the ER through ryanodine receptors, as it can be 
suppressed by dantrolene (Teixeira et al., 2006). Later, studies with human 
neuroblastoma cells demonstrated that TTR aggregates rapidly induced an increase in the 
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concentration of intracellular calcium due to an influx of extracellular pools, mainly via 
voltage-gated calcium channels (Hou et al., 2007). Although calcium mobilization seems 
to have an important role for cytotoxicity in FAP, the mechanisms underlying this process 
need further investigation. 
 
Apoptosis and mitochondrial dysfunction  
Neuronal death underlies the symptoms of a broad array of neurodegenerative diseases, 
including multiple sclerosis, FAP, Alzheimer’s, Parkinson’s and Huntington’s diseases. 
The mainly shared pathway for neuronal death is apoptosis, a process characterized by 
chromatin condensation, nuclear fragmentation, decreased cellular volume but 
maintenance of organelle integrity (Ghavami et al., 2014). Caspases are evolutionarily 
conserved cysteine proteases and the main propagators of the apoptotic program at the 
cellular level. These enzymes are present in the cytoplasm as inactive forms and need to 
be cleaved by proteolysis for activation. Ligation of external cell death inducing molecules 
(for example tumor necrosis factor α – TNF-α or Fas ligand – FasL) to death receptors, 
such as Fas or p75 neurotrophin receptor, result in caspase-8 activation, which in turn 
activate downstream effector caspases, like caspase-3 (Raoul et al., 2000). Extrinsic 
apoptosis might also be triggered when the extracellular concentrations of trophic factors 
(for example brain-derived neurotrophic factor (BDNF) or nerve growth factor (NGF)) fall 
below a certain threshold, leading to the transduction of lethal signals (Galluzzi et al., 
2012). In contrast, the intrinsic apoptotic pathway is triggered by internal stress 
(starvation, oxidative stress, free radical damage, cytosolic calcium overload or cellular 
dysfunction), with activation of caspase-9 and decrease in mitochondrial transmembrane 
potential, culminating with cytochrome c release into the cytosol. Both death signaling 
pathways lead to activation of the executioner caspase-3 but intercommunication between 
both pathological settings might occur through cleavage of B-cell lymphoma 2  (Bcl-2) 
interacting domain (Bid), forming truncated Bid (t-Bid), which later promotes mitochondrial 
cytochrome c release and caspase-9 activation (Figure 6) (Ghavami et al., 2014). 
Programmed cell death is crucial for normal neural development and physiologic aging, 
playing a key role in the construction of an efficient neuronal network. However, under 
pathologic conditions, it is also co-responsible for the loss of neurons associated with 
neurodegenerative disorders (Tendi et al., 2010). The main molecular components of the 
apoptotic program in neurons include caspases and members of the Bcl-2 family proteins. 
Thus, after an insult, release of apoptotic regulators Bax and Bak from complexes with 
anti-apoptotic Bcl-2 molecules, lead to their insertion into outer mitochondrial membrane 
contributing to cytochrome c release (Figure 6) (Ghavami et al., 2014).  
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Activation of apoptotic signaling platforms in FAP have been demonstrated by evidence of 
DNA fragmentation, increased levels of caspase-3 (Sousa et al., 2001b), Bax, caspase-8 
and overactivation of Fas death receptor (Macedo et al., 2007) in tissues from FAP 
patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Schematic representation of apoptotic platforms. Apoptosis might be triggered by 
binding of external stress ligands (FasL, TNF-related apoptosis-inducing ligand (APO-2L/TRAIL), 
TNF-α) to cell surface death receptors (Fas, DR4, DR5, TNF-R1). The intrinsic apoptotic pathway 
can be activated by p53 upon DNA damage, following exposure to cellular stress. A cross-talk 
between the intrinsic and extrinsic pathways can occur by cleavage of Bid to form tBid, by caspase-
8, which is a strong activator of the mitochondrial apoptotic pathway (from Ghavami et al., 2014).  
 
Together with the ER, mitochondria constitute the major storage compartment for 
intracellular calcium ions (Galluzzi et al., 2012). Calcium might lead to cell death by 
inducing mitochondrial dysfunction and release of cytochrome c. Once this molecule has 
been released into cytosol, it is able to interact with the apoptotic protease activating 
factor 1 (Apaf-1) for the subsequent recruitment of pro-caspase-9 into the apoptosome. 
Thus, formation of apoptosome leads to an amplificatory loop for caspase-9 activation and 
induction of apoptosis (Ghavami et al., 2014). Until some years ago, there was no 
evidence for an important role of mitochondria in FAP, since levels of both Bcl-2 and Apaf-
1 were not altered in tissues with TTR deposition (Macedo et al., 2007). However, 
recently, mitochondrial proteins involved in cell energetics were found differentially 
represented in abdominal white adipose tissue from patients with TTR amyloidosis. By 
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proteomic analysis, ATP synthase subunits α and β were found downregulated in patients, 
which lead authors to hypothesize that impairment in mitochondrial function and energy 
production might play a key role in TTR-triggered cardiomyopathy (Brambilla et al., 2013). 
Mitochondria constitute the most prominent source of ATP and play an additional critical 
role in autophagy. Defects in the autophagic machinery or mitochondrial dynamics might 
play a pathological role in cancer or in neurodegenerative disorders, as neurons are 
among the most energy-consuming cell types (Galluzzi et al., 2012); however, the role of 
autophagy in FAP is yet to be clarified. 
 
Heat shock response 
Molecular chaperones are proteins that assist the folding and the assembly of other 
macromolecular structures, preventing incorrect alterations and aggregation. Many 
chaperones are heat shock proteins (Hsps), that is, proteins expressed in response to 
elevated temperatures, ischemic injury, oxidative or other cellular stresses, constitutively 
and inducibly expressed in the nervous system (Richter et al., 2010). The heat shock 
response is primarily regulated by the transcription factor Hsf-1. In resting cells, Hsf-1 is 
associated with Hsp-90 and Hsp-70 in the cytoplasm. Upon stress, these Hsps dissociate 
from the Hsf-1, allowing for its phosphorylation and nucleus translocation, where it binds 
to the promoter of several Hsp genes, mediating their transcription (Benarroch, 2011). 
There is increasing evidence that Hsps could be crucial modulators of neurotoxicity in 
Alzheimer's, Parkinson's and Huntington's diseases. Likewise, colocalization between 
molecular chaperones Hsp-70 or Hsp-27 with amyloid fibrils has been detected in all 
these neurodegenerative disorders, indicating an inadequate refold and degradation of the 
amyloid species or representing chaperone loss of function (Benarroch, 2011). Substantial 
data indicate heat shock response activation also in FAP. Therefore, increased levels of 
Hsp-70, Hsp-27 and Hsf-1 were noticed in salivary glands and nerve biopsies from FAP 
patients (Santos et al., 2008). Consistent with this view, Santos and coworkers 
demonstrated that the lack of Hsf-1 induced an extensive and earlier mouse phenotype 
when compared with other models of FAP (Santos et al., 2010b). In addition, non-fibrillar 
TTR deposition in the PNS and ANS was achieved, for the first time in an animal model, 
further reinforcing the role of the heat shock response in the modulation of TTR burden. 
Subsequent studies raised the importance of the heat shock response in the pathological 
mechanisms taking place in FAP, namely by the demonstration of increased expression of 
αB-crystallin and clusterin in tissues from FAP patients and mouse models, most likely 
triggered by the deposition of TTR aggregates (Magalhães et al., 2010; Magalhães and 
Saraiva, 2011).  
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Extracellular matrix remodeling 
The extracellular matrix (ECM) is one of the most important regulators of cellular and 
tissue homeostasis. Dynamic remodeling of the ECM is essential for development, wound 
healing, cell proliferation, adhesion, migration and cell differentiation (Lu et al., 2011). 
Despite multiple regulatory mechanisms, sustained dysregulation of the ECM dynamics 
can result in life-threatening pathological conditions, such as Alzheimer’s disease or 
cancer (Lu et al., 2011; Mizoguchi et al., 2011). Excessive ECM dynamics is also a 
feature of FAP. Through microarray analysis of salivary glands from FAP patients, 
increased expression of ECM related genes was noticed, namely biglycan, neutrophil 
gelatinase-associated lipocalin (NGAL) and matrix metalloproteinase-9 (MMP-9) (Sousa 
et al., 2005). Interestingly, although MMP-9 has the ability to degrade TTR aggregates 
and fibrils in vitro, authors observed that in the presence of SAP, TTR fibrils become 
resistant to MMP-9 proteolysis. Later on, these results were corroborated in an FAP 
mouse model being biglycan overexpression already present in the preliminary stages of 
disease while NGAL, MMP-9, tissue inhibitor of metalloproteinase 1 (TIMP-1) and also 
chondroitin sulfate, increased only in amyloid laden tissues (Cardoso et al., 2008). 
Histological examination also revealed increased expression of laminin, fibronectin, 
collagen type IV and heparan sulfate in close association with amyloid fibrils deposition in 
cardiomyocytes (Misumi et al., 2009; Noborn et al., 2011). Thus, the excessive or 
uncontrolled remodeling of the ECM observed in FAP disease, might probably contribute 
to neurodegeneration. 
 
Inflammation and oxidative stress 
Neuroinflammation is a protective immune response involving host cells, blood vessels, 
proteins and other mediators, intending elimination of the initial cause of injury, for cell 
repair. When neuroinflammation is a long-standing and self-perpetuating response, 
persisting long after the initial insult, results in a sustained release of pro-inflammatory 
mediators, increased oxidative and nitrosative stress. The sustained release of cytokines 
and chemokines works to perpetuate the inflammatory cycle, leading to a positive 
feedback loop. Thus, rather than serving as a protective response, chronic 
neuroinflammation is most often detrimental and damaging to the nervous system (Frank-
Cannon et al., 2009). Neurodegenerative disorders, including multiple sclerosis, 
Alzheimer's, Parkinson's and Huntington's diseases have been associated with chronic 
neuroinflammation and elevated levels of pro-inflammatory cytokines. Neuropathological 
studies indicate that neuroinflammation is not a simple response to an already existing 
pathology but may begin prior to significant loss of neuronal populations, modifying 
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disease progression (Rogers, 1995). In this way, activation of the inflammatory response 
was also observed in preliminary stages of FAP with upregulation of TNF-α, interleukin-1β 
(IL-1β) and macrophage-colony stimulating factor, in sural nerve biopsies from 
asymptomatic carriers (Sousa et al., 2001a; Sousa et al., 2001b). Cytokine-driven 
neuroinflammation, occurring in earlier stages of disease indicate that TTR aggregates 
exert a neuronal pro-inflammatory response; however, if an inflammatory stimulus is also 
able to trigger TTR deposition, remains unanswered. With disease progress, levels of 
neuroinflammation increased, with IL-1β mRNA transcripts found mainly in endoneurial 
axons (Sousa et al., 2001b). The proposed mechanism underlying these observations 
was the binding of TTR species to RAGE with activation of extracellular signal-regulated 
kinases (ERK) 1/2, nuclear factor κB (NF-κB) translocation and consequent transcription 
of pro-inflammatory proteins (Sousa et al., 2000b; Sousa et al., 2001b; Monteiro et al., 
2006). NF-κB is a transcription factor essential for amplification, maintenance and tuning 
down of inflammatory responses (Ben-Neriah and Karin, 2011). Under resting conditions, 
NF-κB dimers are bound to inhibitory IκBα (nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha) proteins in the cytoplasm. Several extracellular 
signals might activate the IκB kinase which phosphorylates IκBα, targeting this protein for 
ubiquitination and proteasome degradation. Consequently, NF-κB is released and 
translocates into the nucleus contributing for the transcription of several genes, self-
perpetuating the overactivated inflammatory response (Oeckinghaus et al., 2011). In 
support of this idea, p50, one of the NF-κB subunits was found upregulated, with a 
predominant nucleus distribution, in tissues from FAP patients (Sousa et al., 2000b). 
To explore the eventual balance between pro and anti-inflammatory events in FAP, 
histological analysis for the interleukin-10 (IL-10) was performed in human sural nerve 
biopsies. Surprisingly, expression of IL-10 was noticed only in advanced cases of disease, 
suggesting that activation of anti-inflammatory mechanisms might occur to late, being not 
sufficient to control inflammation (Sousa et al., 2005). A striking feature of FAP is the 
absence of an immune/inflammatory infiltrate, despite the production of pro-inflammatory 
cytokines by axons, indicating that other mechanisms might be operating to prevent 
recruitment of effector cells (Misu et al., 1999; Sousa et al., 2001b). In line with this 
observation, a non-optimal activation of Schwann cells was noted, since upon the injury 
stimulus provided by TTR aggregates, these cells had no ability to express chemokines 
and neurotrophic factors, important for tissue regeneration (Sousa et al., 2001b). Thus, 
this lack of Schwann cells responsiveness may contribute for neuronal dysfunction 
present in FAP.  
Very recently, a novel diagnostic technique was developed, allowing in vivo detection of 
nerve injury. Hence, by magnetic resonance neurography, lower limb nerve injury could 
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be detected and quantified in vivo on microstructural level in symptomatic FAP patients, 
and also in yet asymptomatic gene carriers, in whom imaging detection precedes clinical 
and electrophysiological manifestation (Kollmer et al., 2014). Despite the need for deeply 
interpretation of imaging signals, this new imaging data would be valuable for the 
evaluation of the effectiveness of novel therapeutic agents on halting disease progression 
and may have future implications also for the diagnostic of other distally-symmetric 
polyneuropathies. 
Another link between inflammation and TTR amyloidosis comes from studies in a mouse 
model resembling human senile systemic amyloidosis (SSA). Through a microarray 
screening, it was found that, even before TTR starts to accumulate in the heart, cardiac 
gene transcription differs from that of WT littermates, primarily in the expression of a large 
number of genes associated with inflammation and immune response, raising the 
hypothesis that TTR burden might be triggered in response to multiple subclinical 
inflammatory traumas and that a robust immune inflammatory transcriptional profile might 
precede TTR deposition in tissues (Buxbaum et al., 2012). 
The neuronal cell oxidative stress response has an intense role regarding 
neurodegeneration. Though, oxygen is imperative for life, imbalanced metabolism and 
excess reactive oxygen and nitrogen species generation is believed to be involved in the 
pathogenesis of several neurodegenerative disorders. In this way, free radical attack on 
neural cells contributes for protein or DNA injury, inflammation, tissue damage and 
subsequent cellular apoptosis (Uttara et al., 2009). The involvement of oxidative stress 
also in FAP has been reported. First, markers of lipid peroxidation, such as 
hydroxynonenal (HNE) and thiobarbituric acid reactive substances (TBARS) were found 
increased in human colon biopsy samples of FAP patients (Ando et al., 1997). A 
subsequent study demonstrates the increased expression of inducible form of nitric oxide 
synthase (iNOS) and 3-nitrotyrosine, in nerves from patients and asymptomatic carriers 
(Sousa et al., 2001b). It is known that reactive nitrogen species such as nitric oxide can 
react with superoxide to produce peroxynitrite, a powerful oxidant that in turn nitrates 
thyrosine originating 3-nitrotyrosine (Melo et al., 2011). Therefore, 3-nitrotyrosine is a 
potent biomarker for nitrosative stress. Other markers of oxidative stress, like 8-
hydroxydeoxyguanosine and glutaredoxin 1 were observed increasingly expressed in 
tissues from FAP patients and mouse models of disease (Macedo et al., 2007) further 
reinforcing the role of oxidative stress in the pathomechanisms of this disease. 
Overall, a spectrum of environmental cues, mitochondrial dysfunction, ER stress, calcium 
dysregulation, inflammation, cell death and oxidative stress are known to evolve and form 
as a result of accumulation of aberrant misfolded proteins (Figure 7). Understanding the 
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relationships between disease mechanisms is critical for the development of therapeutic 
modalities to combat the progress of neurodegenerative disorders. 
 
 
 
Figure 7 – Schematic representation of neurotoxicity induced by TTR aggregates. 
Extracellular non-fibrillar TTR aggregates interact with the cell membrane and with membrane 
receptors such as Fas or RAGE, ultimately leading to neurodegeneration. Calcium dysregulation, 
ER stress, apoptosis, activation of kinase cascades and NF-κB, with concomitant transcription of 
pro-inflammatory cytokines and oxidative stress molecules, are central networks in the molecular 
mechanisms underlying FAP disease. Moreover, newly formed oxidized species and inflammatory 
mediators might contribute to extracellular matrix components dysregulation and fibril formation. 
Additionally, other possible receptors may also be involved, particularly membrane receptors, 
subject that needs further clarification (from Saraiva et al., 2012). 
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Therapies for Familial Amyloidotic Polyneuropathy 
FAP is a life-threatening disorder and few treatment options are available yet. Recent 
progress has modified prognosis and management of TTR amyloidosis by targeting 
different disease aspects, such as protein synthesis, stabilization, inhibition of TTR 
aggregation and fibril disruption by selective molecules (Figure 8). We next describe the 
main strategies adopted over the years to prevent or delay FAP pathology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Therapeutical approaches put forward so far for FAP (adapted from Adams et al., 
2014). 
 
 
Liver transplantation 
Liver transplantation is so far the best therapeutic strategy for FAP. Liver transplant 
removes the main source of mutated TTR, slowing disease progression. However, it does 
not prevent development of arrhythmia and, in some cases, neuropathy might progress 
even after surgery. This suggests continued secretion of variant TTR from the choroid 
plexus, which may reach the endoneurium through the subarachnoid space (Ando et al., 
2004; Planté-Bordeneuve and Said, 2011). In addition, preformed amyloid deposits might 
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act as a nidus enhancing further polymerization (Ueda and Ando, 2014). Nevertheless, 
improvement of the autonomic function with general well-being has been reported.  
Very recent findings indicate that CNS clinical involvement occurs in TTR V30M patients, 
regardless of liver transplantation. In this way, focal neurological episodes arise due to 
progression of TTR deposition from the meninges and its vessels towards meningocortical 
vessels and the superficial brain parenchyma; suggesting that novel disease modifying 
therapies should consider brain TTR as a target (Maia et al., 2015). 
Explanted FAP livers can be grafted into selected patients in domino liver transplantation. 
However, symptomatic neuropathy seems to occur after about 5 years (Stangou et al., 
2005). 
The best outcomes achieved with liver transplant occur when the procedure is done early 
in the course of FAP (de Carvalho et al., 2002). Thus, patients with severe 
polyneuropathy, poor nutritional status or autonomic dysfunction are not eligible for the 
procedure (Planté-Bordeneuve and Said, 2011). An additional number of limitations such 
as shortage of donors, surgery requirement, cost of the procedure, lifelong administration 
with immunosuppressants and lack of responsiveness regarding ocular or CNS 
complications put forward the development of novel alternative less-invasive therapeutic 
strategies for this disease (Ando, 2005).  
 
Gene therapy  
Gene therapy has arisen as a promising therapeutic strategy for FAP by preventing the 
transfer of genetic information from DNA to protein. It is a new non-invasive method 
preventing production of both mutant and wild-type TTR, thus reducing plasma TTR levels 
in a sustained fashion. The theory is that blocking TTR production by the liver at the 
translational level will lead to less non-fibrillar TTR species and amyloid deposition, halting 
disease progression (Hanna, 2014). 
Antisense oligonucleotides (ASOs) are short synthetic single-stranded nucleotides, 
selectively binding to the target mRNA, thereby preventing production of the disease 
associated protein (Malik and Roy, 2011). Isis Pharmaceuticals has developed an ASO 
targeting TTR mRNA, designated ISIS-TTRRX, preclinically characterized in transgenic 
mice expressing the human TTR I84S variant. One month treatment resulted in a 
significant decrease in both TTR liver expression and circulating plasma levels (Benson et 
al., 2006). Since ISIS-TTRRX was found to be well tolerated, initiation of clinical trials was 
supported. Preliminary results demonstrate that after a month treatment, up to a 90% 
reduction in TTR levels was achieved in a study with healthy volunteers (Ackermann et 
al., 2012). Clinical trials with FAP patients are currently ongoing (Adams et al., 2014). 
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Another approach using interference RNA (RNAi) has been extensively studied for FAP, 
which take advantage of small interfering RNAs (siRNA) that mediate cleavage of target 
mRNA, thus silencing gene expression. A lipid nanoparticle formulation was developed by 
Alnylam Pharmaceuticals (ALN-TTR02) targeting a conserved sequence in mutant and 
non-mutant TTR mRNA, expressed specifically by the liver. In this way, the nanoparticle 
efficiently delivers the siRNA to hepatocytes where they are taken up by LDL receptors 
and released into the cytoplasm (Hanna, 2014). Animal models, healthy volunteers and 
FAP patients were already treated with ALN-TTR02 that was generally safe and well 
tolerated. In addition, sustained suppression of TTR plasma levels was observed, 
establishing proof of concept for an RNAi therapeutic tool, with Phase III clinical trials 
currently ongoing (Alvarez et al., 2010; Coelho et al., 2013; Adams et al., 2014). For 
intravenous injections of ALN-TTR02, premedication with steroids and anti-histaminic is 
necessary; therefore a formulation to be given subcutaneously has been tested, showing 
similar significant decrease in TTR plasma levels (Adams et al., 2014; Hannan et al., 
2014). 
These promising future therapeutic approaches can be extended to all forms of TTR 
amyloidosis since they are designed to prevent the expression of all TTR variants. 
Based on previous results showing that incorporation of one subunit of TTR T119M into a 
predominantly V30M tetramer strongly stabilized the mixed tetramer against dissociation 
(Hammarström et al., 2001), a novel gene therapy approach using AAV vectors to deliver 
the TTR T119M variant into the liver of transgenic mice carrying the TTR V30M mutation, 
was very recently tested. Collectively, the authors described that somatic gene delivery of 
TTR T119M significantly reduced non-fibrillar TTR V30M deposition, BiP and MMP-9 
levels in the gastrointestinal tract of treated animals, suggesting the possible use of this 
gene therapy approach in a prophylactic way to prevent FAP pathology (Batista et al., 
2014).  
 
Stabilization of transthyretin tetramers 
It is widely accepted that dissociation of the TTR tetramer into compact non-native 
monomers, with low conformational stability, is the rate-limiting step for the process of 
amyloid fibril formation. Miroy and coworkers have shown that binding of T4 to TTR 
tetramer stabilizes the native state over dissociation, thus inhibiting amyloidogenesis in 
vitro (Miroy et al., 1996). Because more than 99% of the T4 binding sites are unoccupied, 
the strategy of administering small molecules that binds in the central hydrophobic 
channel to stabilize the native tetrameric structure, has been developed (Sekejima et al., 
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2008). Several small molecules stabilizing TTR are now available but thus far only two 
drugs have come to the forefront to clinical development, namely diflunisal and tafamidis.  
Diflunisal is a non-steroidal anti-inflammatory drug, which binds to T4 binding sites, 
stabilizing serum TTR in amyloidotic patients (Tojo et al., 2006). It is being relatively well 
tolerated and in an open label study, some patients show amelioration of autonomic 
symptoms (Takahashi et al., 2014). 
Tafamidis is another pharmacological chaperone, selectively binding to T4 pocket for TTR 
stabilization. Safety was overall good with the most side effects being urinary tract 
infections and diarrhea. This potent stabilizer was approved in Europe and Japan for the 
treatment of FAP patients in the early stage of disease (Ueda and Ando, 2014). Results 
from clinical trials demonstrate that patients treated with tafamidis showed less 
neurological deterioration and slower disease progression (Bulawa et al., 2012; Coelho et 
al., 2012). 
A number of structurally different small molecules that bind to TTR, increasing its stability 
have also been tested, such as epigallocatechin-3-gallate (EGCG) or curcumin. Similarly 
to diflunisal and tafamidis, curcumin interacts with TTR in the T4 binding pocket, while 
EGCG binds at the protein surface. It was found that curcumin strongly suppressed TTR 
amyloid fibril formation by generating small "off-pathway" aggregates, while EGCG 
maintained most of the protein in a non-aggregated soluble form (Ferreira et al., 2009; 
Ferreira et al., 2011). Animal testing provide strong evidence for the benefic role of these 
selected polyphenols (Ferreira et al., 2012; Ferreira et al., 2013); however, clinical trials 
with FAP patients are still awaited. 
Cyclodextrins are cyclic oligosaccharides composed of glucose units and one of its 
derivatives showed potent stabilization of TTR conformation by interacting with protein 
hydrophobic amino acids, especially tryptophan, in turn, suppressing TTR amyloid fibril 
formation (Jono et al., 2011). Additionally, a lys-specific molecular tweezer CLR01 has 
been shown to inhibit TTR aggregation and toxicity by interfering with hydrophobic and 
electrostatic interactions, redirecting TTR aggregation into the formation of innocuous 
assemblies (Sinha et al., 2011). When tested in a mouse model of FAP, CLR01 showed 
positive therapeutic effects thus being a promising disease-modifying agent for TTR 
amyloidosis (Ferreira et al., 2014). 
 
Fibrils disrupters and amyloid clearance 
Once TTR amyloid fibrils have deposited in the extracellular space, they are resistant to 
degradation and although they are currently not seen as the primary cause of FAP, it is 
known that amyloid deposits can induce organ dysfunction (Pepys, 2001). Consequently, 
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other therapeutic strategies for FAP involve molecules acting as fibril disruptors for the 
modulation of cellular stress and toxicity. 
4'-iodo-4'-deoxydoxorubicin (IDOX) was described as an agent that could efficiently bind 
to TTR amyloid fibrils, disaggregating them into non-toxic species (Merlini et al., 1995; 
Cardoso et al., 2003). Nevertheless, since the use of this drug is associated with 
cardiotoxicity, less toxic compounds, such as doxycycline, have been evaluated (Cardoso 
et al., 2003). In vitro and in vivo studies showed that doxycycline was able to disaggregate 
TTR amyloid fibrils and to decrease biomarkers associated with the pathology (Cardoso et 
al., 2003; Cardoso and Saraiva, 2006), thus being a potential useful drug for FAP. Very 
recently, novel nanoconjugates based on doxycycline exhibited greater potential towards 
TTR fibril disaggregation being a promising therapeutics for advanced stages of disease 
(Conejos-Sánchez et al., 2015). 
In addition, the above mentioned natural compounds EGCG and curcumin have also 
showed potential for TTR fibril disruption by converting existing fibrils into non-fibril 
conformers (Ferreira et al., 2009; Ferreira et al., 2011).  
Since no inflammatory infiltrate is usually found near to amyloid deposits (Sousa et al., 
2001b), immune therapies for the treatment of FAP may arise. By immunizing FAP 
transgenic mice with the TTR variant Y78F, Terazaki and coworkers observed reduction of 
both fibrillar and non-fibrillar TTR deposition within mice intestine, together with infiltration 
of lymphocytes and macrophages at sites of TTR deposition (Terazaki et al., 2006). These 
results indicate that immune therapies might be major candidates for the treatment of TTR 
amyloidosis.  
Serum amyloid P component (SAP) is a universal element of amyloid fibrils, retarding their 
breakdown and clearance (Pepys, 2001). In this way, SAP has been proposed as a 
possible target for amyloidosis therapeutics (Pepys et al., 2002). Data from animal models 
receiving anti-human-SAP antibodies indicate that antibody mediate removal of this 
component, facilitating endogenous clearance of amyloid fibrils, without apparent adverse 
side effects (Bodin et al., 2010). This treatment seems to be clinically reasonable, 
therefore clinical trials with patients carrying systemic amyloidosis will be carried out soon 
(Hanna, 2014). 
 
Anti-oxidant and anti-apoptotic treatments 
Oxidative stress and apoptosis have been implicated in the pathological mechanisms 
underlying FAP disease (Saraiva et al., 2012). Therefore, anti-oxidant and anti-apoptotic 
therapy was attempted for the treatment of FAP by administrating tauroursodeoxhycholic 
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acid (TUDCA), a natural compound derived from biliary acids, to a mouse model of 
disease. Macedo and colleagues demonstrate that TUDCA decreases toxic TTR non-
fibrillar aggregates deposition, as well as several disease associated biomarkers, but 
without a significant effect on mature fibrils (Macedo et al., 2008). A subsequent study 
combined the action of doxycycline with TUDCA for preclinical analysis (Cardoso et al., 
2010). The authors showed a synergistic effect on lowering TTR deposits and associated 
biomarkers than either of the compounds alone. Based on this animal data, a Phase II 
open label study was conducted over a 12-month period. Preliminary results indicate that 
the combination of doxycycline with TUDCA stabilizes disease progression for at least 1 
year (Obici et al., 2012). 
In a different study, Macedo and coworkers postulated a possible therapeutical application 
of another anti-oxidative compound, carvedilol, a lipophilic non-selective β-adrenoreceptor 
antagonist with strong anti-oxidative effect, commonly used in different cardiovascular 
settings. Similarly as TUDCA, carvedilol was shown to decrease non-fibrillar TTR 
deposition and disease associated biomarkers namely, HNE, 8-OHdG and markers of ER 
stress as BiP and peIF2α (Macedo et al., 2010). 
Hence, non-amyloid targets modulating the molecular pathways involved in aggregate-
induced oxidative stress, cell death or inflammatory response, might be promising 
prophylactic strategies for FAP. Given the extensive number of proposed drugs, most 
likely the future therapy for FAP will encompass by a combinatorial approach. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
57 
 
Peripheral nerve regeneration 
Nerve injury is a complex multi-cellular response that might be triggered by traumatic, 
inflammatory or autoimmune stimulus. In 1850, Augustus Waller described the 
disintegration of the frog nerves after axotomy, phenomena that have been collectively 
termed Wallerian degeneration (Waller, 1850). Decades later, Ramon y Cajal confirmed 
Waller observations and provided new histological insights, namely regarding axonal 
degeneration, leukocyte infiltration, Schwann cell responses and their importance for the 
regenerative process (Ramon y Cajal and May, 1928).  
In practical terms, nerve TTR aggregates and amyloid fibrils deposition may behave 
similarly as an injury stimulus by compressing nerve fibers, ultimately leading to 
neurodegeneration. The major issues concerning Wallerian degeneration will be next 
described. 
 
Wallerian degeneration 
Wallerian degeneration comprises the rapid disintegration of the distal axons and the 
subsequent influx of immune cells, allowing the clearance of resulting debris and the 
formation of a favorable environment for regeneration to occur (Figure 9). Upon injury, 
axonal membrane of the distal stump undergoes beading and swelling (Gaudet et al., 
2011). Within minutes after damage to the axonal membrane, calcium influx from 
extracellular and intracellular stores activates calpain, promoting local protein synthesis, 
increased cAMP levels and cytoskeleton rearrangements (George et al., 1995; Tedeschi 
and Bradke, 2013). Calcium entry into axoplasm and activation of the ubiquitin-
proteasome system are required steps for granular disintegration of the cytoskeleton, 
characterized by the disassembly of microtubules and filaments that ultimately lead to 
axonal fragmentation and degradation. These processes are closely regulated by p38 
mitogen-activated protein kinase and caspase-3, the former involved in axon degeneration 
by trophic factors withdrawal (Simon et al., 2012; Tedeschi and Bradke, 2013). 
Simultaneously, the blood-nerve barrier is compromised along the distal nerve portion, 
increasing perineurial permeability with consequent entry of blood-borne factors and 
inflammatory cells, crucial for tissue repair (Mizisin and Weerasuriya, 2011). Nerve 
degeneration and regenerative ability of the PNS are thus active processes, dependent on 
extrinsic and intrinsic factors. Besides the immune response, the role played by Schwann 
cells comprises the extrinsic category, while intrinsic factors include the transcriptional 
profile of the neuron cell body (Scheib and Höke, 2013). 
 
Introduction 
 
58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 – Wallerian degeneration after peripheral nerve injury. A schematic representation of 
a single axon is shown. 1. Normal nerve fiber maintaining synaptic contact with target cells. 2. 
Injury results in distal fragmentation of axon and myelin. Schwann cells dedifferentiate with 
cytokine and growth factors production. 3. Following, hematogenous macrophages are recruited 
contributing for clearance of myelin debris. 4. Injured axons formed the growth cone and begin to 
regenerate along the bands of Büngner, originated from the Schwann cell alignment. 5. Finally, 
successful regeneration and axon connection with peripheral targets takes place (from Gaudet et 
al., 2011).    
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The role of Schwann cells in Wallerian degeneration 
Schwann cells arise from the neural crest during development and are the glial cells of the 
PNS (Figure 10). They constitute 90% of nucleated cells within the peripheral nerve and 
play crucial roles regarding nerve physiology, more precisely, trophic support to neurons 
and myelin insulation (Jessen and Mirsky, 2005; Gaudet et al., 2011). These cells can be 
divided in myelinating or ensheating Schwann cells. Myelinating Schwann cells associate 
to a single large caliber axon and form compact multi-layer myelin lamellae, providing 
insulation, pivotal for fast nerve conduction (Figure 10). In contrast, ensheating Schwann 
cells have multiple unmyelinated axonal segments embedded within grooves of its 
cytoplasmatic processes and plasma membrane, a structure termed Remak bundle 
(Figure 10).   
 
 
 
 
 
 
 
 
 
 
 
Figure 10 – Schematic illustration of the developmental transitions and Schwann cell 
organization in peripheral nerves. The embryonic phase of Schwann cell development involves 
three transient cell populations, namely migrating neural crest cells, Schwann cell precursors and 
immature Schwann cells. Myelination occurs only in Schwann cells that envelop large diameter 
axons; Schwann cells that wrap several small diameter axons, forming a Remak bundle, progress 
to become mature non-myelinating cells (from Jessen and Mirsky, 2005). 
 
Soon after nerve damage, Schwann cells of the distal stump have the ability to revert back 
to a nondifferentiated, proliferative phenotype. This dedifferentiation stage involves 
transcriptional changes with downregulation of genes related to myelination, such as 
myelin-associated glycoprotein, with concomitant increased expression of trophic factors 
and regeneration-associated genes (like BDNF, NGF or growth associated protein 43 
(GAP-43)) (Jessen and Mirsky, 2008; Gaudet et al., 2011). In addition, danger-associated 
molecular patterns (DAMPs), released from early axonal degeneration, induce toll-like 
receptor (TLR) signaling, mediated by myeloid differentiation primary response gene 88 
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(Myd88), leading to the breakdown of myelin and recruitment of immune cells (Boivin et 
al., 2007). Schwann cells express a variety of TLRs, including TLR2, TLR4, TLR7, TLR9 
and TLR1 (Figure 11), the former upregulated after injury, making them the PNS sentinel 
cells (Goethals et al., 2010). When intracellular cascades are activated with nuclear 
translocation of NF-κB, Schwann cells are induced to express a variety of cytokines 
important for effective Wallerian degeneration, such as TNF-α, IL-6, IL-1α and β. TNF-α 
and IL-1 peaked at day 1 post-injury, before entry of inflammatory cells, and elicit 
production of chemokine C-C motif ligand 2 (CCL2), stressing the idea of their 
involvement in immune cell recruitment (Figure 11). Expression and activation of 
phospholipase A2 (PLA2) is also triggered by these pro-inflammatory cytokines and is a 
required step for the initiation of myelin breakdown. Furthermore, TNF-α and IL-1β prompt 
the production of MMP-9, necessary for the collapse of the blood-nerve barrier, 
stimulation of initial myelin disruption and monocyte migration (Defrancesco-Lisowitz et 
al., 2014; Brosius Lutz and Barres, 2014). Cytokines produced by Schwann cells might 
stimulate fibroblasts which in turn release IL-6 and granulocyte macrophage colony 
stimulating factor (GM-CSF), important for galectin-3 production by macrophages and 
Schwann cells (Saada et al., 1996) (Figure 12). Collectively, the fine-tune inflammatory 
response will be amplified with the ultimate goal of immune cell chemotaxis. 
Upon myelin breakdown, Schwann cells begin to proliferate and align along their basal 
lamina to form bands of Büngner, which provide support and guide regenerating sprouts 
for axon growth (Scheib and Höke, 2013). The aligned Schwann cells induce nerve 
regeneration by secreting growth factors, their receptors and cell adhesion molecules, as 
laminin, one of the most prevalent ECM components in the PNS, essential for axon 
growth (Gaudet et al., 2011). 
The best characterized axonal signals prompting phenotypic changes in Schwann cells, 
upon injury, are neuregulin-1 and c-Jun (Figure 12). In healthy nerves, neuregulin-1 
induces proliferation and myelin production via the ErbB family of receptors. Ablation of 
this molecule during Wallerian degeneration results in severe defects regarding 
remyelination. Therefore, neuregulin-1 has shown a key role in reparative processes after 
nerve injury and might be partially involved in Schwann cell phenotypic changes (Fricker 
et al., 2011). c-Jun is a transcription factor required for efficient axonal regeneration. 
Recently, Arthur-Farraj and coworkers demonstrate that c-Jun reprograms the Schwann 
cell transcriptional profile to generate a repair cell, looking forward correct reinnervation 
and functional recovery after nerve insult (Arthur-Farraj et al., 2012). Denervated 
Schwann cells are the major phagocytic cells during the first days following injury. Several 
findings report that Schwann cells are immune competent cells able to express both major 
histocompatibility complex (MHC) classes I and II, upon stimulation, and behave as 
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primary antigen-presenting cells (Ydens et al., 2013). Some studies have proven that 
these cells are effective presenters of self-antigen, as they can phagocyte and degrade 
myelin or extracellular debris (Lilje, 2002). In summary, dedifferentiated Schwann cells 
promote nerve repair by proliferating, phagocyting myelin debris and mounting an immune 
response, with secretion of trophic factors, cytokines and chemokines, crucial for the 
activation and chemotaxis of innate immune cells.  
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Schematic representation of possible mechanisms elicited on Schwann cells 
after nerve insult. A) Despite expressing RAGE, low-density lipoprotein receptor-related protein-1 
(LRP-1), C-type lectin and mannose receptors (CTR and MR, respectively), Schwann cells also 
express a broad range of TLR and NOD-like receptors, resulting in NF-κB activation upon injury. B) 
Dedifferentiated cells produce several cytokines, chemokines and other immune mediators, which 
further attract inflammatory cells. C) Schwann cells are immune competent cells since they have 
the ability to present antigen via the MHC type I and type II. Abbreviations not yet mentioned; 
CARD: caspase recruitment domain, ICAM: intercellular adhesion molecule, LIF: leukemia 
inhibitory factor, LMP-2: low molecular mass peptide-2, LRR: leucine rich repeat, MCP-1: monocyte 
chemoattractant protein-1 (also known as CCL2), NOD: nucleotide binding and oligomerization 
domain, PYD: pyrin domain, TAP1: antigen peptide transporter 1, TIR: Toll/interleukin receptor 
(from Ydens et al., 2013). 
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The immune cell response to peripheral nerve injury 
Peripheral nerve injury is a complex response and involves multiple cell types. Whereas 
Schwann cells mediate myelin clearance in early stages of Wallerian degeneration, they 
are not the only important cell type in the distal nerve environment. Removal of myelin 
debris, growth factors production and remodeling of the ECM is also achieved by resident 
and recruited macrophages (Scheib and Höke, 2013). Resident endoneurial macrophages 
account for 2-9% of all cells in the uninjured nerve and express MHC molecules or 
complement receptor 3, essential for their functions regarding antigen presentation and 
surveillance (Mueller et al., 2003; Barrette et al., 2008). Evidence suggests that resident 
macrophages respond in the injured nerve before the accumulation of blood-derived 
monocytes, having an active phagocytic activity. In addition, together with Schwann cells, 
they produce cytokines and chemokines important for the recruitment of innate immune 
cells (Tofaris et al., 2002). Breakdown of the blood-nerve barrier allows the influx of serum 
components, like antibodies and complement, which then facilitate leucocyte recruitment 
and opsonize debris, enabling phagocytosis (Brück and Friede, 1990; Vargas et al., 
2010). Neutrophils are the first innate immune cells to invade the injured tissue (Figure 
12). They phagocyte debris and activate monocytes, having an important role regarding 
neuropathic pain (Austin and Moalem-Taylor, 2010; Gaudet et al., 2010).  
By four days post-injury, large numbers of hematogenous monocytes begin to accumulate 
within the injured nerve, peaking between 7-14 days. Once in the tissue, monocytes 
differentiate into macrophages, which start to express cytokines and trophic factors, 
contributing for removal of inhibitory debris, ultimately aiding axon regeneration (Gaudet et 
al., 2010; Defrancesco-Lisowitz et al., 2014). Days or months after nerve damage, 
macrophages migrate through the basal lamina to nearby blood vessels or die by 
apoptosis (Kuhlmann et al., 2001).  
Recently, studies on macrophage heterogeneity delineated this population into M1 (pro-
inflammatory and cytotoxic) and M2 (anti-inflammatory and alternatively stimulated) 
stages of activation (Bastien and Lacroix, 2014). M1 macrophages are quickly recruited to 
injured nerves and are mostly involved in inflammation (releasing among others TNF-α, 
IL-1β and IL-6), proteolysis and phagocytosis. M2 macrophages are implicated in immune 
surveillance, tissue repair and wound healing, producing IL-10, arginase-1 (Arg-1) and 
several growth factors (Figure 12) (Ydens et al., 2012). M1 macrophages are present 
early after nerve insult but chemokine production by Schwann cells and resident 
macrophages, such as CCL2, drives macrophages towards an M2 phenotype, important 
for the control of inflammation (Sierra-Filardi et al., 2014). As a consequence, the levels of 
IL-10 start to increase, peaking at day 7 and remaining elevated through day 14 (Be’eri et 
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al., 1998). IL-10 activation gradually inhibits production of pro-inflammatory cytokines and 
downregulates expression of MMP-9 by macrophages, lowering leucocyte infiltration and 
myelin breakdown (Moore et al., 2001; Defrancesco-Lisowitz et al., 2014).  
 
 
Figure 12 – Cellular types and intermediaries involved in Wallerian degeneration after nerve 
damage. Representative illustration denoting Schwann cell dedifferentiation consequent to calcium 
entry, axonal breakdown and upregulation of c-Jun and ErbB. Through TLR signaling, these cells 
produce pro-inflammatory cytokines and chemokines essential for the recruitment of innate 
immune cells. Fibroblasts also respond earlier with secretion of IL-6 and GM-CSF leading to 
galectin-3 expression by macrophages and Schwann cells, important for myelin phagocytosis. 
Neutrophils are the first innate cells to invade the peripheral nerve after injury. Hematogenous 
macrophages are recruited and enter the damaged tissue through the blood-nerve barrier 
disruption. Together with the resident macrophages, they can differentiate into M1 or M2 subtypes, 
with different cytokine profiles, and contribute for the clearance of myelin debris and nerve repair 
(from Defrancesco-Lisowitz et al., 2014).  
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The last phase of the immune response triggered after nerve injury is shaped by T 
lymphocytes which produce several pro or anti-inflammatory cytokines, modulating 
neuropathic pain behavior (Moalem et al., 2004).  
Overall, these data suggests that the inflammatory response after nerve injury encompass 
a spectrum of activation stages that must be sensibly controlled, allowing for subsequent 
regeneration and repair. 
 
Injury signaling to the cell body 
Intrinsic and extrinsic cues are highly interconnected in the axon growth equation; for 
instance extrinsic signals are able to produce a multitude of changes in the neuronal cell 
body gene expression, following injury. This de novo synthesis of mRNAs and proteins 
mark a phenotypic switch characterized by a reduction in the machinery supporting 
synaptic transmission on behalf of axonal regeneration and survival (Defrancesco-Lisowitz 
et al., 2014). Upon injury, axons are depolarized due to an inversion in the calcium/sodium 
flux and this signal travels toward the cell body, stimulating local activation of protein 
synthesis (Bradke et al., 2012). When this calcium wave invades the ganglion soma, it 
triggers nuclear export of histone deacetylase 5 (HDAC5), leading to an increase in 
histone acetylation and further activation of the regenerative transcriptional program (Cho 
et al., 2013) (Figure 13). Then, newly synthesized molecules and structural components 
need to be shipped to the distant axon tip through anterograde transport (Figure 13). 
Besides axonal maintenance, anterograde transport is particularly relevant for axon 
supply with synaptic proteins, vesicles and organelles, especially mitochondria (Mar et al., 
2014). Furthermore, the alteration of neuronal activity is dependent on axonal signaling 
that must be retrogradely transported to the cell soma. This aspect is achieved by the 
activation of adaptor proteins, such as dynactin, vimentin or importin, which facilitate the 
association of molecules with motor dynein for transport along cytoskeletal microtubules 
(Mar et al., 2014). Several injury signals locally activated are transported in a retrograde 
manner back to the cell body, like dual leucine kinase (DLK), ERK, signal transduction by 
the c-Jun N-terminal kinase (JNK) and signal transducer and activator of transcription 3 
(STAT3) (Figure 13).  
Recent observations highlight a dual role for DLK since this kinase might promote 
apoptosis or axon growth, depending on the neuron transcriptional program (Tedeschi 
and Bradke, 2013). Evidence with DLK null mice show that this molecule is likely involved 
in axon formation and neuronal migration and that it might regulate regeneration through 
influence on other injury driven molecules, such as STAT3 and JNK (Hirai et al., 2006; 
Shin et al., 2012). STAT3 is a positive injury signal contributing to axonal regeneration, the 
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expression of regeneration-associated genes (RAGs) and neuronal survival (Ben-Yaakov 
et al., 2012). Nerve injury also induces local activation of JNK that upon phosphorylation is 
translocated to the cell body within vesicular structures. Once in the neuron, JNK is 
required for the activation of the transcription factor c-Jun, thus increasing the expression 
of RAGs (Barnat et al., 2010). Another positive injury stimulus activated by 
phosphorylation is ERK. In the initial phase of Wallerian degeneration, ERK contribute for 
the dedifferentiation of Schwann cells and is then coupled to the retrograde transport 
machinery, in a process dependent on vimentin (Glenn et al., 2013). All together, these 
studies indicate that, in addition to neuronal cell bodies, axonally synthesized proteins are 
crucial for nerve regeneration.  
The importance of axonal transport relies on the fact that its disruption leads to the onset 
of several neurodegenerative disorders, including amyotrophic lateral sclerosis, Charcot-
Marie-Tooth, Alzheimer’s and Huntington’s diseases (Roy et al., 2005). However, wheter 
transport defects are cause or consequence of neurodegeneration is still under debate. 
The study of axonal transport in FAP is not yet disclosed and should be a topic of interest 
for future studies.  
 
 
 
Figure 13 – Axonal transport following nerve injury. Most of the axonal transport is made along 
the microtubules dependent on cAMP, which in turn activates protein kinase A (PKA), signaling to 
DLK and promoting local protein synthesis and axonal elongation. Loss of electrical activity and 
removal of negative cues triggers axonal regeneration. When the calcium wave arrives to the cell 
body promote HDAC5 nuclear export and activation of the regenerative transcriptional program. 
Retrograde transport of positive injury signals including ERK, JNK and STAT3 is a potent driving 
force behind the intrinsic neuronal growth capacity. On the other hand, RAGs and other proteins 
expressed in the cell body reach the axon tip through anterograde transport. Abbreviation not yet 
mentioned; VIP: vasoactive intestinal peptide (from Mar et al., 2014). 
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Axonal elongation 
After peripheral nerve injury, the distal stump undergoes Wallerian degeneration while the 
proximal stump begins regeneration. In this way, nerve fibers regrow from the distal tip of 
the proximal growing axon, the growth cone, to the distal end. Growth cones are highly 
specialized structures that control the rate and direction of axon elongation during 
development or after peripheral nerve damage. They are dynamic, actin-supported 
structures, shaped by assembly and reorganization of cytoskeletal elements (Bradke et 
al., 2012). To achieve a successful reinnervation, several key processes and extracellular 
cues need to be precisely regulated for correct directional guidance towards appropriate 
synaptic targets. These signals include neurotrophins, ECM proteins, neuronal adhesion 
molecules, expression of growth-associated proteins and RAGs. Neurotrophic factors, 
together with laminin, promote axon elongation by modulating cytoskeleton-binding 
proteins through activation of protein kinase B (AKT), which in turn inhibits glycogen 
synthase kinase-3β (GSK-3β), with consequent increase in microtubule speed in the 
growth cone, thus enhancing axon regeneration (Chen et al., 2007; Liz et al., 2014).  
The first RAG to be identified was GAP-43 (Skene and Willard, 1981). It is a nervous 
tissue-specific cytoplasmic protein, expressed at high levels in neuronal growth cones and 
crucial for actin assembly and axon elongation. Overexpression of GAP-43 following injury 
is achieved by the retrogradely transported phosphorylated STAT-3 that in turn is a 
downstream molecule from the signal transduction of IL-6 and LIF, reinforcing the 
importance of cytokines in regeneration (Chen et al., 2007). 
Arg-1 is a critical enzyme in polyamine synthesis and has been tied to axonal elongation 
due to its ability to overcome neurite growth inhibition by myelin associated glycoproteins 
(Cai et al., 2002). 
The PKA-dependent pathway involved in cAMP mediated axon growth requires the 
downstream activation of several key transcription factors, including cyclic AMP-
dependent transcription factor (ATF-3). This molecule is a reliable neuronal marker of 
injury and has demonstrated pro-regenerative qualities when neurons are cultured on 
permissive substrates, such as laminin (Seijffers et al., 2007). In addition, ATF-3 has been 
shown to influence neurite outgrowth and elongation (Defrancesco-Lisowitz et al., 2014). 
Since the axonal skeleton is composed mainly by microtubules and microfilaments, 
successful axonal elongation depends also on tubulin and actin synthesis (Mar et al., 
2014). 
Upon appropriate length of axonal regrowth, Schwann cells redifferentiate in a proximal-
to-distal direction and express myelin specific genes for timely remyelination. Once 
remyelination is complete, the expression of neurotrophins and their receptors return to 
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basal levels, target organs are finally reached and action potentials propagate normally. 
Overall, effective peripheral nerve regeneration has to be preceded by successful 
assembly of a new growth cone, increase in de novo protein synthesis, appropriate 
retrograde and anterograde transports, heightened responsiveness to trophic support and 
downregulation of inhibitory extracellular cues (Brosius Lutz and Barres, 2014). It is a 
robust but sometimes incomplete process with some drawbacks. Hence, in several cases 
regrowth does not lead to a complete functional recovery due to misrouting of 
regenerative sprouts, lack of efficient guidance mechanisms or increased branching of 
regenerating axons. These erroneous processes lead to incorrect reinnervation, motor 
deficits and disturbed sensory function (Hamilton et al., 2011). 
 
 
Final remarks 
In summary, successful regeneration depends on tightly controlled cellular and molecular 
programs and is only achieved in the presence of a permissive environment. So far, the 
regenerating properties of FAP peripheral nerves or their behavior to an injury stimulus 
remains unanswered. As such, further knowledge is needed to improve axonal 
regeneration or prevent neurodegeneration caused by the deposition of TTR aggregates 
and associated toxic signaling cascades. The present study addressed some of these 
issues to provide new insights on molecular signaling mechanisms associated with FAP 
pathology, in order to establish new potential therapeutic targets. 
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Research Goals 
In the present research project we proposed to clarify the FAP peripheral nerve response 
to an injury stimulus and the impact of inflammation and ECM remodeling in non-fibrillar 
TTR deposition. Alternative strategies for TTR amyloidosis are still awaited and this 
knowledge will allow for the development of novel therapeutic interventions. Additionally, 
we investigated the hypothesis of TTR internalization by cellular components of the PNS. 
Specifically, the following aims were covered:  
 
Chapter I: Evaluate in vivo the influence of heparan sulfate proteoglycans in nerve TTR 
deposition;  
 
Chapter II: Characterize the nerve response to injury, using an FAP mouse model, and 
investigate the effect of neuroinflammation over TTR deposition, contributing for a better 
understanding of the pathogenesis of TTR related amyloidosis; 
 
Chapters III and IV: Propose a new therapeutic strategy for FAP, by in vivo preclinical 
studies with the anti-inflammatory drug Anakinra, and assess the effect of this protective 
approach regarding neuroregeneration after peripheral nerve insult. 
 
Chapter V: Investigate the ability of glial cells for TTR internalization and degradation in 
tissues from an FAP mouse model and in sural nerve biopsies from FAP patients or 
healthy control subjects. 
 
 
 
 
 
 
 
 
  
  
 
  
  
 
 
 
 
 
 
 
Chapter I 
A novel nanoparticle delivery system for in vivo targeting 
of the sciatic nerve: evaluation of heparan sulfate 
influence on transthyretin deposition 
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Abstract 
Familial Amyloidotic Polyneuropathy (FAP) is an autosomal dominant neurodegenerative 
disorder characterized by extracellular deposition of mutant transthyretin (TTR) 
aggregates and amyloid fibrils, particularly in the peripheral nervous system (PNS). 
Recent studies indicate the potential involvement of heparan sulfate proteoglycans with 
amyloidogenic proteins and in modulation of TTR deposition. In the present work, nerve 
biopsies from human asymptomatic carriers and FAP patients were analyzed for heparan 
sulfate content and although mainly associated with amyloid fibrils, this molecule is also 
upregulated in earlier stages of disease, in association with non-fibrillogenic aggregates. 
Therefore, to study in vivo the role of glycosaminoglycans (GAGs) in TTR deposition, we 
developed a novel local delivery system into mice sciatic nerve using heparin/chitosan 
(CH) nanoparticles. To address drug release and diffusion throughout nerve tissue, 
fluorescently labeled CH and heparin were used and applied to sciatic nerves of wild-type 
(WT) mice. Our results show maximal absorption throughout the nerve extracellular matrix 
(ECM) at day 15 and no major inflammatory response activation, indicating this as a safe 
and biocompatible system for nerve delivery. Using this optimized system, heparin/CH 
nanoparticles were locally injected into sciatic nerve of transgenic mice carrying the most 
prevalent TTR mutation – V30M, in a Ttr null background and heterozygous for the heat 
shock factor 1 (Hsf-1), having in average 14 months of age. Contralateral nerve receiving 
uncoupled CH particles was used as control. Fifteen days after nanoparticles application, 
both heparan sulfate levels and non-fibrillar TTR deposition significantly increased in 
treated nerves, although no amyloid was detected, by Congo red staining. Our work 
demonstrates that changes in proteoglycan type and distribution could possibly account 
for alteration of the physical properties of tissues, increasing TTR deposition in vivo. 
Moreover, this new and versatile nanoparticle delivery system opens novel avenues in the 
field of neuropathology and probably in the design of therapeutic strategies targeting 
directly nerve tissue. 
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Introduction 
Peripheral neuropathy is associated with damage to the peripheral nervous system (PNS), 
outside the brain and the spinal cord. PNS problems are common and encompass a large 
spectrum of traumatic injuries, diseases, tumors or iatrogenic lesions (Rodriguez et al., 
2004). In peripheral neuropathies, such as diabetic neuropathy, polyradiculopathy, 
Charcot-Marie Tooth disease, Familial Amyloidotic Polyneuropathy (FAP), traumatic nerve 
lesions or secondary neuropathies due to alcoholism or HIV-1 infection are major causes 
to morbidity, being the conventional treatments primarily palliative rather than curative 
(Apfel, 1999). Symptoms depend on the type, number and localization of the affected 
nerves in the body, with pain or loss of sensation often produced.  
FAP is an autosomal dominant neurodegenerative disorder characterized by extracellular 
deposition of mutant TTR aggregates and amyloid fibrils, particularly in the PNS (Coimbra 
and Andrade, 1971b). It is well known that extracellular matrix (ECM) remodeling 
contribute to the progress of this disease; some ECM-related genes are upregulated in 
nerve biopsies from FAP patients (Sousa et al., 2005) carrying the most prevalent TTR 
mutation, the V30M (Saraiva et al., 1984), and in tissues from FAP transgenic mouse 
models (Cardoso et al., 2008). One of those genes is biglycan that was found 
overexpressed at early stages of disease, before amyloid deposition (Sousa et al., 2005; 
Cardoso et al., 2008). Neutrophil gelatinase-associated lipocalin (NGAL), chondroitin 
sulfate and matrix metalloproteinase-9 (MMP-9) are upregulated only when TTR fibrils are 
already present, all colocalizing in later stages with amyloid deposits (Sousa et al., 2005; 
Cardoso et al., 2008). Heparan sulfate proteoglycans are glycoproteins of the ECM, 
covalently attached to chains of the glycosaminoglycan (GAG) heparan sulfate (Häcker et 
al., 2005). They have been identified as a codeposited component of amyloid in amyloid-
related disorders (Ancsin, 2003), indicating that ECM remodeling occurs continuously until 
the later stages of disease. Moreover, recent in vitro studies and in vivo approaches in a 
Drosophila model indicate the potential involvement of heparin and heparan sulfate 
proteoglycans as enhancers of the amyloidogenic cascade, prompting TTR fibrillogenesis 
(Bourgault et al., 2011; Noborn et al., 2011; Di Domisio et al., 2012). In the present work 
our aim was to evaluate, in a mouse model of FAP, how changes in GAGs type and 
distribution could alter the nerve metabolism promoting TTR fibrillogenesis and deposition. 
In order to deliver drugs directly into the nerve tissue, while improving the half-life and 
efficacy of agents, a novel cationic nanoparticle-based delivery system composed of 
chitosan (CH) and heparin was established, having as long-term objective the 
development of novel therapeutic tools. We selected CH as a starting material in the 
design of vectors for heparin delivery to the nerve due to its well-established properties: 
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high biocompatibility, biodegradability, non-toxicity and non-antigenicity (Luo and Wang, 
2014). Furthermore, CH presents a mucoadhesive character, which increases residual 
time at the target of absorption (Liu et al., 2007). In addition, it was previously reported 
that this biomaterial did not cause any damage to the nerve tissue when applied in nerve 
guides (Li et al., 2010). 
Heparin is a polyanionic mucopolysaccharide and a well-known anticoagulant, associated 
to gastric ulcer healing (Lin et al., 2009). It has been used to optimize and extend the 
delivery kinetics of growth factors, prevent its degradation and enhance binding to cell 
surface receptors (Chu et al., 2010). Heparin has a similar structure with heparan sulfate; 
however, has a short biologic half-life (approximately one hour) and if directly injected in 
the sciatic nerve it will be rapidly cleared by phagocytic cells. Indeed the development of a 
delivery system that allows the release of heparin in a local and controlled fashion to the 
nerve tissue is paramount. 
Main technical challenges are posed in order to achieve a safe and efficient delivery 
system to the peripheral nerve: (i) the drug must be efficiently absorbed; (ii) the 
administration has to be minimally invasive as not to induce severe secondary 
inflammatory reactions; (iii) sustained drug delivery must be attained and (iv) the delivered 
molecules need protection from biodegradative agents. Heparin, due to its highly negative 
charge can interact electrostatically with CH forming stable nanoparticles that will protect it 
from degradation while allowing it to be slowly released to the tissue (Liu et al., 2007; 
Boddohi et al., 2009). Thus, in the present work we prepared heparin/CH nanoparticles, 
studied heparin delivery as a function of time, evaluated the inflammatory response 
resulting from the nanoparticle delivery system and applied it to an FAP mouse model to 
address TTR nerve deposition. 
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Materials and Methods 
 
Materials 
Fluorescein labeled heparin (heparin-fluor) was purchased from Molecular Probes. The 
heparin used in the FAP mouse model (14 kDa, a kind gift from Dr. Jin Ping-Li, Upsala 
University, Sweden), was prepared from pig intestinal mucosa and had no anticoagulant 
activity. Technical grade CH (Chimarin™, degree acetylation (DA) 13%, apparent 
viscosity 8 mPas) was supplied by Medicarb. The average molecular weight of the starting 
material was found to be 7.8 ± 0.5x104 (GPC in 0.5 M CH3COOH - 0.2 M CH3COONa, 
25ºC) (Moreira et al., 2009). Endotoxin levels of the purified CH extracts were assessed 
using the Limulus Amebocyte Lysate Assay (QCL-1000®), following the manufacturer’s 
instructions. Endotoxin levels were found to be below 0.1 EU/mL, respecting the US 
Department of Health and Human Services guidelines for implantable devices. MatrigelTM, 
with a protein concentration of 9.5 mg/mL and 2.0 EU/mL endotoxin units, was obtained 
from BD Biosciences. Unless mentioned otherwise, all reagents were obtained from 
Sigma-Aldrich and were of analytical grade. 
 
Preparation of heparin/CH nanoparticles 
A rhodamine activated derivative [5(6)-Carboxy-X-rhodamine N-succinimidyl ester, ROX; 
Fluka®] was used to label CH. In brief, 10 mg of CH was dissolved overnight in 10 mL of 
1% acetic acid solution and added to an equal volume of ROX solution (0.13 mg/mL-1 in 
dehydrated methanol, Molecular Sieves, Merck). The reaction was let to occur for 3 h, 
under constant stirring, protected from light. The fluorescently-labeled CH (CHROX) was 
recovered by precipitation with 5 mL of 0.5 M NaOH. The precipitated polymer was 
washed with deionized water until no fluorescence was detected in the supernatant and, 
subsequently, freeze-dried. CH and CHROX solutions were prepared as follows: 10 mg of 
polymer was dissolved overnight in 4 mL of 1% acetic acid. Afterwards, 4 mL of 5 mM 
acetate buffer pH 5.5 was added and the pH of the solution adjusted to 5.5 with 1 M 
NaOH. The volume was completed to 10 mL with 5 mM acetate buffer pH 5.5 and the 
resulting solutions were stored at -20ºC until further use. Heparin-fluor was suspended in 
filtered ultrapure water to a final concentration of 1 mg/mL. Three kinds of CH particles 
were prepared, CH/heparin-fluor, CHROX/heparin-fluor and CH/heparin. All nanoparticle 
types were obtained by the addition of 10 µL of heparin solution into 25 µL of CH solution 
under vortex (100 rpm) for 30 s, at room temperature, according to Liu et al., (2007). 
Subsequently, the nanoparticles were let to stabilize for 15 min at room temperature 
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before further use. For comparison, 10 µL of heparin solution was mixed with 25 µL of a 
matrigel solution. 
 
Characterization of heparin/CH nanoparticles 
Particle size, polydispersity index (PDI) and zeta potential measurements were carried out 
on a dynamic light scattering (DLS) instrument (Zetasizer® Nano ZS). The Smoluchowski 
model was applied for zeta potential determination and cumulative analysis was used for 
mean particle size determination. All measurements were performed in triplicate, at 25°C. 
The morphology of prepared nanoparticles was examined by transmission electron 
microscopy (JEM-1400TM). A total of 10 µL of nanoparticle suspension was placed onto a 
300 mesh carbon-coated nickel grids for 2 min and after air-drying the samples were 
observed. 
 
Human samples 
Human tissue biopsy was performed after informed consent and approval from the Ethics 
Committee of the Hospital Geral de Santo António (Porto, Portugal), following the 
declaration of Helsinki. Archival sural nerve biopsy samples obtained from FAP V30M 
patients (n=3), asymptomatic carriers (n=3) and normal control subjects (n=3) were 
previously characterized for TTR deposition.  
 
Animals and surgical procedures 
Wild-type (WT) mice (in the 129/sv background with an average age of 12 months) and an 
FAP mouse model carrying the human V30M mutation, in an Hsf-1 heterozygous 
background (Santos et al., 2010b), with 14 months-old, were used in the experiments 
(total n=48 for WT and n=5 for transgenic mice, as described throughout the text). The 
required total number of animals was approved by the Institute Ethical Committee (Porto, 
Portugal) as well as by the National General Veterinarian Board (Lisbon, Portugal). All 
animal experiments were carried out in accordance with the European Community Council 
Directive. The animals were anesthetized by intraperitoneal injection with a premixed 
solution containing ketamine (75 mg/kg) plus medetomidine (1 mg/kg). After skin incision 
and muscle dissection, the sciatic nerve was exposed in the mid-thigh and dissected free 
from the surrounding tissue. In the left side, heparin/CH nanoparticles were applied under 
the nerve; the right side served as control nerve for uncoupled CH nanoparticles. Animals 
were kept in the animal facility in a controlled-temperature room, maintained under a 12 h 
light/dark period and with water and food ad libitum. Mice were sacrificed and their sciatic 
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nerves exposed and excised either for direct observation by confocal microscopy or for 
processing in frozen and paraffin sections. 
 
Fluorescence Microscopy 
Sciatic nerves from mice that received CHROX/heparin-fluorescein labeled nanoparticles 
were taken to direct observation by confocal microscopy (Leica SP2 AOBS SE) for 
colocalization of heparin-fluor with CHROX in the tissue.  
In most experiments that followed, the sciatic nerves were collected to a solution 
containing sodium m-periodate, L-lisine and 4% paraformaldehyde (MERCK) and left 
overnight at 4ºC followed by washing in 0.1 M Sorrenson´s phosphate buffer solution and  
cryoprotection (20% anhydrous glycerol and 0.4 M Sorrenson´s phosphate buffer). Eight 
µm frozen sections were cut using a freezing cryostat; immunofluorescence was 
performed and the slides were directly mounted with Vectashield with 4’.6-diamino-2-
phenylindole (DAPI) (Vector). Antibodies used were: rabbit anti-collagen IV (1:600, 
Abcam), rabbit anti-protein gene product 9.5 (PGP 9.5, 1:800, Serotec) and rabbit anti-S-
100 (1:100, DAKO). The secondary antibody was goat anti-rabbit Alexa Fluor 568 
(Molecular Probes), diluted 1:1,000 in 4% fetal bovine serum and 1% bovine serum 
albumin in PBS blocking buffer. The slides were visualized in a Zeiss Axio Imager 
microscope. 
Quantification of intensity of green fluorescence was performed using frozen sections of 
sciatic nerves. Each sample was evaluated in 4 or 5 different areas, using an inverted 
fluorescent microscope (Axiovert 200M, Zeiss). Fluorescence intensity was determined by 
image analysis using Axiovision software (4.8, Zeiss). 
 
Immunohistochemistry and Double Immunofluorescence 
In other experiments, sciatic nerves were collected to 10% formalin and embedded in 
paraffin blocks. Three μm-thick sections were deparaffinated in histoclear (National 
Diagnostics) and hydrated in a descent alcohol series. Endogenous peroxidase activity 
was inhibited with 3% hydrogen peroxide solution in methanol and sections were blocked 
with 4% fetal bovine serum and 1% bovine serum albumin in PBS. Primary antibodies 
used were: goat polyclonal anti-TNF-α (1:50, Santa Cruz Biotechnology), goat polyclonal 
anti-IL-1β (1:50, Santa Cruz Biotechnology), goat polyclonal anti-ionized calcium-binding 
adapter molecule 1 (IBA1), for macrophage detection, (1:200, Abcam), rabbit polyclonal 
anti-TTR (1:500, DAKO) and mouse monoclonal anti-heparan sulfate (1:100, Amsbio). 
Antigen visualization was performed with the 3.3´-diaminobenzidine (Sigma-Aldrich).  
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Semi-quantitative analysis of the immunostained area was performed with the Image Pro-
plus software (Media Cybernetics). Results shown represent the area occupied by pixels 
corresponding to the immunohistochemical substrate's color that is normalized relatively 
to the total area, with the corresponding standard error of the mean (SEM). Each animal 
tissue was evaluated in five different areas with 20 X magnification. 
For confocal microscopy, paraffin sections of human sural nerve biopsies and sciatic 
nerves from the FAP mouse model were deparaffinated, hydrated and double stained with 
rabbit anti-TTR (1:100, DAKO) and mouse anti-heparan sulfate (1:100, Amsbio). Donkey 
anti-rabbit Alexa Fluor 568 and goat anti-mouse Alexa Fluor 488 were used as secondary 
antibodies. 
 
Congo red staining  
The presence of amyloid deposits in treated sciatic nerves was investigated by Congo red 
staining and observation performed under polarized light. Briefly, deparaffinized tissue 
sections were incubated for 20 min with 0.01% sodium hydroxide in 80% ethanol 
saturated with sodium chloride followed by staining with 0.5% Congo red in the previous 
solution (Puchtler and Sweat, 1965). Next, preparations were washed with distilled water, 
stained with hematoxilin and analyzed under polarized light. In the positive controls, 
amyloid was identified by characteristic green birefringence. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 5.0 for Windows. Results are 
reported as mean ± SEM. Student’s t-test or two-way analysis of variance (ANOVA) 
followed by Bonferroni post-test, were used and considered statistically significant when 
*p<0.05. 
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Results 
 
Evaluation of heparan sulfate levels in human nerve biopsies 
It was previously found in vitro, in a Drosophila model and in heart human specimens that 
TTR fibril extracts contain heparan sulfate proteoglycans (Bourgault et al., 2011; Noborn 
et al., 2011). Thus, we started by comparing heparan sulfate levels on sural nerve 
biopsies from FAP patients, asymptomatic carriers and healthy control subjects (n=3 per 
group). Histological examination revealed that this GAG is already upregulated in the 
earlier asymptomatic stage of disease, when only non-fibrillar TTR deposits are present in 
the peripheral nerve (Figure 1A). With disease progress, heparan sulfate immunoreactivity 
increases, in a pattern similar to TTR deposition (Figure 1A). In addition, using confocal 
microscopy, colocalization between TTR and heparan sulfate was noticed, corroborating 
the notion that this GAG is incorporated in FAP amyloid deposits (Figure 1B). 
 
 
Figure 1 – Heparan sulfate immunoreactivity in human sural nerve biopsies. A) Histological 
examination of heparan sulfate levels in sural nerve biopsies from healthy control individuals 
(Normal), FAP asymptomatic carriers (FAP 0) and FAP patients with different patterns of amyloid 
deposition (FAP 1, 2 or 3). Scale bar 100 µm. B) Representative photomicrographs obtained with 
confocal microscopy showing colocalization (yellow and orange in merged panel, arrows) between 
TTR (red) and heparan sulfate (green) in sural nerve biopsies from FAP patients. Scale bar 15 μm.  
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Vehicle for the delivery system: Heparin/CH nanoparticles versus Matrigel 
Based on the previous results, we aimed at developing a delivery system for the release 
of heparin into sciatic nerves of FAP mice, with the ultimate goal of understanding the 
heparan sulfate influence on TTR polymerization in vivo. 
CH and matrigel were first assessed as vehicles for heparin nerve release. Distribution of 
fluorescent heparin in nerve frozen sections was compared 5, 10 and 15 days after 
application (n=3 WT animals for each time and each vehicle). Five days post-surgery, the 
spreading of heparin fluorescence was similar for both vehicles (Figure 2); at day 10 or 
15, fluorescence was found at the surface of the nerve, most likely in the perineurium, in 
the group treated with heparin/matrigel while animals receiving heparin/CH nanoparticles 
showed heparin diffused into the nerve tissue, as documented in Figure 2 (day 15 not 
shown).  
 
 
 
 
 
 
 
 
 
 
Figure 2 – Heparin-fluorescein diffusion pattern in nerve tissue, when conjugated with CH or 
matrigel. Representative fluorescence intensity of heparin, 5 and 10 days after CH nanoparticle or 
matrigel conjugate application. Sciatic nerve frozen sections were analyzed with an Axiovert 
microscope. Scale bar 50 µm. 
 
These results, plus the biological advantages of CH, lead us to choose the CH-based 
system to continue the heparin delivery studies. 
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Characterization of Heparin/CH nanoparticles 
The heparin/CH nanoparticle size (diameter, nm), PDI and zeta potential (mV) values are 
reported in Figure 3. As observed in Figure 3A a monomodal population was obtained in 
terms of size, with a positive net charge. The nanoparticles were spherical in shape as 
determined by electron microscopy analysis (Figure 3C) that corroborated the results of 
DLS in terms of the nanoparticle size.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Characterization of heparin/CH nanoparticles. A) & B) Size, PDI and zeta potential 
measurements, using DLS. C) Assessment of nanoparticle morphology and size by microscopy. 
 
Heparin release in the sciatic nerve as a function of time 
In order to monitor heparin release by CH and its diffusion throughout sciatic nerve, we 
conjugated CH with rhodamine (CHROX) before mixing with heparin-fluor; after 5, 10, 15, 
30 and 45 days of application of CHROX/heparin-fluor nanoparticles in the sciatic nerves 
(n=3 animals for each time point), fresh, unprocessed nerves were analyzed by confocal 
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microscopy (Figure 4A). On day 5, both fluorochromes were detected at the surface of the 
nerve and merging suggested colocalization of CHROX with heparin-fluor. This surface 
colocalization was partially observed at day 10; however, at this time point, heparin-fluor 
was also found in the interior of the nerve, without CHROX colocalization as indicated by 
an arrow in Figure 4A. A control nerve with CHROX alone shows CH distribution only at 
the surface of the nerve. All together, these results indicated that heparin was being 
released by the CH nanoparticle, located at the surface and then diffused into the tissue. 
At day 15, CH particles were also diffusing into the nerve and heparin was released since 
regions with no colocalization were found, suggesting continuous delivery of the drug from 
the nanoparticle (arrows in Figure 4A). At day 10 the intensity of the green fluorescence 
signal was greater than on day 5 and this had increased by day 15 (Figure 4B). On day 30 
a very weak green staining was visible, without CHROX signal, while at day 45 no signal 
was detected (data not shown). We therefore considered 15 days after application to be 
the best time for subsequent analyses of heparin tissue distribution. 
  
Figure 4 – Heparin release as a function of time studied in fresh unfixed nerve. A) Confocal 
photomicrographs denoting heparin-fluor in green and rhodamine-labeled CH in red. Superposition 
of the labels is shown (Merge). No colocalization of the two labels is indicated by arrows. Control 
nerve is rhodamine-CH (CHROX). Scale bar 50 µm. B) Semi-quantitative analysis of fluorescent 
heparin in the interior of the sciatic nerve. Bars represent normalized fluorescence intensity of 
analyzed image area reported as the mean ± SEM. SEM values are too small and would be 
virtually invisible on chart. *p<0.05, compared with 5 days.  
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Heparin localization within nerve structures 
We next investigated the localization of released heparin in sciatic nerves, 15 days post-
application (n=4). Frozen sections were analyzed by immunofluorescence with molecular 
markers of different nerve structures to colocalize with heparin-fluor (Figure 5). PGP 9.5 
was used as a neuronal marker and S-100 as a marker of Schwann cells; with these 
markers few or none colocalization with fluorescent heparin was observed. Colocalization 
between heparin and collagen IV was clear; since collagen IV is the major constituent of 
the ECM, the results are indicative that heparin localized in the ECM and possibly at 
basement membranes of Schwann cells. 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Localization of heparin-fluorescein within nerve structures at day 15 after 
application of heparin/CH nanoparticles. Frozen sections through mice sciatic nerve were 
labeled with antibodies to collagen IV (red), PGP 9.5 (red) and S-100 (red). The green panel 
represents heparin-fluor. Superposition of the labels is shown (Merge). Colocalization was detected 
with collagen IV, in a higher extent than with axons (PGP 9.5) or Schwann cells (S-100), 
suggesting heparin delivery into the ECM. The control nerve derives from application of uncoupled 
CH in the contralateral nerve. Scale bar 100 µm. 
 
Inflammatory Reactions 
Macrophages and the pro-inflammatory cytokines TNF-α and IL-1β were evaluated by 
semi-quantitative immunohistochemistry (SQ-IHC) in paraffin sections at days 15, 30 and 
45 (n=3 animals for each group) post-application of CH/heparin-fluor nanoparticles; as 
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control we used the contralateral nerves where uncoupled CH particles were deposited; 
n=2 mice treated with the same volume of water and sacrificed at day 15 served as sham.  
We could perceive some degree of macrophage activation on the time point of maximal 
heparin release to the interior of the nerve tissue when compared to the sham nerve; the 
slight activation was found to decrease with time, being virtually abolished at 45 days after 
nanoparticle application (Figure 6). The level of activation was similar to the control side 
(uncoupled CH), suggesting that the mild immunological reaction was attributable to the 
vehicle. TNF-α levels were increased in both nerves (CH/heparin and control uncoupled 
CH nanoparticles) at day 15 and also decreased with time (Figure 6). Forty-five days after, 
stabilization of the reactivity was observed. Comparing this response with sham nerve, we 
also concluded that the mild inflammatory reaction is due to CH and that a low percentage 
is due to surgery. The same situation was evident concerning IL-1β staining (data not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Evaluation of the inflammatory response. A) Macrophage (scale bar 50 µm) and 
TNF-α (scale bar 100 µm) labeling in sciatic nerves treated with heparin coupled or uncoupled CH 
nanoparticles. Sham represents application of water. B) Histological examination demonstrated an 
increase in the levels of TNF-α and activated macrophages in treated nerves as compared with 
sham. In addition, a significant decrease of the inflammatory response with time was noticed 
(*p<0.05). 
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Effect of heparin delivery over TTR deposition in an FAP mouse model  
After optimization and characterization of the delivery system, heparin/CH nanoparticles 
were applied into the sciatic nerve of TTR transgenic mice, to evaluate the effect of 
heparin on TTR deposition, in vivo (n=5). After 15 days, nerves were analyzed by 
immunohistochemistry and the levels of heparan sulfate and non-fibrillar TTR were both 
significantly increased in heparin treated nerves as compared with sham (Figure 7A). 
Congo red staining was negative, possibly because deposits were too small to be 
Congophilic. Moreover, areas of colocalization between TTR and heparan sulfate were 
perceived, suggesting that increase in heparan sulfate might contribute for TTR 
polymerization and deposition (Figure 7B).  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Heparin release to the sciatic nerve upregulate local non-fibrillar TTR deposition 
in a mouse model of FAP. A) Representative SQ-IHC for TTR in sciatic nerve of Hsf/V30M mice 
treated with heparin/CH or uncoupled nanoparticles (sham). Scale bar 100 µm. Histograms 
represent quantification of immunohistochemical images and data is presented as percentage of 
area occupied ± SEM (*p<0.05). B) Double immunofluorescence between TTR and heparan sulfate 
in Hsf/V30M heparin/CH treated sciatic nerve, demonstrating colocalization between the 2 proteins 
(merged panel, scale bar 5 µm). Nuclei stained blue with DAPI. 
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Discussion 
In this study, our primary goal was to evaluate if heparan sulfate was associated with TTR 
deposition in peripheral nerve biopsies from FAP patients. Immunohistological 
examination of sural nerves from patients, asymptomatic carriers and control individuals 
revealed substantial heparan sulfate accumulation within TTR amyloid deposits and also 
colocalization with non-fibrillar species. This finding prompts us to explore the potential of 
this GAG in TTR behavior and aggregation pathway in a mouse model of FAP disease. 
However, to address this point, a local delivery system into the sciatic nerve, based on 
heparin, need to be optimized. 
Growing interest has been focused on nanomedicine as it can bring novel approaches 
towards the prevention, diagnosis and treatment of various diseases (Gharagozloo et al., 
2015). CH is a natural polymer, with a cationic character that due to its biocompatibility 
and low cytotoxicity is emerging as a drug vehicle in tissue engineering and as a non-viral 
vector for gene therapy (Moreira et al., 2009).  
Previous studies have been done to deeply characterize heparin/CH nanoparticles (Liu et 
al., 2007; Boddohi et al., 2009). Therefore some delivery systems were optimized in order 
to improve the absorption of heparin by the blood flow, locally by the gastric epithelium or 
by the lungs (Lin et al., 2009; Chen et al., 2009; Trapani et al., 2013). In these studies, 
nanoparticles were produced by combining positively charged chitosan with negatively 
charged heparin, in a ratio that produce minimum particle size with a positive zeta 
potential, strategy also followed in the present work. Initially CH and matrigel, in the form 
of nanoparticles and physical gel, respectively, were compared as vehicles for heparin 
release in the nerve. As CH-based nanoparticles were the only able to efficiently deliver 
heparin inside the nerves, this last was the chosen system to apply in the subsequent 
steps of the study. Nanosized heparin/CH particles were efficiently produced and found to 
be in the size range of what has been previously described in the literature (Mao et al., 
2001; Oliveira et al., 2010), presenting several advantages regarding intra-nerve delivery. 
The condensation in the form of nanoparticles allows the penetration into the tissues and 
at the same time enables the escape from a number of cellular barriers, enzymatic 
degradation and cellular uptake, therefore enhancing drug delivery in the target tissues 
(Huang et al., 2002). Moreover, if a successful drug delivery system is aimed, a localized, 
effective and sustained release is paramount for its success. In view of these 
requirements, this novel delivery system has several advantages over other local 
systems, like miniosmotic pumps since these have a large size and could not be placed 
on mouse sciatic nerve for continuous delivery in time. 
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The degradation rate of the delivery system is a paramount factor when considering a 
sustained release throughout time. Indeed, CHROX based nanoparticles were detected 
up to 15 days post-administration, reinforcing its potential for a long-term drug release. As 
previously described, when CH (degree of de-acetylation 90%) was used as a vehicle for 
drug delivery, and after subcutaneous implantation in mice, its biodegradation occurred 
within 3 up to 14-28 days after the injection (Kofuji et al., 2002). In our case, we observed 
that on day 30 post-administration no signal was detected for CHROX based 
nanoparticles, suggesting that the polymer might be degraded in 15 to 30 days post-
surgery. CH biodegradation by lysozyme leads to release of amino sugars of variable 
length, which have rapid clearance by the liver and kidney or can be incorporated into 
GAG metabolic pathways, ending up in skeletal muscle, articular cartilage or connective 
tissue (Baldrick et al., 2010). 
CH nanoparticles promoted a mild inflammatory response, with activation of macrophages 
and increased cytokine production that decreased with time, being virtually abolished at 
45 days after nanoparticle application. This observation complies with the expected 
intrinsic defense response of the body upon a mild exogenous stimulus. As no significant 
inflammatory reaction was triggered, CH seems to be an interesting material for use in the 
PNS, as previously shown with its use in the preparation of nerve guides (Li et al., 2010).  
Finally, CHROX nanoparticles distribution throughout the nerve shows that this 
biomaterial, in the shape of nanoparticles, has the ability to enter into the nerve matrix. 
However, the majority of the nanoparticles are mainly detected in the periphery of the 
tissue, possibly due to the high surface densities of lipid moieties at the nerve surface that 
inhibit elevated penetration of the biomaterial (Pavinatto et al., 2007). Colocalization of CH 
and heparin occurred to some extent, indicating heparin continuous release from the 
nanoparticles and diffusion through the nerve matrix, as pointed out by colocalization with 
collagen IV. 
ECM acts mechanically supporting the cells and regulates their behavior through specific 
interactions mediated by integrin receptors and proteoglycans, having high influence in 
axons or Schwann cells homeostasis (Sorokin et al., 2010). Thus, changes in the 
structure and composition of the ECM may alter tissue metabolism in several ways, such 
as triggering TTR nerve deposition. With optimization of the delivery system, we employed 
heparin/CH or uncoupled nanoparticles into sciatic nerves of FAP transgenic mice. In 
agreement with an earlier report using transgenic flies (Noborn et al., 2011), we confirmed 
that heparin was able to induce TTR aggregation in vivo also in transgenic mice carrying 
the V30M mutation; however, no positive Congo red material was detected, possibly 
related to the size of the aggregated species. It would be valuable to perform further 
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experiments using heparin with different lengths or sulfation degree or even using 
proteoglycans with different chain composition. 
Understanding the pathological mechanisms and molecules underlying TTR deposition is 
of major value for prevention and treatment of TTR amyloidosis. Our data illustrate the 
important role of heparan sulfate/heparin in TTR aggregation and may assist in the design 
of potential therapeutic agents. For instance, the use of heparanase, an enzyme able to 
degrade this GAG, might be a promising future strategy for the exposure or breakdown of 
amyloid deposits (Jendresen et al., 2014). Furthermore, due to the extreme simplicity and 
versatility of this delivery system, it might open new avenues for the establishment of 
more suitable animal models and bring new viewpoints for study the influence of 
modulating proteins involved in neurodegeneration/regeneration. 
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Abstract 
Inflammation is a hallmark of several neurodegenerative disorders including Familial 
Amyloidotic Polyneuropathy (FAP). FAP is associated with extracellular deposition of 
mutant transthyretin (TTR), leading to degeneration of cells and tissues, particularly in the 
peripheral nervous system (PNS). With this work, our goal was to characterize the 
expression/deposition of TTR and the associated inflammatory immune response, 
induced by nerve injury, in wild-type (WT) mice and in a mouse model carrying the most 
common TTR mutation in FAP (V30M). Our results indicate that upon nerve injury TTR is 
significantly produced by Schwann cells and is dynamically regulated over time in V30M 
mice, accompanying a peak of inflammation. Strikingly, TTR V30M deposition in nerve 
tissue occurred, suggesting that inflammation contributes to TTR polymerization. In 
response to nerve injury, V30M mice display a downregulated innate immune response 
when compared to WT mice. More specifically, we saw decreased expression of cytokines 
and chemokines important for the recruitment of immune cells like macrophages and 
neutrophils, known to be important for the tissue regenerative process, which was found 
impaired in V30M mice. In conclusion, with this work we were able to characterize the 
biology of TTR both in WT and V30M animals, upon nerve injury, and found that TTR 
V30M impairs the inflammatory response necessary for nerve regeneration. Taken 
together, our findings suggest that inflammation is an important target to be considered in 
therapeutic strategies for FAP. 
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Introduction 
Amyloidoses constitute a large group of acquired and hereditary disorders characterized 
by the extracellular accumulation of misfolded proteins, sharing a crossed β-sheet 
structure (Westermark, 2005). Among them, transthyretin (TTR) amyloidosis is the most 
common form of hereditary dominant systemic amyloidosis, in which TTR point mutations 
result in deposition of amyloidogenic species in different tissues (Benson and Kincaid, 
2007). The TTR mutation most commonly associated with Familial Amyloidotic 
Polyneuropathy (FAP) is V30M (Saraiva et al., 1984) that leads to extracellular TTR 
deposition particularly at the peripheral and autonomic nervous systems (PNS and ANS, 
respectively), with neuropathy as a cardinal feature. TTR reaches the PNS through the 
cerebrospinal fluid, the  blood-nerve barrier and over contact with peripheral nerve roots 
(Sousa and Saraiva, 2003) accumulating in the endoneurium, near Schwann cells, blood 
vessels and collagen fibrils, ultimately leading to neurodegeneration and cell death 
(Coimbra and Andrade, 1971b).  
TTR functions as a carrier for thyroxine and retinol (Kanai et al., 1968) and is synthesized 
mainly by the liver and the choroid plexuses of the brain (Soprano et al., 1985). Recently, 
minute levels of TTR expression were also found in Schwann cells of the sciatic nerve 
(Murakami et al., 2010). The mechanism leading to TTR deposition in tissues include a 
decrease in its conformational stability with dissociation of the mutant homotetrameric 
form into unfolded monomers that self-assemble forming aggregates, oligomers and 
amyloid fibrils (Quintas el al., 2001).  
The inflammatory response has been shown to be important for the development of 
peripheral neuropathies either by leading to deterioration or to amelioration of the disease 
process (Ydens et al., 2013). In the case of FAP, previous work with nerve biopsies from 
FAP patients shows the close association between production of inflammatory mediators 
and TTR non-fibrillar aggregates or amyloid fibrils deposition, suggesting a prominent role 
for inflammatory pathways in the progress of the disease (Sousa et al., 2001b). 
Additionally, infiltration of inflammatory cells in response to TTR aggregates or amyloid 
fibrils deposition in tissues from FAP patients would be expected. However, despite 
cytokine production by axons, no influx of such cells is found in FAP nerve biopsies (Misu 
et al., 1999; Sousa et al., 2001b), suggesting that mechanisms must operate to prevent or 
inhibit the correct innate immune response. TTR aggregates or amyloid material were 
never found in the PNS of the classical FAP animal models carrying the V30M mutation 
(Sasaki et al., 1986; Nagata el al., 1995; Kohno et al., 1997) which led us to hypothesize 
whether neuroinflammation might be a contributor for TTR production and deposition in 
the PNS. To address this possibility we induced nerve injury, in both wild-type (WT) and in 
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a well-described transgenic mouse for human TTR V30M, in a Ttr null background 
(V30M), and tested in vivo the local effect on TTR synthesis, deposition and the elicited 
inflammatory response.  
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Materials and Methods 
 
Animals  
Six months-old male and female WT and V30M mice, in the 129/Sv background, were 
used for the experiments. This was the chosen age since by this period, V30M mice have 
TTR non-fibrillar deposition in both the gastrointestinal tract and skin but not in the PNS 
(Kohno et al., 1997). Animals were housed in a controlled-temperature room, maintained 
under a 12 h light/dark period, with water and food ad libitum. One or 7 days after injury, 
mice were sacrificed with a lethal injection of a premixed solution containing ketamine and 
medetomidine.  
All animal experiments were carried out in accordance with the European Community 
Council Directive (2010/63/EU) and the number of total animals for this research was 
approved by ethical committee and by National General Veterinarian Board. 
 
Surgical procedures: Sciatic nerve injury 
Anesthesia was induced with a premixed solution containing ketamine (75 mg/kg) plus 
medetomidine (1 mg/kg) and animals received a subcutaneous injection of butorfanol (1 
mg/kg) prior to surgery. The thigh and legs were shaved, disinfected, the eyes coated to 
protect from drying and animals were then placed in abdominal position on a 37ºC heating 
pad. A skin incision of approximately 1 cm was made over the gluteal region exposing the 
left sciatic nerve from the sciatic notch to the point of trifurcation. The ischiocrural 
musculature was prepared with minimal tissue damage to ensure optimal conditions for 
functional recovery. Sciatic nerve ligation, adapted from the method described by 
Brumovsky et al., (2004) was performed using one ligature placed around the sciatic 
nerve at the mid-thigh level, with 5.0 silk. A sham operation was performed similarly at the 
contralateral side, except that the sciatic nerve was not constricted. The skin incision was 
closed with 5.0 silk suture and physiological saline solution was injected subcutaneously. 
Mice were kept in a recovery room with infrared heating lamp for 1-2 h. Post-surgical pain 
treatment consisted of supplying mice subcutaneously with butorfanol every 12 h for the 
first 48 h. The degree of constriction for each nerve after sacrifice and fixation was 
estimated under the dissection microscope and by microscopical observation of 
immunostained sections of the nerve. In all animals a decrease in the diameter of the 
nerve (without marked translucence) and swelling, proximal to the site of constriction, 
were observed. Animals did not show guarding behavior or autotomy, indicating slight 
constriction and not transection (Brumovsky et al., 2004). 
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Nociception evaluation 
To compare the nociceptive response between WT and V30M mice after injury, hot-plate 
and Von Frey tests were performed.  
The thermal response was assessed using the hot-plate test, with a standard 
temperature-controlled plate, prior to (day 0), 2 and 6 days after injury (n=9 WT and n=10 
V30M mice). Mice were placed within a transparent Plexiglas box on a metal surface (hot-
plate analgesia meter, IITC Life Science) at 52°C. Thirty seconds cut-off time was used for 
nonresponsive mice, to avoid possible tissue damage. The latency to respond with a 
hindpaw lick or shake/jump was measured and used as an index of nociception. 
Von Frey filaments were used for the study of mechanical allodynia, before surgery and 5 
days after injury (n=9 WT and n=10 V30M mice). Animals were placed in an opaque cage, 
to avoid visual stimulation, and let 20 min to adapt. Each Von Frey hair was applied to the 
skin of the mid-plantar surface of the hindpaw. This procedure was repeated 10 times with 
each filament, with an average of 20 s between consecutive applications. The force used 
started below the threshold of detection (0.026 g hair) and was increased until 5 or more 
positive scores had been obtained. The withdrawal threshold was expressed in grams. 
 
Walking tract analysis  
Walking tract analysis was performed in WT (n=9) and V30M mice (n=10) to compare 
functional recovery after injury. The hind feet of the mice were coated bilaterally with black 
nontoxic paint and the animals were then allowed to walk along a dark corridor, with 
ordinary white paper on the floor.  
To calculate sciatic functional index (SFI) three classical parameters were determined 
both on the experimental and sham sides, namely: the distance from the heel to the third 
toe (print length), the distance from first to fifth toe (spreading of toes) and the distance 
from the second to the fourth toe (intermediary toe spreading). Footprints made at the 
beginning or the end of the trial were excluded and 3 values were measured from each 
run, for individual step parameter calculation. Tracks were analyzed according to the 
empirical equation developed by de Medinaceli et al., (1982) and adapted by Bain et al., 
(1989) and Hare et al., (1992): SFI = (-38.3 × print length factor) + (109.5 × toe spread 
factor) + (13.3 × intermediary toe spread factor) -8.8. 
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Immunohistochemistry (IHC) and double immunofluorescence 
Sciatic nerve and L4-L6 dorsal root ganglia (DRG) from WT (n=5) and V30M mice (n=5), 
were excised, post-fixed in 10% formalin, embedded in paraffin blocks and cut 
longitudinally at 3 µm. Histoclear (National Diagnostics) was used to deparaffinate the 
sections that were thereafter hydrated in a descent alcohol series. Endogenous 
peroxidase activity was inhibited by 3% hydrogen peroxide in methanol and sections 
blocked with 4% fetal bovine serum and 1% bovine serum albumin in PBS. Primary 
antibodies used were: rabbit polyclonal anti-human TTR (1:1,000, DAKO), rabbit 
polyclonal anti-mouse TTR (1:1,500; Q-Biogen), goat polyclonal anti-TNF-α and IL-1β 
(1:25, Santa Cruz Biotechnology), rat monoclonal anti-F4/80 (1:50, Serotec), rabbit 
polyclonal anti-GAP-43 (1:1,000, Abcam), rabbit polyclonal anti-peripherin (1:1,500, 
Millipore) and rabbit polyclonal anti-ATF-3 (1:100, Santa Cruz Biotechnology). Secondary 
antibodies were biotinylated anti-rabbit, anti-rat (1:200, Vector) or anti-goat IgG (1:200, 
Abcam). ABC kit (Vector) with extravidin-peroxidase was used and labeling was 
performed with 3.3´-diaminobenzidine for antigen visualization. For densitometry analysis 
of the immunostained sections, 5 pictures at 20 X magnification were taken from different 
areas and quantified using the Image pro-plus 5.1 software. Results shown represent the 
area occupied by pixels corresponding to the substrate reaction color that is normalized 
relatively to the total image area, with the corresponding standard error of the mean 
(SEM).   
For double immunofluorescence analyses in the PNS (n=4 mice per group), primary 
antibodies against human TTR (1:1,000), mouse TTR (1:1,500), mouse monoclonal anti-
albumin (1:2,000, DAKO), mouse monoclonal anti-TAU (1:50, Calbiochem) and goat 
polyclonal anti-Oct-6 (1:25, Santa Cruz Biotechnology), were diluted using a blocking 
solution containing 10% fetal bovine serum, 1% bovine serum albumin and 0.5% Triton X-
100. Secondary antibodies included donkey anti-rabbit Alexa Fluor 488, donkey anti-goat 
Alexa Fluor 568 and donkey anti-mouse Alexa Fluor 568 (1:1,000, Molecular Probes). 
Slides were mounted with Vectashield containing 4’.6-diamino-2-phenylindole (DAPI) 
(Vector) and visualized in a Zeiss Axio Imager or confocal microscope. 
 
Congo red 
The presence of amyloid deposits in PNS sections (n=5 WT and n=5 V30M mice) was 
investigated by Congo red staining according to the method of Puchtler and Sweat (1965). 
Briefly, deparaffinized tissues sections were incubated for 20 min with 0.01% NaOH in 
80% ethanol saturated with NaCl followed by staining with 0.5% Congo red in the previous 
solution. The slides were then washed with tap water, stained with hematoxilin and 
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analyzed under polarized light. Amyloid was identified by the characteristic green 
birefringence, present in positive controls (stomach of old V30M mice). 
 
ELISA IL-1β  
The levels of IL-1β in injured and sham sciatic nerves from both WT (n=3) and V30M 
(n=3) mice were quantitatively determined by enzyme-linked immunosorbent assay 
(ELISA). Briefly, samples were homogenized in cell lysis buffer (Bio-Rad) containing a 
protease inhibitor cocktail (Bio-Rad) and 500 mM phenylmethylsulfonyl fluoride. After 3 
times sonication with 10% power and 40% cycle, 4 s each, samples were centrifuged at 
13,000 rpm for 15 min at 4ºC, supernatants collected and total protein concentration 
determined by the Bradford protein assay (Bio-Rad) for normalization. Sciatic nerves were 
diluted in 0.5% bovine serum albumin in PBS, as needed to a final concentration of 1.5 
mg/mL.  
Samples were run in duplicate and cytokine levels were analyzed according to the 
manufacturer’s instructions (Bio-Rad Laboratories). 
 
ELISA TTR 
Determination of human TTR levels in plasma from V30M uninjured (n=6) and injured 
animals (n=6) was performed by ELISA, normalized to the total protein levels. A 96 well-
plate was coated with rabbit anti-human TTR (Abcam) in 50 mM carbonate/bicarbonate 
buffer 9.6 pH, followed by application of TTR standards (2-37.5 ng/mL) and samples. After 
extensive washes, incubation with primary (sheep anti-hTTR, Abcam) and secondary 
antibodies (donkey anti-sheep, Sigma-Aldrich) was performed. SIGMAFASTTM p-
nitrophenyl phosphate tablets (Sigma-Aldrich) were used for color development and 
values obtained by measuring absorbance at 405 nm in a multiskan ascent microplate 
spectrophotometer (Thermo). Data were analyzed in 2nd-order polynomial quadratic 
equation, accordingly with guidelines from Alnylam Pharmaceuticals. 
 
Real-time polymerase chain reaction (qPCR) 
For messenger RNA (mRNA) extraction, injured and sham sciatic nerves from each strain 
(n=6 per group) were dissected free from surrounded tissues and frozen in RNA later 
(Ambion). Total mRNA was purified using RNeasy Mini columns (Qiagen), according to 
the manufacturer’s instructions, and the quality of extracted mRNA was measured using 
Experion RNA StdSens Analysis Kit (Bio-Rad). Liver mRNA (n=5 per group) was purified 
using phenol extraction (Invitrogen). First-strand cDNA was synthesized using the 
SuperScript double-stranded cDNA Kit (Invitrogen) and subjected to qPCR, in duplicate, 
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using iQ Syber Green Super Mix (Bio-Rad). Reactions were analyzed on Bio-Rad iQ5 
software. Primer sequences were designed using the Beacon software for the following 
genes: mouse Ttr, human TTR, Il-1β, Il-6, Tnf-α, Il-10, Cxcl-3, Cxcl-2, Cxcl-12 and Gapdh 
(Annex). Calibration curves for target and housekeeping genes were constructed using 
10-fold serial cDNA dilutions in duplicates and efficiency accepted between 95 and 117%. 
Differential expression was determined by the 2^-∆∆CT method using Gapdh as the 
housekeeping gene. 
 
Flow cytometry 
After mice anesthesia, injured sciatic nerves of both mouse models (n=9 per group) were 
dissected free from surrounding tissue and digested in fresh culture medium containing 
RPMI 1640 (Lonza), 10 mM HEPES, 5mg/mL bovine serum albumin, 1.6 mg/mL 
collagenase type IV, 200 μg/mL DNase I and 5 mM CaCl2 (all from Sigma-Aldrich), 1 h at 
37ºC. Single cell suspensions were filtered on a 70 µm cell strainer, pre-incubated with 
FcBlock reagent (BD Bioscience) and stained for their surface expression of CD11b and 
Ly6G (Biolegend). Characterization of neutrophil population was CD11b+ and Ly6G+. 
Samples were run on a FACS CALIBUR flow cytometer and analysis performed using 
FlowJo software. 
 
Interference RNA experiment 
For in vivo TTR-silencing studies, TTR or control siRNA (vehicle) were formulated into a 
lipid nanoparticle delivery system (Semple et al., 2010). WT (n=10) and V30M mice 
(n=10) were injected in the tail vein with mouse or human TTR siRNA, respectively, at a 
concentration of 1 mg/kg. A control group receiving vehicle was used, in both mouse 
models (n=9 WT and n=10 V30M). Two days after injection, sciatic nerve injury was 
performed as described above. Two days after injury, a re-injection was made and mice 
were sacrificed 7 days after the surgery. Sciatic nerve was processed as described above 
for IHC against mouse and human TTR and liver extracts used for TTR qPCR.  
 
Immunogold labeling 
Ultrathin sections of distal sciatic nerve stumps from V30M mice (n=4) were fixed on 0.2% 
glutaraldehyde and 2% paraformaldehyde, in phosphate buffer solution, for 2 h and 
subsequently embedded in LR white resin. Nerves were mounted onto nickel grids and 
after 10 min of sodium borohydrate treatment, grids were incubated in 2% gelatin for 20 
min. Blocking in 2% bovine serum albumin in TBS for 1 h followed 5 min incubation in 20 
mM glycine. Anti-human TTR (DAKO) diluted 1:100 in blocking buffer, was used as 
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primary antibody, overnight at 4ºC. In parallel, control sections without primary antibody 
were used. As secondary antibody, anti-rabbit immunoglobulins (British Biocell 
International, 1:20) coupled to 10 nm gold particles were used for 1 h at room 
temperature. Grids were subsequently washed 6 times for 10 min each in pure water and 
stained with uranyl acetate for 3 min and lead citrate for 30 s. Observation was performed 
in a Jeol JEM-1400 electron microscope. 
 
Morphometric analysis 
Morphometric studies were performed on the distal stump of injured sciatic nerves from 
WT (n=4) and V30M mice (n=4), 7 days after injury. A few mm length tissue was removed 
and fixed overnight in a 0.1 M phosphate buffer solution containing 1% glutaraldehyde 
and 4% paraformaldehyde. Tissues were washed for 30 min in 0.1 M phosphate buffer 
and post-fixed with 1% osmium tetroxide in 0.2 M phosphate buffer for 2 h. After a new 
wash of 30 min, the tissue was dehydrated using a series of graded alcohols and 
propylene oxide and finally embedded in epon. Half µm thick transverse sections were cut 
(using SuperNova Reichest Leica ultramicrotome) and stained with 1% toluidine blue, for 
15 s, in an 80°C heating plate, before being examined on a light microscope. 
Using semithin sections, total counts of myelinated fibers were carried out per animal, by 
counting 40 X magnified photographs covering the whole nerve area. To determine the 
density of unmyelinated fibers, ultrathin transverse sections were cut and stained with 
lead uranyl acetate. Sections were then mounted on mesh grids and visualized on a Zeiss 
10C TEM. For each animal density analysis, 20 non-overlapping photographs (7,000 
amplification), corresponding to 7052 µm2 of each ultrathin section, were taken and fibers 
counted. 
 
Statistical analysis 
Quantitative data are expressed as mean ± standard error of the mean (SEM) and were 
analyzed by Student t-test, one-way or two-way ANOVA, followed by Bonferroni post-test. 
Statistical significance was established for *p<0.05, **p<0.01, ***p<0.001. 
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Results 
 
Sciatic nerve injury results in increased local TTR mRNA expression in the V30M 
mouse model  
 
The expression of low levels of TTR mRNA in the sciatic nerve, in basal conditions, both 
in TTR V30M transgenic and WT mice was recently described (Murakami et al., 2010). In 
our study we first assessed expression of TTR mRNA in the sciatic nerve upon injury by 
ligation and found that one day post-injury, TTR mRNA expression in the nerve was 
downregulated both in WT and V30M mice when compared to the respective shams 
(Figure 1A). However, at 7 days post-lesion, expression of TTR mRNA in V30M mice was 
significantly upregulated as compared to the respective sham nerves, in contrast with WT 
mice where differences were not found (Figure 1A). Next, we investigated whether the 
increased TTR mRNA levels in the V30M mice resulted in TTR deposition in the nerve 
tissue. By SQ-IHC of injured and sham nerves of both mice strains, 7 days following 
damage, we found that nerve injury led to TTR immunoreactivity in both nerve segments 
being more prominent in the distal stump (Figure 1B). However, TTR relative 
concentration change was higher in the V30M mice as they presented a TTR fold change 
of 74 in the distal portion versus 26 fold in the WT animals, when compared to the 
respective sham nerves (Figure 1B). Importantly, WT mice have similar levels of TTR in 
plasma (Oliveira et al., 2011), when compared to V30M mice, and therefore this fold 
differences are not due to different copies of the human gene being expressed. 
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Figure 1 – Sciatic nerve injury leads to local upregulation of TTR V30M expression. A) 
Histograms represent TTR mRNA levels in the sciatic nerve of WT (left chart) and V30M mice (right 
chart), 1 and 7 days after lesion (n=6), as compared with sham nerves (n=6). B) Representative 
SQ-IHC against mouse (left panels) and human TTR (right panels) in the proximal and distal 
stumps, 7 days after sciatic nerve injury, as compared with respective sham nerves. Charts 
represent quantification of immunohistochemical images (n=5 V30M and n=5 WT mice; scale bar 
100 μm; **p<0.01 and ***p<0.001).  
 
TTR V30M deposition in the PNS is tissue specific and locates at the extracellular 
matrix 
 
Next, we wondered if the striking TTR deposition after injury in V30M mice was related to 
local synthesis and tissue reactivity or could derive from blood contamination. We started 
by determining if systemic TTR production was recapitulating the striking increase in TTR 
mRNA found in nerves of V30M mice. We found TTR plasma levels of injured and naïve 
V30M mice to be similar (Figure 2A), indicating that liver does not react to this injury 
model. Using double immunofluorescence and an antibody for albumin, an abundant 
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plasma protein, we observed that in WT mice the vast majority of TTR being present in 
the tissue derives from blood contamination (Figure 2B, Merge). However, the partial 
colocalization between albumin and TTR V30M, indicated that only some TTR V30M 
protein reached the nerve via the blood stream (Figure 2B, Merge). To confirm that, we 
further used immunogold for injured nerves of V30M mice and found TTR aggregates in 
the extracellular space, in close association with collagen fibrils (Figure 2C), indicating 
TTR deposition in V30M nerve to be tissue specific. However, the tissue was negative for 
amyloid deposits (data not shown), probably because these aggregated TTR forms are 
not sufficiently mature to appear as Congophilic deposits. 
It was previously shown that siRNA targeting TTR expression by the liver is able to 
remove TTR deposits from tissues (Alvarez et al., 2010). Thus, by using this tool, and 
silencing TTR expression specifically in the liver (99% reduction of TTR synthesis, Figure 
2D) we were able to prevent TTR deposition after injury (Figure 2E). Moreover, several 
cells in the sciatic nerves of V30M mice, but not of WT, still present intracellular TTR 
staining (Figure 2E, right panel). These cells showed colocalization of TTR with Oct-6 
(Figure 2F), a standard marker for differentiated Schwann cells.  
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Figure 2 – TTR V30M present in the sciatic nerve after injury, derived for a minor extent from 
blood and also from local synthesis by Schwann cells. A) TTR V30M plasma levels in 
uninjured and injured animals (7 days after injury, n=6 each). B) Double immunofluorescence of 
TTR (green) and albumin (red). Nuclei stains blue with DAPI. Merged panel shows colocalization in 
yellow. Scale bar 50 μm, n=4. C) Representative image obtained by electron microscopy showing 
TTR V30M aggregates at the nerve extracellular space and in close association with collagen fibrils 
(pointed by red arrows, n=4). Scale bar 100 nm. D) Chart represents Ttr WT (n=5) and TTR V30M 
mRNA (n=5) expressed in liver after treatment with siRNA or vehicle (***p<0.001). E) 
Representative pictures obtained with IHC for TTR in sham, proximal and distal stumps of sciatic 
nerves from WT (left panel, n=10) and V30M (right panel, n=10) mice receiving siRNA or vehicle 
(n=9 WT and n=10 V30M). Scale bar 20 μm. F) Double immunofluorescence between TTR (green) 
and Oct-6 (red) in V30M nerve, denoting colocalization (yellow) and TTR intracellular staining. 
Superposition of the labels, with DAPI, is shown (merge, n=4). Scale bar 5 μm. 
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Additionally, in the V30M mice, sciatic nerve injury triggered TTR deposition in ipsilateral 
and contralateral L4, L5 and L6 DRG (Figure 3A), suggesting the importance of a local 
stimulus in the PNS for mutant TTR deposition. Since TTR deposits in DRG do not 
colocalize with albumin or TAU (Figure 3B and 3C, top panel), we conclude that they were 
tissue specific and located in the extracellular space. Also, using TAU as a marker for 
neurons in the sciatic nerve, TTR presence in axons was ruled out (Figure 3C, bottom 
panel). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Nerve injury leads to TTR deposition in lumbar DRGs of V30M mice. A) 
Representative pictures from IHC for TTR in WT and V30M lumbar DRGs, ipsilateral and 
contralateral to the injury side, 7 days after damage (n=5 WT and n=5 V30M). Scale bar 100 μm. 
B) Merged images of double immunofluorescence between TTR (green) and albumin (red), 
showing that TTR V30M deposition in DRG is not derived from blood contamination (n=4 per 
group). Scale bar 50 μm. C) Double immunofluorescence of TTR and TAU, a neuronal marker, in 
DRG (top panel, scale bar 20 μm) and proximal nerve stump (bottom panel, scale bar 10 μm), 
ruling out TTR localization in neurons after injury (n=4 per group). 
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In response to nerve injury, V30M mice present downregulation in the innate 
immune response when compared to WT mice  
 
It has been shown that, after peripheral nerve injury, dedifferentiated Schwann cells 
produce a pro-inflammatory response which is followed by infiltration of immune cells 
important for tissue recovery (Ydens et al., 2013). In our study, we started by 
characterizing the inflammatory infiltrate after injury in both mice strains. Overall, using 
flow cytometry and SQ-IHC we saw a decrease in the frequency of neutrophils (Figure 4A) 
and macrophages (Figure 4B) in V30M injured nerves when compared with WT nerves, 7 
days after lesion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – Decreased innate immune cell infiltration, after injury in the V30M mouse model. 
A) Seven days following nerve injury, cell suspension was analyzed by flow cytometry (n=9 
mice/group) and the frequency of neutrophils calculated, as shown in the histogram. B) 
Representative SQ-IHC for F4/80, a macrophage marker, in injured sciatic nerves of WT (left 
panel, n=5) and V30M mice (right panel, n=5). Scale bar 50 μm. Chart represents the quantification 
of immunohistochemical images. *p<0.05, **p<0.01 and ***p<0.001. 
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Since V30M mice showed a lower frequency of innate cells in the injured sciatic nerve, we 
next asked if also the production of cytokines was diminished. We found that, after nerve 
injury, V30M animals had lower expression and production of TNF-α (Figure 5A and 5B) 
and IL-1β (Figure 5C and 5D), when compared to WT mice. Additionally, when we looked 
for the expression of another pro-inflammatory cytokine such as Il-6 no differences were 
observed when comparing the two mouse strains (Figure 5E). Interestingly, regarding the 
expression of Il-10, an important anti-inflammatory cytokine (Saraiva and O’Garra, 2010), 
we saw substantial upregulation of this molecule earlier after nerve injury in V30M, in 
contrast with WT mice (Figure 5F). 
Considering the observation that in V30M mice decreased frequency of infiltrating innate 
cells in the nerve occurs we hypothesized if important cues for their recruitment towards 
the nerve were also diminished. We started by analyzing the expression of Cxcl-2, an 
essential chemokine for the recruitment of neutrophils (Haraguchi et al., 2012), Cxcl-3, a 
chemokine important for migration and adhesion of monocytes (Smith et al., 2005) and 
Cxcl-12 that contributes to neurite growth, axon regeneration and mobilization of 
hematopoietic cells (Sheu et al., 2012; Heskamp et al., 2013). Indeed, we found that 
expression of Cxcl-3, Cxcl-2 and Cxcl-12 was downregulated in ligated V30M nerves 
compared to those from WT mice (Figure 5G), 7 days after injury. Moreover, the 
expression of toll-like receptor 1 (Tlr-1) that is typically strongly induced after injury 
(Goethals et al., 2010), was also decreased in V30M mice (Figure 5G). Together, these 
results indicate an overall decreased inflammatory immune response after nerve injury in 
the V30M mouse model in contrast with WT mice. 
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Figure 5 – Decreased innate immune response, after nerve injury, in V30M mice. A) 
Histogram represents Tnf-α mRNA levels, assessed by qPCR, 1 and 7 days after injury in the WT 
(n=6) and V30M mice (n=6). B) Representative SQ-IHC for TNF-α, 7 days after nerve injury, in 
both mouse models (n=5 each, scale bar 50 μm). Chart represents the quantification of 
immunohistochemical images. C) Levels of IL-1β determined by ELISA, in injured and sham nerves 
of both mice strains, 7 days after nerve damage (n=3 each). D) Representative SQ-IHC of IL-1β, 7 
days after nerve injury, in both mouse models (n=5 each, scale bar 50 μm). Chart represents the 
quantification of immunohistochemical images. E) and F) Histograms represent Il-6 and Il-10 
mRNA levels, assessed by qPCR, 1 and 7 days after injury in the WT (n=6) and V30M mice (n=6). 
G) Histogram represents Tlr-1, Cxcl-3, Cxcl-2 and Cxcl-12 mRNA levels, assessed by qPCR, 7 
days after injury in the WT (n=6) and V30M mice (n=6). *p<0.05, **p<0.01, ***p<0.001.  
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After nerve injury, V30M mice present impaired sensory and functional recovery, as 
compared to WT mice 
To compare the sensory response of WT and V30M mice after injury, we performed the 
hot-plate and Von Frey tests. Hot-plate, a standard procedure to measure nociceptive 
response to a noxious thermal stimulus was carried out on day 0, 2 and 6 days after 
injury. In both time points post-injury, WT mice had a quicker response to thermal stimulus 
compared to V30M mice that took in average 29 s to respond (Figure 6A), indicating 
severe hypoalgesia to heat.  
Five days after injury, mechanical allodynia was assessed with Von Frey hair stimulation 
and the nominal force necessary for mice to shake or lick its paw was registered. As 
shown in Figure 6B, even before any nerve injury the values for mechanical pain 
hypersensitivity were different between the two strains. More specifically, V30M mice were 
less sensitive to mechanical touch stimulus. When the mechanical stimulus was applied 
on the plantar surface of the nerve-injured paw, a significant decrease in the paw 
withdrawal threshold was observed in both strains, as mice developed mechanical 
allodynia to a normally innocuous stimulation with the Von Frey filaments (Figure 6B). 
However, V30M mice tended to be less sensitive than WT mice (Figure 6B), suggesting 
reduced neuropathic pain after nerve lesion. 
Finally, recovery of neurological function was also assessed by measuring the sciatic 
functional index (SFI) at day 0, 2 and 6 days after injury (Figure 6C). No differences were 
found at day 0 among the two mice groups but after 2 days, a significant difference was 
revealed as V30M animals presented locomotor deficits compared to WT mice (Figure 
6C). Although not statistically significant, a trend for poor functional recovery of V30M 
mice was also noted 6 days after nerve injury (Figure 6C). 
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Figure 6 – Delayed sensorimotor recovery after injury in V30M mice. A) Nociception 
evaluation with the hot-plate test, showing severe hypoalgesia in V30M mice (n=10), as compared 
with WT (n=9), 2 and 6 days after injury. B) Paw withdrawal threshold evaluated by the Von Frey 
test, 5 days after sciatic nerve injury (n=9 WT and n=10 V30M mice), denoting neuropathic pain 
and a late response in V30M mice before injury. C) Walking tract analysis evaluation (n=9 WT and 
n=10 V30M mice) with poor sciatic functional index regarding V30M mice. *p<0.05 and ***p<0.001. 
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Nerve injury leads to reduced fiber density and lower levels of regeneration 
associated molecules 
 
To evaluate the degree of post-injury neurodegeneration, we performed morphometric 
analysis of the distal stump of ligated nerves versus sham nerves, in WT and V30M mice. 
Thus, we started by analyzing the density of myelinated fibers and found a decrease of 
78% and 93% in WT and V30M injured nerves, respectively, as compared with shams 
(Figure 7A). Using electron microscopy, unmyelinated fiber density was determined 
indicating a reduction of 90% and 98% in injured nerves of WT and V30M, respectively, in 
relation to shams (Figure 7B). Moreover, when comparing fiber density between sham 
nerves, a significant difference was detected, suggesting that mutated non-aggregated 
TTR or the presence of a heterologous human TTR in the nerve of V30M mice decreases 
fiber density, even in the absence of an injury stimulus (Figure 7A and 7B).  
Since 7 days post-injury is near the mid-point of active axonal regrowth (Arthur-Farraj et 
al., 2012), we also investigated levels of regenerating factors in injured nerves of V30M 
mice as compared with WT. Thus, we chose GAP-43, peripherin and ATF-3 as growth 
association markers since their activation after nerve injury and contribution for nerve 
regeneration were previously described (Sensenbrenner et al., 1997; Pearson et al., 2003; 
Girard et al., 2008). As shown in Figure 8, labeling of all biomarkers was significantly 
higher in WT injured nerves as compared with V30M, suggesting a significant delay in 
axonal regeneration in the FAP mouse model. Nadeau et al., (2011) showed that the 
presence of neutrophils is not essential for nerve regeneration; however, macrophages 
arising from resident endoneurial population (Mueller et al., 2003) and from circulating 
blood monocytes are necessary for neural repair after injury (Barrette et al., 2008; Niemi 
et al., 2013). Therefore, it is possible that the phenotype observed for V30M mice 
regarding regeneration results from lower macrophage infiltration to their injured nerves. 
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Figure 7 – Prominent nerve degeneration and lower regeneration ability in V30M mice, after 
injury. A) Morphometric analysis of distal sciatic nerve stumps, 7 days after injury (n=4 each 
strain). Representative images from semithin sections showing decrease in myelinated fibers after 
injury in both WT and V30M mice. Scale bar 20 μm. B) Representative electron microscopy images 
showing fewer unmyelinated fibers after injury, in both mouse strains. Histograms indicate the 
corresponding fiber densities (*p<0.05, **p<0.01 and *** p<0.001).  
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Figure 8 – Impaired activation of regeneration associated molecules in sciatic nerves of 
V30M mice. Representative SQ-IHC for GAP-43, peripherin and ATF-3, 7 days after injury, in WT 
(n=5) and V30M mice (n=5). Scale bar 50 μm. Charts represent the quantification of 
immunohistological images (*p<0.05, **p<0.01, ***p<0.001). 
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Discussion 
FAP is a devastating disorder driven by the accumulation of TTR in its amyloidogenic 
conformation in the PNS (Coimbra and Andrade, 1971b). However, the full spectrum of 
FAP´s pathophysiology has not been completely characterized. Dissection of the cellular 
pathways involved in this disease is of utmost importance for the development of new 
treatment strategies. In FAP patients, with progress of the disease, there is an increase on 
the inflammatory response associated with higher TTR deposition in the peripheral nerve 
(Sousa et al., 2001b). Based on this finding, our hypothesis was that inflammation would 
lead to TTR aggregation and deposition. To answer this question we induced nerve injury 
in the FAP mouse model carrying the V30M mutation but lacking TTR deposits in the PNS 
at a basal state.  
In a basal situation (no injury), the expression of TTR V30M in the sciatic nerve by 
Schwann cells has been already reported by Murakami et al., (2010). However, our study 
shows that upon sciatic nerve injury there is an increased in the expression of local TTR 
V30M by Schwann cells, leading to increase deposition as compared with WT mice. 
Furthermore, we observed that triggering of TTR V30M expression was related with the 
inflammatory threshold since by day 7 following injury, inflammation was considerably 
lower compared to day 1, but still higher than in sham V30M nerves. Sham nerves of both 
V30M and WT mice presented a similar inflammatory response; however, only synthesis 
of TTR V30M was upregulated after injury, thus the altered inflammatory profile in V30M 
mice after nerve lesion can correlate with the TTR mutation itself.  
Schwann cells have the ability to regulate local immune responses by secreting cytokines 
and chemokines thus amplifying the local immune response (Gaudet et al., 2011; Ydens 
et al., 2013). Typically, in V30M human FAP nerve biopsies, despite the continuous 
cytokine production, no immune inflammatory cellular infiltrate is observed around TTR 
aggregates/amyloid deposits thus contributing to slow down TTR clearance and 
aggravating the pathophysiology of the disease (Misu et al., 1999; Sousa et al., 2001b). In 
line with this observation, in our V30M model we found that, 7 days post-injury, neutrophil 
and macrophage infiltration is lower when compared to WT mice. Moreover, it is possible 
that a non-optimal activation of Schwann cells occurred since, after injury, decreased 
expression of Tlr-1, pro-inflammatory cytokines and chemokines was observed, thus 
culminating in a diminished immune cellular activation and infiltration in V30M nerves. In 
accordance with our results, in nerves of FAP patients, Schwann cells are impaired in 
their ability to express chemokines and neurotrophic factors important to drive tissue 
regeneration, contributing this way for neuronal dysfunction present in the disease (Sousa 
et al., 2001b). Additionally, in support of an impaired immune activation, we found a peak 
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of Il-10 expression in V30M mice, but not WT mice, early after nerve injury, which could 
be a hint on the mechanism by which inflammation is hampered in V30M mice in a later 
time point. In fact, increased levels of IL-10 after TTR fibril deposition in FAP biopsies was 
noticed (Sousa et al., 2005).  
It is known that different pH conditions, namely acidified environments, promote TTR 
aggregation (Colon and Kelly, 1992; Lai et al., 1996; Noborn et al., 2011). Also, due to its 
intrinsic unstable quaternary fold, TTR V30M mutant is prone to dissociation into toxic 
aggregates (Quintas el al., 2001; Sousa et al., 2001a). Additionally, levels of heparan 
sulfate proteoglycans increase after injury (Murakami and Yoshida, 2012) and have been 
implicated in the TTR aggregation pathway (Noborn et al., 2011; Gonçalves et al., 2013). 
Taken together, it is possible that nerve injury results in strong non-fibrillar TTR deposition 
in the peripheral nerves of V30M mice due to local increase of heparan sulfate promoted 
by the inflammatory insult and the acidic environment. 
Considering that inflammation is an important feature for tissue regeneration (Gaudet et 
al., 2011; Niemi et al., 2013), we questioned if in our system axonal growth was 
compromised in V30M mice. We found that V30M mice not only showed less sensorial 
response but also presented augmented neurodegeneration with decrease densities of 
both myelinated and unmyelinated fibers, accompanied by decreased levels of 
regeneration markers. Importantly, it should be noted that fiber loss is likely related to the 
conformational structure of mutated TTR and/or with non-fibrillar TTR deposition. In fact, 
Koike et al., (2004) showed that V30M FAP patients with late-onset disease have 
extensive nerve fiber loss in spite of small amount of amyloid deposition. Altogether, these 
results indicate that axons degenerate even when only small amyloid deposits are 
present, supporting cytotoxicity from non-fibrillar TTR (Koike et al., 2004). Differences in 
neuropathic pain and thermal sensitivity, observed in the present work, could be explained 
by reduced neutrophil infiltration in V30M injured nerves (Austin and Moalem-Taylor, 
2010).  
In our model, more than a consequence of absolute increased levels of TTR production in 
nerve, tissue degeneration seen in transgenic mice could also be the direct effect of the 
V30M mutation. Accordingly, we described for the first time sensory and nerve 
morphometric differences in naïve V30M mice as compared to WT, which is indicative of a 
specific phenotype associated with the V30M mutation. In contrast, in WT mice, TTR has 
been shown to be important in sciatic nerve regeneration as compared with TTR-null mice 
(Fleming et al., 2007). 
Senile systemic amyloidosis (SSA), characterized by TTR WT fibrils deposition in the 
heart, has been shown to affect 25% of the elderly population (Pitkänen et al., 1984). In a 
mouse model of SSA, prior to TTR WT local deposition, the heart presents a robust 
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immune inflammatory transcriptional profile (Buxbaum et al., 2012), which supports 
previous data that showed local transcription of inflammatory mediators in nerve biopsies 
from V30M asymptomatic carriers (Sousa et al., 2001b). Based on these observations, 
and on our study, it is fair to speculate that FAP and SSA patients may lay down TTR in 
response to multiple subclinical inflammatory traumas and that inflammation might 
precede TTR deposition in tissues.  
In summary, by promoting an inflammatory local insult we were able to show for the first 
time TTR V30M expression and deposition in the sciatic nerve of a mouse model that 
usually depicts TTR deposition only in the gastrointestinal tract and skin. Overall, we 
provide evidence that inflammation plays an important role at the initiation of FAP 
pathogenesis. This novel finding paves the way to new treatment strategies not only for 
this disease but also for other neurodegenerative disorders where neuroinflammation play 
an important role. 
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Abstract 
Inflammation is a key pathological hallmark of several neurodegenerative disorders 
including Alzheimer’s disease, Parkinson’s disease and Familial Amyloidotic 
Polyneuropathy (FAP). Among all inflammatory cytokines associated with FAP, IL-1β in 
particular has been implicated in playing a key pathogenic role. In the present study we 
sought to investigate whether blocking IL-1β signaling provides disease-modifying benefits 
in an FAP mouse model. 
We assessed the effect of subchronic administration of Anakinra, an IL-1 antagonist, on 
FAP pathogenesis in vivo, using real-time polymerase chain reaction (qPCR), semi-
quantitative immunohistochemistry (SQ-IHC), western blot and nerve morphometric 
analyses. We found that treatment with Anakinra prevents transthyretin (TTR) 
extracellular deposition in sciatic nerve, protecting unmyelinated nerve fibers from 
aggregate-induced degeneration. Moreover, Anakinra administration significantly 
suppressed IL-1 signaling pathway and inhibited apoptosis and endoplasmic reticulum or 
nitrosative stress. The present work highlights the relevance of the IL-1 signaling pathway 
in the pathophysiology of FAP. Our results bring to light the importance of non-amyloid 
targets in the therapeutic strategies for this disorder. Thus, we propose the use of 
Anakinra as a potential therapeutic agent for TTR-related amyloidosis.  
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Introduction 
Inflammation is an essential protective response being a major cofactor involved in the 
pathogenesis of numerous conditions that are often considered non-inflammatory such as 
diabetes (Ehses et al., 2009), atherosclerosis, cancer or amyloid related disorders 
(Hallegua and Weisman, 2002). Different neurodegenerative diseases share an excessive 
activation of common pathogenic pathways, including overexpression of tumor necrosis 
factor α (TNF-α) and interleukin-1β (IL-1β) as in Alzheimer´s, Huntington’s, or Parkinson´s 
disease (Pizza et al., 2011). Inflammation is also observed in Familial Amyloidotic 
Polyneuropathy (FAP) (Sousa et al., 2001b), an autosomal dominant hereditary disorder 
characterized by the extracellular deposition of mutant transthyretin (TTR) aggregates and 
amyloid fibrils, particularly in the peripheral nervous system (PNS). Accumulation of TTR 
aggregates in the PNS leads to peripheral neuropathy, with reduced nerve fiber density 
and destruction of endoneurial blood vessels (Coimbra and Andrade, 1971b).  
TTR is mainly expressed by the liver and the choroid plexuses of the brain (Soprano et al., 
1985) and more than one hundred single point mutations have been described for TTR 
promoting amyloidogenesis (http://amyloidosismutations.com). The most common TTR 
mutation in FAP results from an exchange of a methionine for a valine at position 30 – 
TTR V30M (Saraiva et al., 1984). The mechanism underlying TTR amyloid fibril formation 
is not fully understood. It has been proposed that fibrillogenesis requires dissociation of 
TTR homotetrameric structure into misfolded monomers which self-assemble forming 
non-fibrillar oligomers, protofibrils and finally mature amyloid fibrils (Colon and Kelly, 1992; 
Quintas et al., 2001).  
It has been shown that oligomeric and fibrillar TTR species bind to the receptor for 
advanced glycation end products (RAGE) leading to activation and nuclear translocation 
of nuclear factor κB (NF-κB) (Sousa et al., 2000b), which is known to bind as dimers to 
promoters and enhancers of a variety of inflammation-associated molecules and oxidative 
stress intermediaries, regulating their transcription (Collins et al., 1995; Rhee et al., 2007). 
The pro-inflammatory cytokines will in turn promote NF-κB activation (Hayden and Ghosh, 
2004) with consequent upregulation of RAGE expression via the NF-κB binding elements 
in the RAGE promotor (Li and Schmidt, 1997) ending up in a feedback loop that prompts 
disease, with destructive cell responses. Pro-inflammatory mechanisms are likewise 
upregulated in FAP, especially in endoneurial axons, with increased expression of TNF-α, 
macrophage colony-stimulating factor and IL-1β, since earlier stages of disease and 
increasing with the ongoing neurodegenerative process (Sousa et al., 2001a; Sousa et al., 
2001b). IL-1 exists in two forms: IL-1α and IL-1β exerting its pleiotropic effects by binding 
to the IL-1 type I receptor. IL-1β is a primary regulator of inflammatory and immune 
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responses being also involved in hypotension, fever, neutrophilia, thrombocytosis and in 
the production of acute-phase proteins (Gabey et al., 2010). This cytokine can induce 
apoptosis of different types of cells and stimulate inducible nitric oxide synthase leading to 
stress responses (Schwarznau et al., 2009). IL-1 receptor antagonist (IL-1Ra) is a 
member of the IL-1 family and is a natural endogenous inhibitor of both IL-1α and IL-1β, 
which competitively bind to the IL-1 type I receptor without activating it and thus prevents 
binding and intracellular IL-1 signal transduction. It is produced by hepatocytes, smooth 
muscle cells and macrophages as an anti-inflammatory acute-phase protein (Arend et al., 
1998). 
A non-glycosylated recombinant human IL-1Ra (Anakinra), with similar properties to 
endogenous IL-1Ra, inhibits IL-1 by binding to the IL-1 type I receptor; it is a Food and 
Drug Administration approved drug with application in several human diseases (Dinarello, 
2011; Dinarello et al., 2012) and successful results in clinical trials of human patients with 
rheumatoid arthritis (Botsios et al., 2007) or type 2 diabetes (Larsen et al., 2007).  
Since neuroinflammation is associated with FAP peripheral nerve, the aim of the present 
study was to investigate the effect of blockage IL-1 signaling pathway, by Anakinra, on 
pathological cascades of the disease. To perform this work we used a recent developed 
mouse model (Santos et al., 2010b), carrying the human TTR V30M gene, in a Ttr null 
background and heterozygous for the heat shock factor-1 (Hsf-1), here designated as 
Hsf/V30M mice. 
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Materials and Methods 
Ethics statement 
All animal experiments were carried out in accordance with the European Community 
Council Directive (2010/63/EU) and were approved by the Institutional and National 
General Veterinarian Board ethical committees. 
 
Experimental groups and treatment 
Transgenic mice for human TTR V30M, in the 129/Sv and endogenous Ttr null 
background, heterozygous for Hsf-1 (labeled as Hsf/V30M), with 4.5 months (n=10) were 
treated daily with subcutaneous injections of Anakinra at 25 mg/kg (Kineret®, Biovitrum), 
over 6 weeks. Age-matched control Hsf/V30M untreated mice were injected with 
phosphate buffer saline (PBS, n=10). Animals were housed in a controlled-temperature 
room and maintained under a 12 h light/dark period, with water and food ad libitum. At the 
end of treatment, mice were euthanized with a lethal injection of a premixed solution 
containing ketamine (75 mg/kg) plus medetomidine (1 mg/kg). Unless otherwise 
mentioned, all reagents were obtained from Sigma-Aldrich and were of analytical grade. 
 
Messenger RNA (mRNA) extraction, cDNA synthesis and quantitative real-time 
polymerase chain reaction (qPCR)  
 
mRNA from livers was isolated by phenol extraction (Invitrogen) (n=10 controls and n=10 
treated mice). Dorsal root ganglia (DRG) were dissected free from the spinal cord and 
mRNA extraction (n=7 of each group) performed with RNeasy Mini columns (Qiagen). 
cDNA was synthesized using the SuperScript double-stranded cDNA Kit (Invitrogen). The 
quality of extracted mRNA was measured using Experion mRNA StdSens Analysis Kit 
(Bio-Rad); qPCR was performed with duplicates using iQ Syber Green Super Mix (Bio-
Rad) and reactions were run on an Bio-Rad iQ5 software.  
Primer sequences were designed using Beacon DesignerTM 8 (Premier Biosoft, Annex) for 
the following genes: TTR, Il-1β, Tnf-α, interleukin-1 receptor-associated kinase 1 (Irak1), 
myeloid differentiation primary response gene 88 (Myd88), heat shock protein-27 (Hsp-27) 
and glyceraldehyde 3-phosphate dehydrogenase (Gapdh). Differential expression was 
determined by the 2^-∆∆CT method using Gapdh as housekeeping gene. 
 
 
 
 
IL-1 as a novel target in FAP 
133 
 
Semi-Quantitative Immunohistochemistry (SQ-IHC) 
Sciatic nerve, DRG, stomach and colon (n=10) were collected to 10% formalin, embedded 
in paraffin blocks and 3 μm-thick sections were cut, deparaffinated in histoclear (National 
Diagnostics) and hydrated in a descent alcohol series. Endogenous peroxidase activity 
was inhibited with 3% hydrogen peroxide solution in methanol and sections blocked in 
10% fetal bovine serum and 0.5% Triton X-100 in PBS. Primary antibodies used were: 
rabbit polyclonal anti-human TTR (1:600, DAKO), goat polyclonal anti-IL-1β (1:25, Santa 
Cruz Biotechnology), rabbit polyclonal anti-Fas death receptor (1:100, Santa Cruz 
Biotechnology), rabbit polyclonal anti-cleaved caspase-3 (1:100, R&D Systems), rabbit 
polyclonal anti-3-nitrotyrosine (1:500, Chemicon, Temecula, CA, USA) and rabbit 
polyclonal anti-NF-κB p65 (1:25, Santa Cruz Biotechnology). Antigen visualization was 
performed with biotin-extravidin-peroxidase ABC kit (Vector) using 3.3´-diaminobenzidine 
(Sigma-Aldrich) as substrate. Semi-quantitative analysis of the immunostaining area was 
performed with the Image Pro-plus 5.1 software (Media Cybernetics). Results shown 
represent the area occupied by pixels, corresponding to the immunohistochemical 
substrate color, normalized relatively to the total area. Immunohistochemistry analysis 
was blind to treatment and each animal tissue was evaluated in five different areas, with 
20 X magnification.  
 
Total protein extracts and Western blot analysis 
Protein extracts were obtained by homogenizing, in ice, DRG from control (n=7) and 
Anakinra treated mice (n=7), in lysis buffer containing 5 mM ethylenediamine tetraacetic 
acid, 2 mM ethylene glycol tetraacetic acid, 20 mM 3-(N-morpholino)propanesulfonic acid, 
0.5% Triton X-100, 30 mM sodium fluoride, 40 mM sodium pyrophosphate, 1 mM sodium 
orthovanadate, 1 mM phenylmethylsulphonyl fluoride and a Protease Inhibitor Mix (GE 
Healthcare). Total protein concentration was determined by the Bradford protein assay 
(Bio-Rad). 
Total protein from each extract (50 µg per lane) was separated in 12% SDS-PAGE gels 
and transferred onto a nitrocellulose WhatmanTM membrane (GE Healthcare) using a Mini 
Trans-Blot Cell system (Bio-Rad). After blocking in 5% bovine serum albumin in PBS, the 
membrane was incubated overnight at 4ºC with rabbit polyclonal anti-binding 
immunoglobulin protein (BiP; 1:1,000, Abcam) and mouse monoclonal anti-α-Tubulin 
(1:10,0000, Sigma-Aldrich), followed by incubation with anti-rabbit or anti-mouse 
antibodies conjugated to horsederadish peroxidase (1:5,000, 1:2,500 respectively, The 
Binding Site). Detection was performed by the LuminataTM Crescendo (enhanced 
chemiluminescence, Millipore). Quantitative analysis was carried out by densitometry 
IL-1 as a novel target in FAP 
134 
 
using Quantity One software (Bio-Rad). Density values were normalized to α-Tubulin 
levels. 
 
Morphometric analysis 
Sciatic nerves from control (n=6) and Anakinra treated (n=6) animals were removed and 
fixed overnight in a 0.1 M sodium cacodylate solution containing 1.25% glutaraldehyde 
and 4% paraformaldehyde. Tissues were washed 3 x 30 min in 0.1 M sodium cacodylate 
and post-fixed with 2% osmium tetroxide in the cacodylate solution, overnight at 4ºC. After 
a new wash of 3 x 30 min, the tissue was dehydrated using a series of graded acetone 
and finally embedded in spurr. Transverse sections were cut (0.5 µm thick) with a 
SuperNova Reichert Leica ultramicrotome (Wetzlar) and stained with 1% toluidine blue, 
for 15 s, in an 80°C heating plate, before being examined on a light microscope. For each 
animal, the total number of myelinated fibers present in one semithin section was 
determined by counting 40 X magnified photographs covering the whole nerve area. 
Regarding unmyelinated fibers, ultrathin transverse sections were cut and stained with 
lead uranyl acetate. Sections were then mounted on 400 mesh copper grids and 
examined by transmission electron microscopy (Jeol JEM-1400). For unmyelinated fiber 
density analysis, 40 non-overlapping photographs (12,000 X amplification) per sciatic 
nerve were selected and fibers counted, normalized to the area of each ultrathin section. 
 
Statistical Analysis 
All data are expressed as mean values ± standard error of the mean (SEM). Comparison 
between Anakinra treated and control group was performed using the Student’s t-test. p-
values of less than 0.05 were considered to be significant (*p<0.05; **p<0.01; ***p<0.001). 
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Results 
Anakinra prevents non-fibrillar TTR deposition in sciatic nerve and does not alter 
TTR expression by the liver 
 
We decided to test the effect of Anakinra in preventing TTR aggregation using the 
Hsf/V30M FAP mouse model. In this model, when animals have 6 months of age, non-
fibrillar deposits are observed, not only in the gastrointestinal tract but also in the 
autonomic and PNS (Santos et al., 2010b). We treated 4.5 months-old Hsf/V30M mice, 
thus before TTR starts to deposit in the PNS. In this way, we were able to evaluate the 
effect of Anakinra on preventing non-fibrillar TTR aggregates deposition in the PNS and to 
investigate the contribution of IL-1 signaling in the pathological mechanisms of disease. 
Some reports show that mice respond to Anakinra in a dose range of 1 mg/kg to 100 
mg/kg (Abbate et al., 2008; Salloum et al., 2009) with no signals of toxicity. Based on this 
and to be as closest as possible to the clinical human dose, in our study we chose the 
dose of 25 mg/kg. Since Anakinra has a short half-life, daily subcutaneous injections were 
selected. Accordingly with previous literature (Fleischmann et al., 2006), no major 
secondary effects besides the topic reaction in the local of the injection were detected. 
At the end of the treatment period, animals were 6 months-old and displayed widespread 
TTR non-fibrillar deposition along the gastrointestinal tract and PNS. Treated mice 
presented a markedly reduction on TTR deposition in sciatic nerve (43%) as compared to 
non-treated animals, and a trend, although not statistically significant, was observed in 
DRG (Figure 1A).  
In the gastrointestinal tract, no difference regarding TTR deposition was observed 
between treated and control mice (data not shown). 
We next investigated TTR mRNA levels by qPCR and found that Anakinra did not alter 
liver TTR transcription (Figure 1B). 
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Figure 1 – Anakinra prevents TTR deposition in the sciatic nerve and does not alter TTR 
expression by the liver. A) Representative pictures of TTR load in sciatic nerve and DRG of 
Hsf/V30M mice treated with Anakinra (right panels, n=10) and age-matched controls (left panels, 
n=10). Scale bar 50 µm. Charts represent the quantification of immunohistochemical images. B) 
Histogram represents TTR mRNA levels in the liver of Anakinra treated mice (n=10), as compared 
with controls (n=10). Gapdh was the housekeeping gene for normalization; *p<0.05. 
 
Anakinra prevents neurodegeneration 
Fiber degeneration, first affecting the unmyelinated and low diameter myelinated fibers, is 
a clinical feature of FAP (Coimbra and Andrade, 1971b). We next analyzed the density of 
myelinated and unmyelinated fibers in sciatic nerve of Anakinra treated animals and 
untreated age-matched controls. Treatment prevented loss of 46% of unmyelinated fibers, 
as compared with controls, with no impact on myelinated fibers (Figure 2). 
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Figure 2 – Anakinra prevents neurodegeneration in the Hsf/V30M transgenic FAP mouse 
model. Morphometric analyses of sciatic nerve segments in Anakinra treated and control animals. 
A) Fiber density assessed in semithin sections showing no impact of IL-1 blocking on myelinated 
fibers. Scale bar: 50 µm, n=6 animals within each group. B) Representative images from electron 
microscopy and correspondent chart, indicating higher unmyelinated fiber density in Anakinra 
treated animals, as compared to controls. Scale bar: 2 µm, n=6 animals per group; *p<0.05. 
 
Anakinra decreases expression of IL-1 signaling pathway mediators and NF-κB p65 
nucleus translocation 
 
Transcription of pro-inflammatory mediators in DRG was analyzed by qPCR. Il-1β, Myd88 
and Irak1 levels were found reduced in Anakinra treated animals (77%, 36%, 48% 
reduction, respectively; Figure 3A). Regarding Tnf-α expression, we did not observed any 
significant difference between control and Anakinra treated animals (Figure 3A).  
Since Il-1β mRNA was downregulated in DRG of Anakinra treated mice, we next 
assessed IL-1β protein levels in the PNS by SQ-IHC. We found that this pro-inflammatory 
cytokine was significantly reduced in treated as compared with untreated animals, in both 
sciatic nerve and DRG (Figure 3B).  
A previous report has shown that TTR aggregates bind to RAGE and activate NF-κB 
(Sousa et al., 2000b). Since Anakinra prevented TTR deposition in nerve tissue, 
associated with neuroprotection, we next addressed whether these effects influence or 
might be influenced by NF-κB activation. By SQ-IHC analysis we found minor cytoplasmic 
and nuclear labeling of NF-κB p65 subunit in sciatic nerve of mice treated with Anakinra, 
suggesting a reduction of this transcription factor nucleus translocation (Figure 3C, 
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arrows). Thus, our data indicates Anakinra suppression of the general activity of IL-1 and 
NF-κB p65 nucleus translocation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Expression of IL-1 signaling pathway mediators and evaluation of NF-κB 
activation throughout p65 subunit translocation to the nucleus. A) Downregulation of pro-
inflammatory mediators expression in DRG of Anakinra treated animals (n=7), as compared to 
controls (n=7) B) IL-1β protein levels in the PNS assessed by SQ-IHC (n=10 per group), with 
respective semi-quantification, demonstrating lower immunostaining in Anakinra treated mice in 
both nerve and DRG. Scale bar 50 µm. C) Representative SQ-IHC pictures of NF-κB p65 subunit in 
sciatic nerve of mice treated with Anakinra as compared to age-matched controls (n=10 in each 
group). Mice treated with Anakinra presented lower p65 nuclear staining as compared with controls 
(arrows), suggesting a reduction in p65 nucleus translocation. Scale bar 50 µm. Chart show 
quantification of immunohistochemical images. *p<0.05, **p<0.01 and ***p<0.001. 
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Blocking IL-1 activity prevents neuronal apoptosis and Hsp-27 transcription  
Prevention of apoptosis by Anakinra was previously described in a rat islet model and in a 
model of experimental acute myocardial infarction (Abbate et al., 2008; Schwarznau et al., 
2009). Since apoptosis has also been implicated on the pathogenic mechanisms in FAP 
(Macedo et al., 2008), we next investigated the effect of Anakinra in Fas death receptor 
and cleaved caspase-3 levels in the PNS. Both apoptotic markers were found significantly 
reduced in sciatic nerve and DRG of Anakinra treated mice, as compared with untreated 
age-matched controls (Figure 4A and 4B). These results and the described activation of 
the heat shock response in FAP (Santos et al., 2008), prompted us to investigate the 
transcriptional levels of Hsp-27 in DRG. We observed a significant decrease (70% 
reduction) in Hsp-27 mRNA levels in mice treated with Anakinra as compared to the 
untreated group (Figure 4C). 
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Figure 4 – Anakinra suppresses apoptotic cell death in the PNS and reduce expression of 
Hsp-27. A) Representative SQ-IHC images of Fas death receptor in the PNS and respective 
quantifications (n=10 per group), demonstrating lower levels of Fas in treated animals. B) Cleaved 
caspase-3 immunostaining in sciatic nerve and DRG of Hsf/V30M mice treated with Anakinra (right 
panels, n=10) and age-matched controls (left panels, n=10). Scale bar 50 µm. Charts characterize 
the quantification of immunohistochemical images. C) Inhibition of Hsp-27 mRNA levels in DRG of 
Anakinra treated mice as compared with controls (n=7 of each group). The relative mRNA 
expression was normalized to Gapdh. **p<0.01 and ***p<0.001. 
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Blocking IL-1 signaling pathway prevents endoplasmic-reticulum (ER) and 
nitrosative stress 
 
Evidence suggests a link between inflammation driven by IL-1 and ER stress (Amin et al., 
2012), pathway also involved in the progress of FAP disease (Teixeira et al., 2006). To 
test this hypothesis in our model, we decided to evaluate levels of BiP, a central regulator 
for ER stress, in DRG. By western blotting, we found a significant reduction of BiP in 
treated mice (Figure 5A), indicating a direct effect of Anakinra in ER stress, since TTR 
deposition in this organ is not significantly affected. 
Nitration of tyrosine residues has been suggested as a marker of peroxynitrite-mediated 
tissue injury in TTR amyloidosis (Sousa et al., 2004) being the nitrosative stress an 
integral factor in neurodegeneration. Accordingly, we further investigated whether 
neuroprotection of unmyelinated axons could also result from decreased levels of 
peroxynitrite formation. Sciatic nerve was immunohistochemically examined for evidence 
of 3-nitrotyrosine, a stable biochemical marker for this process. 3-nitrotyrosine reactivity 
was detected within axons and was remarkably decreased after blocking IL-1 (Figure 5B).  
 
 
Figure 5 – Anakinra reduced ER and nitrosative stress. A) Western blot quantification of BiP in 
DRG from mice treated with Anakinra (n=7) and non-treated age-matched controls (n=7). 
Histogram denotes normalized BiP/Tubulin density quantification. B) Representative SQ-IHC 
pictures of 3-nitrotyrosine in sciatic nerve of mice treated with Anakinra (right panel, n=10) and 
age-matched controls (left panel, n=10). Scale bar 50 µm. Chart represent the quantification of 
immunohistochemical images. *p<0.05 and **p<0.01. 
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Discussion 
The presence of Congophilic amyloid deposits is a unifying characteristic of the extensive 
analysis of FAP nerves. Nevertheless, the lack of a cause-effect relationship between 
amyloid deposition and neurodegeneration in FAP suggests that other TTR molecular 
intermediaries, namely non-fibrillar oligomeric species, might be the primary neurotoxic 
culprits (Sousa et al., 2001a; Andersson et al., 2002; Reixach et al., 2004). In fact, it has 
been shown that nerves from FAP 0 patients (asymptomatic individuals presenting 
aggregate deposition but lacking amyloid) exhibit early signs of oxidative damage and 
inflammatory stress (Sousa et al., 2001b). Moreover, TTR non-fibrillar deposition in the 
sciatic nerves of FAP patients has been shown to induce pro-inflammatory cytokine 
synthesis by axons and a correlation between increased IL-1β levels and fiber 
degeneration has been established (Sousa et al., 2001b).   
In the present study we investigated the effect of early administration (before aggregate 
deposition started) of the IL-1 antagonist Anakinra in TTR deposition and neurotoxicity, 
using a well-established mouse model of FAP. 
We found that inhibition of IL-1 lowered non-fibrillar TTR deposition in sciatic nerve, which 
correlated with increased number of unmyelinated fibers. In contrast, Anakinra treatment 
did not interfere with TTR deposition in the gastrointestinal tract. This observation might 
be explained by the presence of endogenous microflora, exposition to oral pathogens and 
specific immune regulatory networks of the gastrointestinal tract, not operating in the 
peripheral nerve.  
IL-1 has been implicated in several chronic degenerative disease processes, including the 
development of atherosclerosis and rheumatoid arthritis (Merhi-Soussi et al., 2005; Kay 
and Calabrese, 2004), being a key player in neuroinflammation and neurodegeneration 
and regulating the expression of several transcription factors, including NF-κB (Beg et al., 
1993). IL-1 activation results in phosphorylation and degradation of IκB proteins, releasing 
NF-κB and allowing its translocation to the nucleus, where it controls the expression of 
downstream pro-inflammatory genes (Hayden and Ghosh, 2004). The involvement of NF-
κB in FAP has been described (Sousa et al., 2000b; Sousa et al., 2005; Santos et al., 
2010b). In this regard, in vitro studies have shown that TTR aggregates interact with 
RAGE triggering nuclear translocation of NF-kB (Sousa et al., 2000b).  
In this study, we assessed the effect of IL-1 inhibition on NF-κB activation in sciatic nerve 
and found a significant reduction of NF-κB p65 nucleus translocation in Anakinra treated 
animals, which is consistent with decreased TTR extracellular load and increased density 
of unmyelinated fibers. It is important to emphasize that the influence of NF-κB on cell 
survival can be protective or deleterious, depending on the cell type, its developmental 
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stage and the pathological conditions (Kaltschmidt et al., 1997). For instance, in glia, NF-
κB is inducible and mediates inflammatory responses that aggravate diseases such as 
ischemia, autoimmune encephalomyelitis and Alzheimer's disease (Kaltschmidt et al., 
1997; Mattson and Camandola, 2001). Thus inhibition of NF-κB in glia might ameliorate 
disease, whereas activation in neurons might enhance memory (Kaltschmidt et al., 1997). 
In FAP, NF-κB activation occurs as a response to extracellular aggregate insult. Whether 
this action is neuroprotective or neurotoxic it is still not fully understood, but there is 
probably a threshold beyond which NF-κB activation starts to be noxious to cells. 
Moreover, the fact that other inflammatory mediators such as Tnf-α levels were not 
affected by the treatment supports the specificity of Anakinra action into the IL-1 signaling 
pathway. 
In FAP, like in other neurodegenerative disorders, accumulation of aberrant misfolded 
proteins activates the unfolded protein response by the ER to restore and maintain 
homeostasis in the ER (Teixeira et al., 2006; Hoozemans et al., 2009). However, if the ER 
stress is continued, or the adaptive responses fail, apoptotic cell death ensues. Thus, we 
further investigate the effect of Anakinra administration on ER chaperone BiP and found 
that it significantly impairs ER-stress in treated animals. 
Compelling evidence has shown that members of the IL-1 family of cytokines are 
intricately involved in inflammatory and death-inducing signaling platforms. Therefore, IL-1 
has been further suggested as rational therapeutic target for several pathological 
conditions. In vivo administration of IL-1Ra in mouse models as diverse as acute 
myocardial infarction (Abbate et al., 2008), spinal cord injury (Nesic et al., 2001), renal 
ischemia-reperfusion (Rusai et al., 2008) or cancer chemotherapy (Wu et al., 2011) has 
been proved efficient in preventing activation of pro-apoptotic molecules or activating pro-
survival signaling transduction pathways. In agreement with these observations, in our 
study early treatment of FAP mice with Anakinra resulted in significantly decreased levels 
of Fas death-receptor, cleaved caspase-3 and chaperone Hsp-27 in the PNS. 
The reaction of nitric oxide with superoxide produces the peroxynitrite anion (Melo et al., 
2011). Peroxynitrite is a powerful oxidant that can nitrate aromatic amino acid residues 
such as tyrosine to form 3-nitrotyrosine. Hence, 3-nitrotyrosine is a valuable marker of 
peroxynitrite production. Immunostaining of FAP nerves with antibody to 3-nitrotyrosine 
demonstrated immunoreactive material in FAP 0 and FAP tissue in an axonal distribution 
(Sousa et al., 2001b). Our results indicate significant decrease of 3-nitrotyrosine in the 
sciatic nerve, which is in accordance with Anakinra inhibitory effect on TTR deposition and 
suggestive of reduction of cytotoxicity and neuroprotection. 
Since Anakinra has no effect on TTR stability (data not shown), we hypothesized that 
decreased TTR aggregation and deposition in tissues might be due to a restored 
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extracellular environment characterized by decreased levels of inflammatory mediators, 
nitrosative species and apoptotic cell death. Thus, by interrupting the positive feedback 
loop between TTR accumulation in tissues and inflammation, Anakinra prevents TTR 
deposition in the PNS. Future studies will further elucidate the molecular mechanisms 
behind Anakinra inhibitory effect on TTR deposition.  
Therapeutic strategies for FAP, other than orthotropic liver transplantation, have been put 
forward as it is the case of tetrameric TTR stabilization (Bulawa et al., 2012; Ferreira et 
al., 2012), inhibition of TTR aggregation (Ferreira et al., 2012; Ferreira et al., 2013) or 
apoptosis (Macedo et al., 2008), disruption of TTR fibrils (Cardoso and Saraiva, 2006), 
suppression of liver TTR synthesis with small interfering RNA (siRNA) (Kurosawa et al., 
2005; Alvarez et al., 2010) and drug combinatorial treatments (Cardoso et al., 2010). In 
what concerns combinatorial therapeutic strategies in FAP, doxycycline and TUDCA 
administration were shown to synergize for disruption and clearance of fibrillar deposits 
and for stabilization of disease progression both in mice and humans, respectively 
(Cardoso et al., 2010; Obici et al., 2012). Considering the therapeutic potential of Anakinra 
shown in our study, we hypothesize that it can be a multi-target drug used as an 
alternative treatment or in a combinatorial approach, improving the efficacy of drugs acting 
on TTR silencing (Alvarez et al., 2010), TTR stabilization (Bulawa et al., 2012; Ferreira et 
al., 2012) or amyloid fibril disruption (Cardoso et al., 2006). 
Overall, the present study brings to light, for the first time, the therapeutic potential of 
Anakinra in the context of FAP. Furthermore, data reinforce the importance of 
inflammation on TTR amyloidosis and further demonstrates an important role of IL-1 in the 
pathogenesis of FAP. 
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Abstract 
Familial Amyloidotic Polyneuropathy (FAP) is characterized by a length-dependent axonal 
loss in the peripheral nervous system (PNS) that results from deposition of extracellular 
non-fibrillar transthyretin (TTR) and amyloid fibrils. Inflammation is a key factor for the 
pathophysiology of FAP, aggravating the disease phenotype, suggesting that the immune 
response in peripheral nerve may have an active role in the progression of the disease. 
We have previously shown that an inflammatory stimulus in the peripheral nerve of a 
mouse model of FAP triggers local TTR expression and deposition, leading to poor 
regeneration. We also demonstrated that blocking interleukin-1 (IL-1) signaling by the IL-1 
receptor antagonist Anakinra is beneficial in preventing nerve TTR deposition and 
associated toxicity. Here, we investigated whether IL-1 signaling influences TTR biology 
after an injury stimulus in a V30M FAP mouse model. Animals were treated with Anakinra 
48 h before sciatic nerve ligation and histopathological changes in sciatic nerve were 
analyzed 7 days post-lesion. Our data shows that, Anakinra decreased TTR expression 
by Schwann cells and extracellular deposition after nerve injury, which resulted in 
improved regeneration. Moreover, treated mice had less apoptotic cell death. In a wild-
type (WT) situation, inflammation is important for regeneration to occur. However, in FAP, 
the threshold of the inflammatory response will differentially regulate TTR, becoming 
detrimental to the system. Taken together, our results show that Anakinra administration 
before injury can modulate TTR-induced pathology in the PNS corroborating the 
protective interference of this drug in a FAP pre-clinical model.  
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Introduction 
Familial Amyloidotic Polyneuropathy (FAP), an autosomal dominant hereditary disorder, is 
primarily characterized by a length-dependent axonal loss consequent to extracellular 
matrix (ECM) deposition of mutated forms of transthyretin (TTR) (Coimbra and Andrade, 
1971b). It is estimated that approximately ten thousand patients are affected worldwide 
with this disease, with endemic foci in Portugal, Japan and Sweden (Said et al., 2012). 
TTR is a 55-kDa tetramer made of identical subunits of 127 amino acids, mainly 
synthesized and secreted by hepatocytes, the choroid plexus and the retinal epithelium 
(Soprano et al., 1985). However, recently, minute levels of expression were also found in 
Schwann cells (Murakami et al., 2010; Gonçalves et al., 2014a). More than 100 TTR 
single point mutations have been reported being the most common mutation associated 
with FAP a substitution of a methionine for a valine at position 30 (V30M) of the 
polypeptide chain (Saraiva et al., 1984) (http://amyloidosismutations.com/mut-attr.php). 
TTR is produced as a monomer and assembles as a tetramer in the endoplasmic 
reticulum. Amyloidogenic TTR mutants induce the exposure of new structural motifs 
promoting tetramer destabilization and dissociation into structurally modified unfolded 
monomers. These unstable and non-native intermediate species lead to the formation of 
soluble aggregates that further self-assemble into insoluble amyloid fibrils (Colon and 
Kelly, 1992; Quintas et al., 2001), predominantly accumulating in the PNS and the 
autonomic nervous system. TTR misfolding, aggregation and deposition culminate in 
distinct patterns of organ involvement, age of onset, and clinical course of FAP disease. 
All these stages share a common determinant factor being the cytotoxicity of early TTR 
non-fibrillar aggregates (Sousa et al., 2001a; Koike et al., 2004). More than mature 
amyloid fibrils, these intermediate species induce oxidative and inflammatory stress in 
neuronal cells, ultimately leading to fiber degeneration and death (Sousa et al., 2001a; 
Sousa et al., 2001b). Additionally, fibrillar TTR binds to the receptor for advanced 
glycation end products (RAGE) in different cellular structures of the peripheral nerve, such 
as axons, vascular smooth muscle cells and Schwann cells, resulting in nuclear factor κB 
(NF-κB) activation and increased IL-1β levels, in a distribution overlapping RAGE 
expression. Consequently, nerve fiber degeneration occurs creating a feed-forward 
mechanism that contributes to the maintenance of neuroinflammation and progression of 
disease (Sousa et al., 2001b; Gonçalves et al., 2014b). In line with this, it has been 
recently shown that an inflammatory stimulus in the PNS triggers local TTR expression 
and deposition which supports the notion that neuroinflammation contributes to the 
pathogenesis and progression of FAP (Gonçalves et al., 2014a).  
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Anakinra is the recombinant form of the endogenous IL-1 receptor antagonist (IL-1Ra) 
and is a U.S. FDA approved drug with successful results in rheumatoid arthritis (Botsios et 
al., 2007) and type 2 diabetes (Larsen et al., 2007). Strong evidence supports a role for 
inflammation in the progress of FAP, through association of IL-1β production and 
deterioration of nerve degeneration (Sousa et al., 2001b; Gonçalves et al., 2014b). In an 
animal model of FAP, Anakinra have proved beneficial when administered prior to TTR 
deposition, preventing activation of toxic cascades associated with the disease 
(Gonçalves et al., 2014b). Thus, in the present work we sought to provide additional 
evidence for the role of IL-1 in the induction and chronicity of FAP. Our goal was to 
determine the influence of this cytokine in triggering TTR deposition and expression in the 
PNS. For that, we administered Anakinra to a transgenic human V30M mouse model 
(Kohno et al., 1997) (V30M), presenting enhanced TTR deposition following nerve injury 
(Gonçalves et al., 2014a).  
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Materials and Methods 
Animal procedures 
Six months-old male and female WT and V30M mice, in the 129/Sv background were 
used for the experiments. V30M transgenic mice carry the human TTR gene bearing the 
V30M mutation, in a mouse Ttr null background (Kohno et al., 1997). Despite the number 
of TTR copies, levels of TTR in plasma are similar in both groups (Oliveira et al., 2011; 
Ferreira et al., 2013). Animals were maintained in a controlled-temperature room (24 ± 1 
°C) under a 12 h light/dark cycle and fed regular chow and tap water ad libitum.  
Sciatic nerve injury was adapted from the method described by Brumovsky et al., (2004), 
as previously reported (Gonçalves et al., 2014a) due to the higher inflammatory response 
that is elicited in response to the ligature. Briefly, sciatic nerve ligation was performed 
using one ligature placed around the sciatic nerve at the mid-thigh level, with 5.0 silk. A 
sham operation was similarly performed at the contralateral side, except that the sciatic 
nerve was not constricted. Mice were kept in a recovery room with infrared heating lamp 
for 1-2 h and post-surgical pain treatment consisted of butorphanol subcutaneous 
injections, every 12 h for the first 48 h.  
Two days before nerve injury, animals were injected once a day subcutaneously with 50 
mg/kg of Anakinra (Kineret®, Biovitrum) and treatment was repeated every day after. 
Seven days after injury, animals were euthanized with a lethal anesthesia of 
ketamine/medetomidine. 
Mice were handled in accordance with the European Community Council Directive 
(2010/63/EU) and the number of total animals for this research was approved by ethical 
committee and by National General Veterinarian Board. 
 
Semi-Quantitative Immunohistochemistry (SQ-IHC)  
Immunohistochemical staining of entire or distal stump of sciatic nerves and L4-L6 
ipsilateral dorsal root ganglia (DRG) (n=5 per group) was carried out using primary 
antibodies against human TTR (1:600, rabbit polyclonal, DAKO); mouse TTR (1:1,500, 
rabbit polyclonal, Q-Biogen); growth associated protein 43 (GAP-43, 1,1000, rabbit 
polyclonal, Abcam); peripherin (1:1,500, rabbit polyclonal, Millipore); cyclic AMP-
dependent transcription factor (ATF-3, 1:100, rabbit polyclonal, Santa Cruz 
Biotechnology); nerve growth factor β (NGF-β, 1:100, rabbit polyclonal, Abcam); cleaved 
caspase-3 (1:100, rabbit polyclonal, R&D Systems); Fas death receptor (Fas, 1:100, 
rabbit polyclonal, Santa Cruz Biotechnology), BH3 interacting domain death agonist (Bid, 
1:100, rabbit polyclonal, Santa Cruz Biotechnology), myeloid differentiation primary 
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response gene 88 (Myd88, 1:200, rabbit polyclonal, Abcam) and cAMP response element-
binding protein (Creb, 1:500, Cell Signaling). The sections were excised, post-fixed in 
10% formalin, embedded in paraffin blocks and cut longitudinally at 3 µm. After tissue 
deparaffinazation with Histoclear (National Diagnostics) and hydration in descent alcohol 
series, the sections were quenched for 30 min in 3% hydrogen peroxide in methanol and 
pre-incubated for 1 h with 10% fetal bovine serum and 0.5% Triton X-100 in PBS. After 
overnight incubation at 4ºC with primary antibody, a 1:200 dilution of biotinylated anti-
rabbit (Vector) for 45 min was performed. Thereafter, sections were washed with PBS, 
incubated with avidin-biotin-peroxidase complex (ABC Elite, Vector laboratories) and 
visualized using 3.3´-diaminobenzidine as a chromogen. For semi-quantitative analyses of 
the immunostained slide, 5 pictures at 20 X magnification were taken from different areas 
and quantified using the Image pro-plus 5.1 software (Media Cybernetics). The area 
occupied by chromogen represents the amount of protein present and all types of brown 
staining were selected by the program. Results shown represent the area occupied by 
pixels corresponding to the substrate reaction color that is normalized relatively to the total 
image area, with the corresponding standard error of the mean (SEM).   
 
Double Immunofluorescence 
After deparaffinazation and hidration of the entire nerve and L4-L6 ipsilateral DRG 
sections (n=5 per group), primary antibodies used for immunofluorescence were: rabbit 
anti-human TTR (1:100; DAKO), mouse anti-heparan sulfate proteoglycan (HSPG, 1:100), 
rabbit anti-cleaved caspase 3 (1:100; R&D Systems), mouse anti-βIII-Tubulin (1:1,000; 
Promega), mouse anti-S100 (1:50; Abcam) and rat anti-F4/80 (1:50, Serotec). Following 1 
h blocking with 10% fetal bovine serum and 0.5% Triton X-100 in PBS, sections were 
incubated with primary antibodies overnight at 4ºC. Secondary antibodies used were anti-
rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 568 and anti-rat Alexa Fluor 594 (1:1,000; 
Invitrogen Molecular Probes), which were incubated for 2 h at room temperature. After 3 
washes with PBS for 10 min each, slides were finally mounted with Vectashield (Vector 
Laboratories) and visualized in a laser scanning Confocal Microscope Leica TCS SP5 II 
(Leica Microsystems). 
 
Immunogold Labeling 
Ultrathin sections of 2% glutaraldehyde-paraformaldehyde-fixed, LR white-embedded 
distal injured nerves (n=4 in each group) were mounted onto nickel grids, treated with 
sodium borohydrate for 10 min and subsequently incubated in 2% gelatin for 20 min. After 
blocking with 2% bovine serum albumin in TBS for 1 h, anti-human TTR (DAKO) was 
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used as primary antibody diluted 1:100 in blocking buffer. Control sections without 
secondary antibody were also used. Anti-rabbit immunoglobulins (1:20, British Biocell 
International) coupled to 10 nm gold particles were used as secondary antibody, 1 h at 
room temperature. The grids were subsequently washed in pure water 6 times for 10 min 
each and finally stained with uranyl acetate for 3 min and lead citrate for 30 s. Samples 
were analyzed in a Jeol JEM-1400 electron microscope. 
 
Messenger RNA (mRNA) isolation, complementary DNA (cDNA) synthesis and real-
time polymerase chain reaction (qPCR) 
 
Whole injured nerves (n=5 per group) from V30M mice were dissected free from 
surrounded tissues and immersed in RNA later (Ambion) for 2 h before being frozen at -
80ºC. Tissue mRNA was isolated by using the mRNA capture kit (RNA tissue lipid mini-kit, 
Qiagen) following the manufacturer’s instructions. mRNA was reverse transcribed using 
the SuperScript double-stranded cDNA Kit (Invitrogen) and subjected to qPCR, in 
duplicate, using iQ Syber Green Super Mix (Bio-Rad). Reactions were analyzed on Bio-
Rad iQ5 software. Primer sequences were designed using the Beacon software (Premier 
Biosoft) for the following genes (Annex): TTR, Myd88, Creb, hepatocyte nuclear factor-4 
(Hnf-4), hepatocyte nuclear factor 3β (Hnf-3β), CCAAT/enhancer binding protein (C/ebp-
β), c-Jun, Synapsin, Persephin, Cathepsin B, Cathepsin D and glyceraldehyde 3-
phosphate dehydrogenase (Gapdh). Calibration curves for target and housekeeping 
genes were constructed using 10-fold serial cDNA dilutions in duplicates. Differential 
expression was determined by the 2^-∆∆CT method, relative to the housekeeping gene 
Gapdh. 
 
Flow cytometry 
Entire injured sciatic nerves from V30M mice (n=5 per group) were dissected and 
subjected to enzymatic digestion using 1.6 mg/mL collagenase type IV,  200 μg/mL 
DNase I,  10 mM HEPES, 5 mM CaCl2 and 5 mg/mL bovine serum albumin (all from 
Sigma-Aldrich) in RPMI media for 1 h at 37ºC. Single cell suspensions were filtered 
through a 70 µm cell strainer (BD Biosciences). Cells were incubated with Fc receptor 
block (CD16/32, eBioscience) at 4ºC for 15 min and then stained with CD11b, Ly6G, 
CD45, CD11c and MHCII (Biolegend) in PBS Fluo (2% fetal bovine serum, 0.1% Azide, 
5mM EDTA in PBS) at 4ºC for 30 min. Cells were washed, ressuspended in PBS Fluo and 
run on a FACS CALIBUR flow cytometer and later analyzed using the FlowJo software. 
The cell population identification for neutrophils, macrophages and dendritic cells was 
performed as follows: CD11b+Ly6G+, CD11b+ Ly6G-, CD45+CD11c+MHCII+, respectively. 
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Total protein extracts and Western blot analysis 
Whole sciatic nerve (n=5 per group) was homogenized, at 4ºC, in lysis buffer containing 5 
mM ethylenediamine tetraacetic acid, 2 mM ethylene glycol tetraacetic acid, 20 mM 3-(N-
morpholino)propanesulfonic acid, 0.5% Triton X-100, 30 mM sodium fluoride, 40 mM 
sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM phenylmethylsulphonyl 
fluoride and a Protease Inhibitor Mix (GE Healthcare, Buckinghamshire). The protein 
concentration of lysates was determined using the Bradford protein assay (Bio-Rad). 
Nerve protein lysates were resolved on 12% polyacrylamide gels (50 µg per lane) and 
transferred to a nitrocellulose WhatmanTM membrane (GE Healthcare) using a Mini Trans-
Blot Cell system (Bio-Rad). Membranes were blocked with 5 % bovine serum albumin in 
PBS supplemented with 0.05% Tween 20 and then probed with rabbit polyclonal anti-
Arginase-1 (Arg-1, 1:1,000, Cell signaling), rabbit polyclonal anti-iNOS (1:1,000, Cell 
signaling) or mouse monoclonal anti-GAPDH (1:3,000, Abcam). After washing, 
membranes were incubated with the appropriate secondary antibodies conjugated to 
horsederadish peroxidase (The Binding Site) and proteins were visualized with enhanced 
chemiluminescence using the LuminataTM Crescendo (Millipore). Protein bands were 
quantified by densitometry using Quantity One software (Bio-Rad). Density values were 
normalized to GAPDH levels. 
 
Sciatic nerve morphometric analysis 
Sciatic nerves were covered with 1.25% glutaraldehyde and 4% paraformaldehyde in a 
0.1 M sodium cacodylate solution for 5 min, before dissection. Then, few mm length 
segments, collected distally from the lesion and proximally to nerve trifurcation (n=4 per 
group) were immersed on fixation solution overnight. After incubation in 2% osmium 
tetroxide in the cacodylate solution overnight, nerves were dehydrated using a series of 
graded acetone and finally embedded in spurr. Half µm thick transverse sections covering 
the complete cross-sectional area of nerves were stained with 1% toluidine blue, for 15 s, 
in an 80°C heating plate and photographed on an optical microscope. For each animal, 
the total number of myelinated axons was counted and normalized to the respective nerve 
area. To determine the density of unmyelinated axons, ultrathin transverse nerve sections 
were cut, placed on 400-mesh copper grids and stained with uranyl acetate and lead 
citrate. For each animal, 40 non-overlapping photomicrographs (12,000 X magnification) 
of each section were taken in a transmission electron microscope (JEOL JEM-1400). The 
area of the total number of photomicrographs per mice was determined to calculate the 
density of unmyelinated axons. 
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Statistical analysis 
Statistical comparison of data was performed using the Student t-test with Graph Pad 
Prism 6 software. Quantitative data are expressed as mean ± SEM. Statistical significance 
was established for *p<0.05, **p<0.01 and ***p<0.001. 
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Results 
 
Blocking IL-1 signaling pathway in the V30M FAP mouse model, decreases TTR 
V30M expression and deposition in sciatic nerve after injury  
 
We have previously reported that TTR expression and deposition in the sciatic nerve is 
triggered by an injury stimulus, leading to poor nerve regeneration (Gonçalves et al., 
2014a). Additionally, we have also found that blocking IL-1 signaling pathway with 
Anakinra, in a pre-clinical FAP model prevents TTR deposition and associated 
neurotoxicity (Gonçalves et al., 2014b), reinforcing the role of IL-1 on the pathophysiology 
of FAP. Since Anakinra was neuroprotective, we hypothesized whether that would also be 
true in a scenario of sciatic nerve injury in an FAP mouse model. To block IL-1, daily 
subcutaneous injections of Anakinra were required due to the short half-life of this 
molecule. The dose used was 50 mg/kg and previously tested (Abbate et al., 2008; 
Salloum et al., 2009; Sgroi et al., 2011). Blocking IL-1 signals have shown neuroprotective 
efficacy when performed before ischemia or spinal nerve injury (Banwell et al., 2009; 
Gabay et al., 2011). Therefore, we started treatment with Anakinra, 48 h before sciatic 
nerve injury. No secondary effects besides the topic reaction in the local of the injection 
were detected. Similarly to previous data (Gonçalves et al., 2014a), nerve injury triggered 
local TTR V30M expression and deposition; however, treatment with Anakinra led to a 
strong inhibition in both TTR V30M synthesis and nerve deposition (Figure 1A and 1B). 
TTR V30M deposits in the sciatic nerve after injury were found predominantly in the ECM, 
as shown with immunogold staining (Figure 1C) and vast colocalization with HSPG, one of 
the main components of the ECM and basement membranes (Häcker et al., 2005) (Figure 
1D, top panel). Moreover, TTR localization in axons was ruled out as no colocalization 
with βIII-tubulin (an axonal and neuronal marker) was found (Figure 1D, bottom panel). 
L4, L5 and L6 DRG, ipsilateral to the injury side, were also analyzed; TTR V30M protein 
levels were found 85% decreased in DRG from animals treated with Anakinra prior to 
injury, as compared with untreated mice (Figure 1E, top panel). It was previously 
described that DRG do not synthesized TTR (Sousa and Saraiva, 2008), thus this 
paradigm probably results from prevention of TTR deposition by Anakinra. Additionally, 
TTR deposits in DRG do not colocalize with βIII-tubulin (Figure 1E, bottom panel), thus we 
conclude that they were located in the extracellular space. 
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Figure 1 – Blocking IL-1 before nerve injury, decreases local TTR V30M expression and 
extracellular deposition. A) Histogram represents TTR V30M mRNA levels (n=5 per group). B) 
Photomicrographs illustrating TTR V30M in injured sciatic nerves; scale bar 50 μm. Chart represent 
quantification of immunohistochemical images (n=5 per group). C) Representative electron 
microscopy pictures of non-treated injured sciatic nerves (scale bars 0.5 µm and 100 nm). D) Top 
panels demonstrate colocalization (arrows) between TTR V30M (green) and HSPG (red) in control 
injured nerve. Double immunofluorescence between TTR (green) and βIII-tubulin (red, bottom 
panels). Nuclei stained blue with DAPI. Scale bar 15 µm. E) TTR V30M IHC in lumbar DRG 
ipsilateral to the injury side (top panel). Scale bar 50 µm. Chart demonstrates quantification of 
histological pictures. Lower panel represents double immunofluorescence between TTR V30M and 
βIII-tubulin; scale bar 15 µm. *p<0.05 and **p<0.01. 
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Pre-treatment with Anakinra in V30M mice decreased the levels of Myd88 adaptor 
and total Creb after injury  
Myd88 is an essential effector in the IL-1 signaling pathway (Burns et al., 1998). In injured 
sciatic nerves from Anakinra treated animals the expression of Myd88 adaptor and its 
protein levels were found downregulated (Figure 2A and 2B). Due to lower TTR V30M 
expression by the nerve in mice treated with Anakinra, we next questioned if this drug was 
affecting the expression of TTR transcription factors. Accordingly, we analyzed the 
expression of Hnf-3β, Hnf-4, C/ebp-β and c-Jun, the latter one acting on TTR promoter 
through interaction with AP-1 (Qian et al., 1995). No differences were detected regarding 
the expression of these molecules in nerve tissue after injury, with or without Anakinra 
(data not shown). Given the mounting evidence for the interrelation of CREB and IL-1β 
(Tang et al., 2005, Wen et al., 2010), we next assessed the mRNA and protein levels of 
this molecule and found lower levels of total CREB in mice treated with Anakinra when 
compared to non-treated mice (Figure 2C and 2D).  
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Figure 2 – Treatment with Anakinra reduces the levels of Myd88 and total Creb after injury. 
A) Histogram represents Myd88 mRNA levels in the sciatic nerve of Anakinra treated animals (n=5) 
as compared with non-treated (n=5). B) Representative SQ-IHC for Myd88, 7 days after injury, in 
V30M Anakinra treated mice (n=5) and controls (n=5). Scale bar 50 μm. Chart represents the 
quantification of immunohistological images. C) Quantification of Creb mRNA levels extracted from 
injured sciatic nerves of mice treated with Anakinra (n=5) as compared with untreated ones (n=5), 
analyzed by qPCR.  D) SQ-IHC against total CREB in injured sciatic nerves of Anakinra treated 
and untreated V30M mice. Scale bar 50 μm. Plot corresponds to the semi-quantification of CREB 
staining represented as the ratio of occupied area in the whole tissue; n=5 per group. *p<0.05, 
**p<0.01 and ***p<0.001. 
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Treatment with Anakinra before nerve injury decreases levels of pro-apoptotic 
markers in V30M mice  
As soon as 1 week after injury, axonal loss and apoptosis occurs which limits nerve 
recovery (Scheib and Höke, 2013). Based on previous results showing that Anakinra 
prevents apoptosis (Abbate et al., 2008; Schwarznau et al., 2009; Gonçalves et al., 
2014b), we analyzed the production levels of apoptotic related molecules such as Fas 
death receptor, Bid (a pro-apoptotic member of the Bcl-2 family) and cleaved caspase-3, 
in our study model. All apoptotic markers were found significantly reduced in Anakinra 
treated mice when compared to non-treated animals (Figure 3A). We next searched for 
cellular localization of cleaved caspase-3 apoptotic marker in untreated animals. With 
confocal microscopy, staining for cleaved caspase-3 localized mainly in Schwann cells 
and endoneural macrophages of the sciatic nerve (Figure 3B, arrows, top and middle 
panels, respectively) while colocalization with axons was barely found (Figure 3B, arrow, 
bottom panel). Additionally, L4-L6 DRG ipsilateral to the injury side were also analyzed for 
cleaved caspase-3 and with histological examination this molecule was found 
downregulated in animals treated with Anakinra (Figure 3C, top panel). Moreover, with 
immunofluorescence analysis, cleaved caspase-3 was found in neurons of the DRG 
ganglia, as illustrated with colocalization with βIII-tubulin (Figure 3C, bottom panel, 
arrows). These results suggest that Anakinra prevents neuronal, glial and immune cell 
apoptosis after injury. Considering that cathepsins B and D have been implicated in 
apoptosis in a variety of animal models (Chwieralski et al., 2006), we also asked if these 
enzymes could be altered in our model. We found that expression of both Cathepsin B 
and D was significantly downregulated in response to Anakinra when compared to non-
treated animals (Figure 3D). All together, these results indicate an overall decreased 
apoptotic response after nerve injury in V30M mice receiving Anakinra as compared to 
untreated mice. 
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Figure 3 – Mice receiving Anakinra, previously to injury, presented less apoptosis. A) SQ-
IHC against Fas death receptor, Bid and cleaved caspase-3 in sciatic nerve of V30M animals 
treated with Anakinra (n=5) or PBS (n=5), 7 days post-injury. Scale bar 50 μm. Histograms 
represent the respective SQ of histological images. B) Double immunofluorescence between 
cleaved caspase-3 and βIII-tubulin (neuronal and axonal marker), S100 (Schwann cell marker) or 
F4/80 (marker for macrophages) in control injured sciatic nerves. Arrows in merged images denote 
colocalization. Scale bar 10 μm. C) SQ-IHC against cleaved caspase-3 evaluated in L4-L6 
ipsilateral DRG (top panels; n=5 each group). Scale bar 50 μm. Chart highlights the significant 
difference obtained with quantification of histological images. In bottom panels, representative 
picture show cleaved caspase-3 localization in neurons of DRG from non-treated mice. Scale bar 
10 μm. D) Chart represents Cathepsin B and Cathepsin D mRNA levels in sciatic nerve, 7 days 
after injury in Anakinra treated and untreated V30M mice (n=5). *p<0.05, **p<0.01 and ***p<0.001. 
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Inhibiting IL-1 signaling activity before injury ameliorates the regenerative process 
in V30M mice 
After a PNS lesion, the distal axonal segment undergoes Wallerian degeneration, while 
the proximal segment regenerates, with Schwann cells playing a crucial role to start 
remyelination through contact with regenerating axons (Defrancesco-Lisowitz et al., 
2014). To evaluate the degree of post-injury neuroregeneration with Anakinra treatment, 
we performed morphometric analysis distal to the injury site. In treated V30M mice, the 
myelinated axon density was 1.7 fold increase when compared to untreated mice (Figure 
4A). Using electron microscopy, the number of unmyelinated fibers, distally to the injury 
site, was determined indicating an increase of 86% in Anakinra treated V30M animals as 
compared with non-treated controls (Figure 4B). No significant changes in the endoneurial 
space between groups were observed. 
 
 
Figure 4 – Increased nerve fiber density in V30M mice receiving Anakinra before injury. 
Morphometric analyses of distal sciatic nerve stumps, 7 days after injury (n=4 animals in each 
group). A) Representative images from semithin sections showing higher number of myelinated 
fibers in V30M mice treated with Anakinra. Scale bar 50 μm. B) Representative electron 
microscopy pictures demonstrating increased unmyelinated fibers after injury, in Anakinra treated 
animals (asterisk). Scale bar 1 μm. Charts presented in the right panel indicate the corresponding 
fiber densities (*p<0.05).  
 
In order to support these findings, we next assessed the levels of NGF-β and 
regeneration-associated markers GAP-43, peripherin and ATF-3 (Sensenbrenner et al., 
1997; Pearson et al., 2003; Girard et al., 2008; Sun et al., 2009) and found that they were 
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significantly increased in animals treated with Anakinra as compared to non-treated mice 
(Figure 5A). Additionally, by qPCR, persephin, a member of the glial derived neurotrophic 
factor family (Milbrandt et al., 1998), important for the support of regenerating axons after 
injury, and synapsin III, a member of the synapsin gene family implicated in 
synaptogenesis and in the modulation of neurotransmitter release (Kao et al., 1998), were 
also upregulated in response to Anakinra when compared to non-treated mice (Figure 
5B). All together, these data suggest an improved regenerative response when IL-1 
signaling is diminished before injury, in this FAP mouse model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Increased activation of regenerating markers in sciatic nerve of V30M Anakinra 
treated mice. A) Representative SQ-IHC for GAP-43, peripherin, ATF-3 and NGF-β, 7 days after 
injury, in V30M Anakinra treated mice (n=5) and controls (n=5). Charts represent the quantification 
of immunohistological images. Scale bar 50 μm. B) Bar graph illustrates mRNA levels for Synapsin 
and Persephin, normalized to Gapdh, in injured V30M sciatic nerves, with and without Anakinra 
treatment (n=5 mice per group). *p<0.05 and **p<0.01. 
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Improved nerve regeneration after injury, results from the downregulation of TTR 
V30M expression and deposition and not directly from Anakinra 
 
Next, we wondered if the striking difference in nerve regeneration after injury with 
Anakinra resulted from the drug itself or from downregulation of TTR V30M expression 
and deposition in the nerve. To address this question, we treated age-matched WT mice 
with Anakinra, following the same strategy used for V30M mice. In contrast to the latter 
condition we found no difference in mouse TTR deposition in nerve tissue after injury in 
animals receiving the drug as compared with controls (Figure 6A). Similarly, no difference 
was detected regarding the regenerating markers GAP-43, peripherin or ATF-3 (Figure 
6B). However, WT animals treated with Anakinra presented lower nerve fiber density after 
injury when compared with WT untreated mice (Figure 6C). Therefore, in a WT condition, 
blocking IL-1 with Anakinra before injury is being deleterious for nerve recovery since IL-1 
is an important cytokine for early peripheral regeneration (Nadeau et al., 2011). These 
results, together with the above mentioned data, strengthen the idea that local TTR V30M 
expression and deposition impairs nerve regeneration. Also, the presence of a 
heterologous human TTR in the nerve of V30M mice might contribute to this paradigm.  
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Figure 6 – Increased levels of regenerating markers and fiber density in V30M Anakinra 
treated mice are consequent to TTR V30M downregulation and not directly from Anakinra. 
A) Mouse TTR immunohistochemical staining of injured sciatic nerve sections from WT mice, with 
respective semi-quantification chart (n=5 per group). Scale bar 50 μm. B) Representative SQ-IHC 
in WT mice treated with Anakinra (n=5) and respective untreated controls (n=5), showing no 
difference regarding GAP-43, peripherin or ATF-3 levels between both groups. Scale bar 50 μm. C) 
Morphometric analyses of injured nerves from WT mice both treated (n=4) and untreated with 
Anakinra (n=4). Scale bar 2 μm. **p<0.01. 
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Innate cellular infiltrate to injured nerve and macrophage phenotype are not 
affected by Anakinra in V30M mice 
 
To compare the inflammatory infiltrate after injury of untreated and Anakinra treated V30M 
mice, we performed flow cytometry of injured nerves. Overall, we saw no differences 
regarding the frequency of neutrophils, macrophages or dendritic cells in V30M treated 
animals when compared with untreated mice (data not shown). Since M2 subsets of 
monocytes/macrophages are necessary for neural repair after injury (Barrette et al., 2008; 
Kigerl et al., 2009), we next analyzed the macrophagic phenotype by western blot. A 
balance between iNOS and Arg-1 production is highly indicative of macrophage 
phenotypes M1 and M2, respectively (Van Ginderachter et al., 2006; Ydens et al., 2012). 
In our study, we found a similar induction of these molecules after injury, regardless of 
Anakinra treatment, indicating a similar M1 and M2 macrophage phenotype pattern in 
both mice groups (Figure 7).  
 
 
 
 
 
 
 
 
 
 
Figure 7 – Treatment with Anakinra did not alter macrophage phenotype. Anti-iNOS and anti-
Arg-1 western blots of injured nerves from Anakinra (n=5) and PBS treated V30M mice (n=5). (-) 
refers to pooled sham nerves (n=5 from each group). Bar graph represents normalized proteins to 
GAPDH. 
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Discussion 
Overwhelming evidence supports a role for neuroinflammation in the pathophysiology of 
several neurodegenerative conditions, such as Alzheimer’s disease, Parkinson’s disease 
and multiple sclerosis. Activation of microglia, vascular changes with infiltration of 
peripheral immune cells into the brain, elevated levels of cytokines and neuronal cell 
death are common deleterious pathways for multiple sclerosis and Parkinson’s disease 
(Van Horssen et al., 2005; Sanchez-Guajardo et al., 2013). In contrast, in Alzheimer’s 
disease, recruitment of monocytes/macrophages from the periphery into the brain would 
probably be beneficial since brain microglia fails at restricting Aβ plaque formation and 
degradation (Rezai-Zadeh et al., 2011). Altogether, these data reinforce the importance of 
new strategies targeting and modulating inflammatory mechanisms in neurodegenerative 
disorders.  
In FAP patients, there is a continuous synthesis of cytokines by peripheral nerve, 
predominantly of IL-1β (Sousa et al., 2001b), starting as early as the asymptomatic stage 
of disease. In line with this, it was recently shown that in a mouse model of senile 
systemic amyloidosis (SSA) the heart presents a robust immune inflammatory 
transcriptional profile before TTR WT start to accumulate in this tissue (Buxbaum et al., 
2012). In accordance with this observation, it has been shown, in a FAP mouse model, 
that the inflammatory milieu might precede and contribute to non-fibrillar TTR deposition in 
the PNS (Gonçalves et al., 2014a). Considering these previous studies on the association 
between inflammation and disease progression, our aim was to evaluate the influence of 
IL-1 signaling in TTR V30M regulation in peripheral nerve, after an inflammatory stimulus. 
The IL-1 family consists of 11 molecules which induce a complex network of pro-
inflammatory cytokines (Garlanda et al., 2013). The most studied agonists are IL-1α and 
IL-1β that bind to the IL-1 receptor type I (IL-1RI) and activate signaling via Myd88 adaptor 
(Burns et al., 1998; Dinarello et al., 2011). When we blocked IL-1RI with Anakinra, the 
recombinant form of the natural and specific receptor antagonist, Myd88 gene expression 
and protein levels in nerve were downregulated, proving treatment efficacy, as previously 
described (Ehses et al., 2009; Gonçalves et al., 2014b). Surprisingly, pre-treatment with 
Anakinra reduced local nerve TTR synthesis induced by sciatic nerve injury in V30M mice. 
TTR is typically described as a negative acute phase protein whose plasma level 
decreases during the acute phase inflammatory response (Gruys et al., 2005). This fact 
was speculated to be secondary to increased protein degradation during inflammation 
(Rosales et al., 1996) or related to lower TTR synthesis by the liver due to decreased 
levels of hepatocyte nuclear factors (Qian et al., 1995). Regarding sciatic nerve, we 
previously showed that TTR production is dependent of the inflammatory threshold 
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(Gonçalves et al., 2014a). Therefore, it is plausible that, depending on the insult and 
threshold of inflammation, the system will regulate TTR expression differently from the 
liver, as it is the case of the present study where inhibition of IL-1 resulted in decreased 
TTR levels in peripheral nerve. TTR V30M should be regulated by the same transcription 
factors known to regulate mouse TTR. No difference was found regarding the most 
important transcription factors known to regulate TTR expression, suggesting the direct or 
indirect modulation by IL-1 of other factors affecting TTR regulation. Creb was found 
downregulated with Anakinra treatment and thus, it is a possible candidate for this 
regulation (Wen et al., 2010). It is also fair to speculate that TTR synthesis by sciatic 
nerve may have a different control mechanism than TTR synthesized by the liver or 
choroid plexus, a topic that will need further investigation. 
As a consequence of axonal lesion, breakdown and clearance of distal fibers, in an active 
self-destruction program, is called Wallerian degeneration (Scheib and Höke, 2013). Early 
after injury, IL-1β is upregulated promoting apoptotic cell death that will contribute to 
neurodegeneration (Rothwell et al., 1997). IL-1β appears to be required for apoptosis in 
several cell types. For example, Mahr et al., (2000) described that IL-1β can trigger cell 
apoptosis by altering the expression of members of the Bcl-2 family (Mahr et al., 2000). 
Increased synthesis and release of IL-1β has also been associated with caspase-3 
induced apoptosis (Nesic et al., 2001). The inhibitory effect of IL-1Ra on cell apoptosis in 
different experimental models has been reported (Nesic et al., 2001; Abbate et al., 2008; 
Rusai et al., 2008; Wu et al., 2011), suggesting that endogenous IL-1 acts at a late stage 
in the pathway of cell death. Importantly, in nerve biopsies from FAP patients, 
simultaneously with the increased expression of IL-1β by the nerve, apoptotic cell death 
becomes evident through activation of caspase-3 (Sousa et al., 2001b). In accordance 
with these observations, in the present study we found that blocking IL-1 before an injury 
stimulus prevented axonal activation of pro-apoptotic molecules, such as Fas death 
receptor, cleaved caspase-3, Bid and cathepsins B/D. Cathepsins are proteases located 
in lysosomes that can be released into the cytoplasm upon cell damage. In this regard, 
oxidative stress, growth factor starvation or Fas receptor activation may all cause 
apoptotic cell death through lysosomal leakage (Brunk and Svensson, 1999). From all 
cathepsins that might be released under lysosomal destabilization, cathepsins B and D 
have been found to play an important role in the regulation of apoptosis (Chwieralski et 
al., 2006). Thus, it is possible that the decreased expression of these enzymes 
contributed to some extent to the diminished nerve injury response in V30M animals 
treated with Anakinra. Taken together, our data suggests that Cathepsins B and D 
decreased expression may prove beneficial in the regulation of apoptosis and in 
prevention of death-inducing signaling platforms. 
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Since it has been previously shown that increased expression of TTR V30M impairs nerve 
regeneration after injury (Gonçalves et al., 2014a), we questioned if in animals treated 
with Anakinra nerve regeneration was ameliorated. We found that V30M mice treated with 
Anakinra not only showed higher nerve fiber densities but also presented increased levels 
of regenerating markers, not related with macrophage infiltration or differentiation stage. 
Treatment with IL-1Ra has been shown to be neuroprotective in hippocampal slice 
cultures after excitotoxic damage (Hailer et al., 2005), in models of focal cerebral ischemia 
(Relton et al., 1996; Loddick et al., 1997; Banwell et al., 2009), in a fluid percussion brain 
injury model (Toulmond and Rothwell, 1995; Lawrence et al., 1998) and on a rat model of 
spinal cord injury (Zong et al., 2012). Thus, to understand if in our model neuroprotection 
was due to direct effects of Anakinra or indirectly, consequent to the downregulation of 
TTR V30M in nerve tissue, we treated WT mice with Anakinra before injury. Our data 
clearly indicate that the increased regeneration after neuronal injury in V30M mice 
receiving Anakinra was due to decreased levels of TTR V30M transcription and deposition 
since treated WT mice showed no difference regarding regenerating markers and, 
importantly, presented lower density of unmyelinated nerve fibers. In naïve mice, IL-1 has 
been associated with early peripheral nerve regeneration; however, the mechanisms by 
which this cytokine mediate regenerating effects remains to be fully elucidated (Nadeau et 
al., 2011). Additionally, the role of IL-1 in axonal growth of WT mice was confirmed by the 
inhibitory action of IL-1Ra on regeneration after axotomy (Guénard et al., 1971). 
Moreover, in contrast with TTR V30M, mouse TTR has an important role regarding 
peripheral nerve regeneration (Fleming et al., 2007). Since Anakinra did not alter mouse 
TTR levels in nerve after injury, the lower fiber density might be explained by decrease 
levels of IL-1 in WT mice. Previous data show that increased TTR V30M deposition in 
nerve after injury, compromise the immune response with lower innate cell infiltration 
(Gonçalves et al., 2014a). In the present work, despite IL-1 signaling inhibition by 
Anakinra, treated V30M mice were able to produce NGF-β and to recruit different immune 
cell subsets, such as neutrophils, pro-inflammatory M1 macrophages and dendritic cells.  
In summary, our results further substantiate the importance of inflammation mediated by 
IL-1 in the regulation of human mutated TTR and, consequently in the pathomechanisms 
activated after nerve injury. Treatment with Anakinra before sciatic nerve injury partially 
rescues the phenotype of FAP mice caused by abnormal TTR V30M synthesis and 
protein deposition in the PNS after an inflammatory stimulus. Despite many recent 
advances, prevention/treatment for FAP or TTR-related amyloidosis is highly complex and 
will most likely require a combination of approaches. We believe that targeting 
neuroinflammation might be one of those approaches and more detailed studies on the 
subject will open new windows of action to improve the neuropathology of these disorders. 
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Abstract 
Transthyretin (TTR) V30M mutation is the most common variant leading to Familial 
Amyloidotic Polyneuropathy (FAP). In this genetic disorder, TTR accumulates 
preferentially in the extracellular matrix (ECM) of peripheral and autonomic nervous 
systems leading to cell death and dysfunction. Thus, knowledge regarding important 
biological systems for TTR clearance might unravel novel insights into FAP 
pathophysiology. Herein, our aim was to evaluate the ability of glial cells from peripheral 
and autonomic nervous systems in TTR uptake and degradation. We assessed the role of 
glial cells in FAP pathogenesis with real-time polymerase chain reaction, 
immunohistochemistry, interference RNA and confocal microscopy. 
Histological examination revealed that Schwann cells and satellite cells, from an FAP 
mouse model, internalize and degrade non-fibrillar TTR. Immunohistochemical studies of 
human nerve biopsies from V30M patients and disease controls showed intracellular TTR 
immunoreactivity in Schwann cells, corroborating animal data. Additionally, we found TTR 
expression in colon of this FAP mouse model, probably being synthesized by satellite 
cells of the myenteric plexus.  
Overall, these findings bring to light the closest relationship between TTR burden and 
clearance from the nervous system extracellular milieu. 
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Introduction 
Familial Amyloidotic Polyneuropathy (FAP) is a rare but fulminant and life-threatening 
neurodegenerative disorder. Approximately ten thousand patients are affected worldwide 
with endemic foci in Portugal, Japan and Sweden (Said et al., 2012). Major 
neuropathological and neurochemical hallmarks of this autosomal dominant hereditary 
disease included extracellular accumulation of mutated transthyretin (TTR) aggregates 
and amyloid fibrils, particularly in autonomic and peripheral nervous systems (ANS and 
PNS, respectively), leading to sensorimotor, motor and autonomic neuropathy (Coimbra 
and Andrade, 1971b).  
Transthyretin is a tetramer of identical subunits of 127 amino acid residues each (Blake et 
al., 1974). It is primarily synthesized by the liver and the choroid plexuses of the brain 
(Soprano et al., 1985; Dikson et al., 1986) and functions as a protein carrier for thyroxine 
and retinol (Kanai et al., 1968; Raz and Goodman, 1969). More than 100 single point TTR 
mutations have been discovered, being the exchange of a methionine for a valine at 
position 30 (V30M) the most common in FAP (Saraiva et al., 1984). TTR is mainly 
produced by the liver as a monomer that assembles into a tetramer and is efficiently 
secreted. This process occurs in most FAP associated mutations, including carriers of the 
V30M mutation (Sekijima et al., 2005). Particular high amyloidogenic mutations, such as 
the L12P associated with leptomeningeal amyloidosis, form intracellular aggregates that 
are transported into liver lysosomes (Batista et al., 2013) and thus these mutants are 
poorly secreted. Contrarily to other TTR amyloidoses, L12P cases present liver TTR 
deposition (Brett et al., 1999).    
The original amyloid cascade hypothesis proposed that circulating TTR dissociation into 
non-native monomers is a determinating step for misfolding. Thus, monomers with low 
conformational stability self-assemble forming non-fibrillar aggregates, protofibrils and 
mature amyloid fibrils (Colon and Kelly, 1992; Quintas et al., 2001) that accumulate in the 
ECM of the gastrointestinal tract, skin, heart, kidney and PNS (Sousa and Saraiva, 2003).  
A particular feature of FAP is organ and tissue tropism for TTR deposition. The 
mechanistic and functional principles that underlie this fact are not fully understood. 
Hence, converging evidence revealed the importance of a dynamic balance between 
formation and clearance of extracellular deposited TTR (Tsuchiya et al., 2008). Cellular 
uptake of soluble TTR by hepatocytes, mouse embryonic fibroblasts, yolk sac cells and 
sensory neurons, was previously demonstrated in vitro (Sousa et al., 2000a; Sousa and 
Saraiva, 2001; Fleming et al., 2009). More recently, intracellular material has been 
observed in fibroblasts and macrophages, through analysis of skin biopsies from FAP 
patients and TTR transgenic mice (Misumi et al., 2013). 
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Since important target tissues of TTR load belong to the ANS and PNS, the aim of the 
present study was to investigate TTR localization in tissues and cells of these systems. To 
perform this work we take advantage of human nerve biopsies and tissues from a well-
established FAP mouse model, carrying the human TTR V30M gene.  
We analyzed TTR expression in the peripheral nerve of the FAP mouse model using 
qPCR analysis and determined the subcellular localization of TTR in satellite cells from 
mice dorsal root ganglia (DRG) and Schwann cells. Schwann cells from patients and 
control subjects were also evaluated, through confocal double immunofluorescence. An 
interference RNA (RNAi) approach was used to study TTR expression/internalization by 
satellite cells from the myenteric plexus.  
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Materials and Methods 
Ethics statement 
All mouse protocols followed the European Union Directive (2010/63/EU) and were 
previously approved by the Institutional and National General Veterinarian Board ethical 
committees. Human tissue biopsy was performed after informed consent and approval 
from the Ethics Committee of the Hospital Geral de Santo António (Porto, Portugal), 
following the declaration of Helsinki. 
 
Human Samples 
Archival sural nerve biopsy samples obtained from FAP V30M patients (n=4) and normal 
disease control subjects (n=4) were previously characterized, after informed consent, for 
TTR and amyloid deposition, with immunohistochemistry and Congo red staining, 
respectively. Samples were kindly provided by the Hospital Geral de Santo António 
(Porto, Portugal). FAP samples analyzed in this study presented TTR amyloid deposition. 
Disease control patients were near-relatives of FAP patients who ultimately turned out not 
to have mutations in TTR. This material was obtained as part of the clinical diagnosis and 
evaluation of polyneuropathy, before the current use of less invasive methods, as 
previously described (Sousa et al., 2001b). 
 
Animals 
Six months transgenic mice for human TTR V30M, in the 129/Sv and endogenous Ttr null 
background, heterozygous for the heat shock factor-1 (Hsf-1), here designated as 
Hsf/V30M (Santos et al., 2010b), were used for the experiments. Although not presenting 
amyloid fibrils in PNS or ANS, non-fibrillar TTR material is widespread in the extracellular 
milieu of these systems at 6 months of age. Additionally, 6 months-old wild-type (WT) and 
TTR knockout (KO) mice (Episkopou et al., 1993), in a 129/Sv background were used as 
controls. Animals were housed in a controlled-temperature room, maintained under a 12 h 
light/dark cycle, with water and food ad libitum and euthanized with a lethal injection of a 
premixed solution containing ketamine (75 mg/kg) and medetomidine (1 mg/kg). 
 
Liver TTR silencing in vivo with RNAi 
For TTR-silencing studies, TTR or control siRNA (vehicle) were formulated into a lipid 
nanoparticle delivery system (Semple et al., 2010). Five months-old Hsf/V30M mice were 
injected in the tail vein with human TTR siRNA (n=6), at a concentration of 1 mg/kg. 
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Untreated age-matched controls received vehicle intravenously (n=6). One injection per 
week was performed during 4 weeks and animals were sacrificed 48 h after the last 
injection. Liver and colon were divided and collected to 10% formalin and frozen at -80ºC.  
 
Messenger RNA (mRNA) isolation, complementary DNA (cDNA) synthesis and real-
time quantitative polymerase chain reaction (qPCR) 
 
Liver and colon mRNA (n=6 per group Hsf/V30M; n=5 WT) was isolated using phenol 
extraction (Invitrogen). Sciatic nerve from Hsf/V30M mice was dissected free from 
surrounding tissue (n=5) and mRNA extraction performed using RNeasy Mini columns 
(Qiagen). cDNA was synthesized with the SuperScript double-stranded cDNA Kit 
(Invitrogen). The quality of extracted RNA was assessed with Experion RNA StdSens 
Analysis Kit (Bio-Rad); qPCR was performed in duplicates using iQ Syber Green Super 
Mix (Bio-Rad) and reactions were run on an Bio-Rad iQ5 software.  
Primer sequences were designed using Beacon Designer 8TM (Premier Biosoft) for human 
TTR, mouse Ttr, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) and 18S. 
Differential expression was determined by the 2^-∆∆CT method. 
 
Immunohistochemistry 
Liver and colon from animals subjected to TTR siRNA treatment and respective controls 
were excised, post-fixed in 10% formalin, embedded in paraffin and cut longitudinally at 3 
µm. Colon from WT and KO mice was used as controls (n=4). Histoclear (National 
Diagnostics) was used to deparaffinate sections that were thereafter hydrated in a 
descent alcohol series. Endogenous peroxidase activity was inhibited with 3% hydrogen 
peroxide in methanol and sections were blocked with 10% fetal bovine serum and 0.5% 
Triton X-100, in PBS. Primary antibodies against human TTR (1:600, rabbit polyclonal, 
DAKO) and mouse TTR (1:1,500, rabbit polyclonal, Q-Biogen) were used. After incubation 
with secondary antibody (anti-rabbit IgG, 1:200, Vector), sections were incubated with 
avidin-biotin-peroxidase complex (ABC Elite, Vector) and visualized using 3.3´-
diaminobenzidine as a chromogen. 
 
Immunofluorescent double labeling  
For double immunofluorescence analyses, sciatic nerve, DRG and colon from Hsf/V30M 
animals were excised and processed as described above. Human sural nerve biopsies 
were also used. Rabbit polyclonal anti-human TTR (1:100, DAKO), sheep polyclonal anti-
human TTR (1:100, Abcam), goat polyclonal anti-Octamer transcription factor 6 (Oct-6, 
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1:25, Santa Cruz Biotechnology), rabbit polyclonal anti-S100 (1:100, DAKO), rabbit 
polyclonal anti-early endosome antigen 1 (EEA1, 1:100, Sigma-Aldrich) and mouse 
monoclonal anti-lysosomal-associated membrane protein 1 (Lamp1, 1:75, Abcam) were 
used as primary antibodies. Secondary antibodies included donkey anti-rabbit Alexa Fluor 
488, donkey anti-goat Alexa Fluor 568, donkey anti-sheep Alexa Fluor 488, goat anti-
rabbit Alexa Fluor 568, goat anti-mouse Alexa Fluor 568 and 488 (1:1,000, Molecular 
Probes). Slides were mounted with Vectashield containing 4’.6-diamino-2-phenylindole 
(DAPI) (Vector) and visualized in a laser scanning Confocal Microscope Leica TCS SP5 II 
(Leica Microsystems).  
TTR-immunopositive Schwann cells in human sural nerve biopsies were detected by 
merged images with anti-TTR antibody and a Schwann cell marker (Oct-6). The number 
of TTR-immunopositive Schwann cells in each group was calculated as an average of 5 
visual fields (447.63 µm x 335.40 µm) per sample (n=4 per group) at an original 
magnification of 20 X, in a Axio Imager Microscope. 
 
Statistical analysis 
Two or three groups’ comparison was performed with Student T-test or One-way ANOVA, 
respectively. For One-way ANOVA, Bonferroni was used as the post-test. Data are 
expressed as mean values ± standard error of the mean (SEM) and p-values of less than 
0.05 were considered to be significant (*p<0.05, **p<0.01 and ***p< 0.001).  
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Results 
 
Non-fibrillar TTR is degraded by Schwann cells of the FAP mouse model Hsf/V30M 
 
Expression of TTR by Schwann cells of sciatic nerve in a mouse model carrying the TTR 
V30M mutation but missing TTR deposition in the PNS and ANS was previously described 
(Murakami et al., 2010). Thus, we questioned whether this feature is recapitulated in an 
FAP mouse model deficient for the Hsf-1 (Hsf/V30M). In this model, non-fibrillar TTR 
deposition is widespread along the gastrointestinal tract since the first month of age. 
Furthermore regarding the nervous system, TTR deposits are found in the ECM of sciatic 
nerve, DRG and parasympathetic ganglia approximately at 6 months of age (Santos et al., 
2010b). For this reason, animals with 6 months-old were chosen for subsequent analyses.  
Using qPCR, TTR expression by the sciatic nerve of Hsf/V30M mice was found (61.7 units 
ratio of TTR mRNA and Gapdh mRNA ± 16.2 SEM). With double immunofluorescence 
between TTR and Oct-6, a Schwann cell marker, TTR intracellular staining in these cells 
was noticed (Figure 1A, arrows), suggesting them as the primary source of TTR in nerve, 
in accordance with previous results from other FAP mouse models (Murakami et al., 2010; 
Gonçalves et al., 2014a).  
To localize TTR within Schwann cells, additional studies were performed using double 
immunofluorescence between TTR and a marker for the early endosome antigen 1 
(EEA1). Looking for cells previously stained with Oct-6, consecutive cross-sectional 
images revealed that indeed Schwann cells presented intracellular punctuate material, 
visible in higher magnification, that colocalize with EEA1 (Figure 1B, arrows). Further 
labeling with TTR and Lamp1 demonstrated colocalization of TTR V30M with lysosomes 
(Figure 1C), indicating that Schwann cells, might also be important for TTR clearance. 
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Figure 1 – Schwann cells express and internalize TTR in the Hsf/V30M FAP mouse model. A) 
Representative picture of double immunofluorescence between TTR (green) and Oct-6 (red) in 
Hsf/V30M nerves, demonstrating TTR intracellular staining in Schwann cells (arrows). 
Superposition of the labels, with DAPI (blue), is shown (merge, n=4). Scale bar 10 μm. B) Double 
immunofluorescence of TTR (green) and EEA1 (red) demonstrating colocalization between the 2 
proteins in Schwann cells of Hsf/V30M mice (arrows). Scale bar 5 μm. C) Confocal representative 
image of a sciatic nerve section stained with anti-TTR antibody (green) and a lysosome marker 
(Lamp1; red). Colocalization between both markers was noticed in yellow; scale bar 5 μm. 
 
Non-fibrillar TTR is internalized by glial cells of sensory ganglia 
Data reported so far indicate that Schwann cells, besides being a source of TTR might 
also be important for TTR clearance in the sciatic nerve. We next investigated TTR 
immunoreactive glial cells from DRG of Hsf/V30M mice. In fact, with double 
immunofluorescence between TTR and S100, TTR intracellular staining was found in glial 
cells of DRG (possibly satellite cells; Figure 2A). Since it was previously shown that TTR 
is not synthesized by cells of DRG (Sousa and Saraiva, 2008) and in this work we found 
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colocalization of TTR with EEA1 (Figure 2B), we hypothesized that satellite cells have an 
active role in TTR internalization. Moreover, we found TTR signal partially colocalized with 
lysosomes (Figure 2C); therefore we can conclude that these cells participate in TTR 
clearance in this animal model.  
 
 
 
Figure 2 – Glial cells from DRG internalize TTR, in a mouse model of FAP. A) Double 
immunofluorescence of TTR (green) and S100 (red), a marker for glial cells, in DRG of Hsf/V30M 
mice, showing TTR localized inside satellite cells. Scale bar 20 μm; higher magnification 5 μm. B) 
TTR colocalizing with EEA1 in satellite cells from DRG of Hsf/V30M animals. Scale bar 20 μm; 
higher magnification 5 μm. C) Representative confocal image demonstrating colocalization 
between TTR (green) and lysosomes (Lamp1; red) in satellite cells from DRG (arrows). Scale bar 8 
μm. 
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Intracellular TTR in human Schwann cells  
Following the previous results with the FAP mouse model, we wondered if intracellular 
TTR could also be observed in nerves from FAP patients. To address this issue, we also 
used sural nerve biopsies from normal individuals (disease free) as controls. In disease 
control individuals, the majority of Schwann cells were negative for TTR WT intracellular 
staining; surprisingly, few positive cells presented TTR WT immunoreactive punctuate 
material (Figure 3A, top panel, and 3B), suggesting that Schwann cells might have an 
important role for uptake and degradation of TTR WT reaching the nerve though the blood 
stream. In FAP carriers, some Schwann cells had generalized TTR V30M intracellular 
staining (Figure 3A, bottom panel, and 3B) and the percentage of TTR positive cells was 
significantly higher than for disease control patients (Figure 3C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 – Intracellular TTR in Schwann cells of human nerve biopsies. A) Representative 
images from double immunofluorescence between TTR (green) and Oct-6 (red) in sural nerve 
biopsies from disease control individuals and FAP patients, demonstrating TTR intracellular 
staining in Schwann cells. Superposition of the labels, with DAPI (blue), is shown (merge, n=4). 
Scale bar 4 μm. B) Low magnification images from longitudinal sections of human sural nerves 
showing colocalization between TTR and Oct-6 (arrows); scale bar 40 μm. Chart represents 
quantification of TTR positive Schwann cells, related to total Oct-6 positive Schwann cells in nerve 
sections. *p<0.05.  
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TTR colocalization with EEA1 was observed in both cases (Figure 4A, arrows), 
corroborating the notion that punctuate intracellular material arise from TTR internalization 
and probably not from cell synthesis. Colocalization between TTR and lysosomes was 
scarce (Figure 4B, arrow), most likely related to sample storage and processing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – TTR is internalized by human Schwann cells. A) Double immunofluorescence of 
TTR (green) and EEA1 (red) showing colocalization spots between the 2 proteins in Schwann cells 
of FAP patients and normal control individuals (arrows). Scale bar 4 μm. B) Confocal 
representative image showing scarce colocalization between TTR (green) and lysosomes (red). 
Scale bar 3 μm. 
 
 
Intracellular TTR in satellite cells from the myenteric plexus  
In FAP disease, ANS is severely affected by TTR deposition ultimately leading to bladder 
dysfunction, diarrhea, malabsorption and motility disturbances (Sousa and Saraiva, 2003). 
Thus, we questioned whether satellite cells from the myenteric plexus may also be able to 
internalize TTR in FAP. By histological analysis of Hsf/V30M mice colon, non-fibrillar TTR 
immunostaining was found in Auerbach plexus (myenteric plexus) especially inside 
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smaller cells surrounding the nerve cell bodies (compatible with satellite cells), in contrast 
with WT and TTR KO animals that were negative for TTR (Figure 5A). Following these 
results, we performed double immunofluorescence between TTR and S100 in colon 
sections of Hsf/V30M animals. Colocalization between the two proteins was observed 
(Figure 5B). Since the TTR staining present in these cells partially colocalized with EEA1 
(Figure 5C, arrows) and Lamp1 (Figure 5D, arrows), it is reasonable to suggest that 
satellite cells have an important role in non-fibrillar TTR uptake and internalization. 
However, we could not discard the possibility of TTR synthesis by these cells of the 
myenteric plexus, especially when TTR production in colon was already previously 
suggested (Loughna et al., 1995).  
To address this question we treated 5 months-old Hsf/V30M mice with TTR siRNA, to 
inhibit TTR deposition in the gastrointestinal tract. With this treatment we were able to 
silence 92% TTR expression by the liver (Figure 6A and B), avoiding TTR circulation in 
plasma and burden in tissues, as previously described (Alvarez et al., 2010). 
Nevertheless, TTR immunostaining in satellite cells from myenteric plexus was equally 
observed in animals treated with TTR siRNA or controls (vehicle treated mice) (Figure 
6C). By qPCR we found TTR expression in colon of Hsf/V30M mice, with similar levels of 
relative expression between siRNA and vehicle treated mice (Figure 6D). Additionally, 
mouse Ttr expression in colon from WT mice was considerably lower than in Hsf/V30M 
mice (Figure 6D). This, together with the fact that no TTR reactivity was found in satellite 
cells from myenteric plexus in WT mice, suggests that FAP colonic myenteric plexus 
might be able to synthesize and clear TTR. 
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Figure 5 – TTR is internalized by satellite cells from the myenteric plexus. A) TTR 
immunohistochemical staining on colon myenteric plexus from WT, TTR KO and Hsf/V30M 
animals. Scale bar 20 µm. B) Double immunofluorescence between TTR (green) and S100 (red), a 
satellite cell marker, showing TTR inside these cells. Scale bar 14 μm; higher magnification 5 μm. 
C) Representative confocal image of myenteric plexus section showing a satellite cell with 
intracellular TTR staining (green) colocalizing with EEA1 (red) (arrows). Scale bar 4 μm. D) 
Confocal microscopy image with anti-TTR antibody (green) and lysosome marker (Lamp1; red). 
Nuclei stained blue with DAPI. Arrows indicate colocalization of TTR with lysosomes. Scale bar 5 
μm. 
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Figure 6 – TTR is expressed by colon of the Hsf/V30M FAP mouse model. A) 
Photomicrographs illustrating TTR staining in liver of Hsf/V30M mice, treated with TTR siRNA or 
vehicle; scale bar 50 µm. B) Histogram represents TTR mRNA levels in liver of Hsf/V30M mice 
treated with TTR siRNA as compared with control animals receiving only vehicle. Data was 
normalized using 18S as the housekeeping gene (***p<0.001). C) Histological images of colonic 
myenteric plexus from Hsf/V30M mice treated with TTR siRNA as compared with vehicle treated 
animals. Scale bar 20 µm. D) Histogram denoting TTR mRNA expression in colon from Hsf/V30M 
mice treated with vehicle or siRNA and Ttr mRNA from WT animals. Data was normalized using 
18S as the housekeeping gene (**p<0.01). 
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Discussion 
FAP is a peculiar form of neuropathy with clinical symptoms generally occurring in the 
second or third decade of life. However, a late-onset form of disease has also been 
described, affecting individuals over 50 years of age and characterized by low penetrance 
rate and different pathological presentations (Koike et al., 2004). Sensory impairment, 
wasting and weakness results from neuronal and axonal loss consequent to 
obliteration/dysfunction of small vessels supplying the nerve tissue, nerve fiber 
compression by TTR deposits or toxic effects of amyloid precursors (Koike et al., 2004; 
Sousa et al., 2001a). Additionally, motor sensory type is often found in FAP, characterized 
by muscle atrophy with distal predominance and decreased motor conduction velocity 
(Yoshioka et al., 2001).  
In peripheral nerve, TTR deposits are predominantly found in the endoneurium, in close 
contact with Schwann cells and collagen fibrils (Coimbra and Andrade, 1971b). Thus, an 
impairment of axon-Schwann cell interaction due to cell dysfunction might contribute to 
axonopathy. Similarly, in nervous ganglia, TTR deposition occurs in the stroma in close 
association to satellite cells (Hofer and Anderson, 1975; Sobue et al., 1990). Satellite cells 
covering sensory neurons are similar to Schwann cells of the peripheral nerve as they are 
both derived from the neural crest of the embryo during development (Hall and Landis, 
1992). They are known as glial supporting cells of the nervous system and have important 
roles on mechanical support to neurons, nutrients/oxygen supply and removal of cell 
debris (Hanani, 2005). TTR expression by glial cells of sensory neurons was previously 
suggested (Murakami et al., 2008). However, this hypothesis was later disputed and the 
results were attributed to TTR contamination by the meninges (Sousa and Saraiva, 2008). 
Glial cells regulate neuron microenvironment and appear to be actively engaged in the 
control of ECM composition (Hanani, 2005). Thus, several studies indicate the ability of 
these cells in the uptake of different substances (Schlaepfer, 1969; Kumamoto et al., 
1986; Paresce et al., 1996; Pannese and Procacci, 2002). Since TTR non-fibrillar deposits 
are found in the ECM in close association with glial cells, we decided to investigate 
whether these cells in sensory neurons and peripheral nerve might be important for TTR 
uptake in vivo. In fact we found immunoreactive TTR in satellite and Schwann cells, both 
in the Hsf/V30M transgenic model and in tissues from FAP patients. Occasionally, the 
observed intracellular TTR presented a punctate-like pattern, compatible with its presence 
within vesicles. Once in the cell, endocytic vesicles are rapidly targeted to the early 
endosomes. Thus, despite the existence of numerous internalization routes, early 
endosomes are a focal point of the endocytic pathway (Jovic et al., 2010). EEA1 is a 
widely used marker for early endosomes due to its colocalization with the transferrin 
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receptor (Mu et al., 1995). In this work, TTR colocalization with EEA1 and a lysosome 
marker (Lamp1) in glial cells of peripheral nerve and sensory ganglia indicate 
internalization and consequent vesicular transport of TTR through early endosomes for 
degradation.  
In Alzheimer disease, Aβ internalization by glia has been observed in vitro and in vivo 
(Paresce et al., 1996; Wyss-Coray et al., 2003) suggesting an important role for these 
cells in Alzheimer pathology. Nevertheless, exposure of glial cells to Aβ aggregates could 
have detrimental consequences with upregulation of inflammatory mediators and nitric 
oxide, resulting in glia and neuron cell death (Mohamed and Posse de Chaves, 2011). 
Another striking feature of FAP is severe autonomic nervous dysfunction, affecting 
particularly the gastrointestinal tract (Sousa and Saraiva, 2003; Koike et al., 2004). Initial 
gastrointestinal symptoms are severe constipation alternating with periods of diarrhea, 
nausea and vomiting (Suhr et al., 1992). Evidence suggests that environmental and 
genetic factors have impact on the clinical pattern of FAP (Ando et al., 2000). For 
instance, in Japanese FAP patients no significant destruction of the enteric nervous 
system is observed (Anan et al., 2001) while Portuguese FAP patients present infiltration 
of amyloid material in the space between two adjacent ganglia, accompanied by different 
degrees of neuronal loss (Guimarães et al., 1980). However, the mechanisms leading to 
neuron cell death remain poorly understood. Some factors that have been associated with 
the pathogenesis of gastrointestinal dysfunction are a depletion of neuroendocrine cells, 
such as serotonin, somatostatin or PYY immunoreactive cells (Anan et al., 1999), 
accumulation of advanced glycation end products (Matsunaga et al., 2002), loss of 
interstitial cells of Cajal (Wixner et al., 2013) and amyloid deposition in sympathetic 
ganglia (Koike et al., 2011). Although amyloid deposits have not been found in the 
myenteric plexus of Hsf/V30M FAP mouse model, this was the first animal model 
presenting non-fibrillar TTR deposition in the ANS of the gastrointestinal tract (Santos et 
al., 2010b). Therefore, we next investigated whether satellite cells were able to internalize 
TTR, also in this system. TTR colocalization with EEA1 and lysosomes indicated that 
endocytic trafficking pathways are activated in satellite cells from the myenteric plexus of 
Hsf/V30M mice. Importantly, this is the first study showing TTR synthesis by the enteric 
tissue, in this FAP mouse model. Therefore, it is reasonable to suggest that satellite cells 
may also be synthesizing mutated TTR which in turn might contribute for the non-fibrillar 
TTR deposition. It would be interesting to confirm these results in biopsy colon specimens 
from FAP patients; however, such specimens are very difficult to obtain since the 
conditions of these patients not often calls for colonoscopy.  
Overall, the present study brings to light new insights into the FAP pathophysiology. 
Besides TTR endocytosis by fibroblasts demonstrated both in vitro and in vivo (Misumi et 
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al., 2013), TTR internalization in vivo by glial cells of peripheral nerve, sensory ganglia 
and myenteric plexus was here demonstrated. However, whether TTR uptake by these 
cells is neuroprotective or neurotoxic leading to glial and neuronal cell death with 
autonomic dysfunction needs further investigation. Furthermore, additional studies are 
needed to clarify the molecular mechanisms and signaling platforms involved in these 
particular systems. 
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Conclusions and future perspectives 
FAP is a severe condition characterized by a loss of sensitive, motor and autonomic 
functions, culminating with lifetime medical care, since the only available therapy halting 
the disease progression is liver transplantation. Thus, development of novel effective 
therapies ameliorating the patient quality of life are still needed. For that purpose, basic 
knowledge regarding disease pathophysiological mechanisms is awaited.  
TTR fibril formation and amyloid deposition is a dynamic process influenced by other 
factors, such as proteoglycans or glycosaminoglycans (GAGs) (Noborn et al., 2011). In 
this regard, we found colocalization of heparan sulfate proteoglycans with TTR in amyloid 
laden nerves from FAP patients. Additionally, to confirm the role of heparan sulfate in FAP 
nerve-specific deposition, in chapter I we proposed a novel nanoparticle delivery system 
targeting the sciatic nerve tissue. This innovative combinatorial approach using 
heparin/CH nanotherapeutics allowed for a sustained release of heparin throughout the 
ECM, without a markedly inflammatory reaction. By immunohistochemistry, levels of TTR 
deposition were markedly increased in sciatic nerves receiving the heparin/CH 
nanoparticles thereby suggesting a positive role for this GAG in TTR pathogenesis. In the 
future, these observations should be taken into consideration for the establishment of new 
animal models or for the development of novel therapeutical strategies. 
Neurodegeneration in FAP has so far been suggested to partially relate to binding of TTR 
aggregates to RAGE with activation of inflammatory cascades, apoptosis and oxidative 
stress. However, one should not exclude the possibility that an inflammatory stimulus 
might also trigger TTR deposition in the PNS, leading to a positive feedback loop. In 
chapter II, we evaluated the effect of neuroinflammation and stress on TTR deposition 
after sciatic nerve ligation. Seven days following injury, non-fibrillar TTR was widespread 
in the PNS of an FAP mouse model initially depicting TTR deposition only in the 
gastrointestinal tract and skin. This observation could be attributed to the lower pH and 
increased levels of heparan sulfate after injury (Figure 1); however, in depth studies are 
needed in the future to clarify this issue. Importantly, we also found that TTR expression in 
Schwann cells is regulated by an inflammatory threshold. A striking feature of FAP is the 
lack of an immune infiltrate despite the production of pro-inflammatory cytokines by axons. 
Accordingly, in our injury model, FAP mice presented lower frequency of neutrophils and 
macrophages as well as less production of Tnf-α, Il-1β, Tlr-1 and chemokines, as 
compared with WT animals (Figure 1). A previous study shows that Schwann cells from 
FAP patients are impaired on their ability to produce neurotrophins in a context of 
neuronal stress (Sousa et al., 2001b). The lack of trophic factors, immune cells and 
regenerating molecules might be relevant for neuronal dysfunction, poor functional 
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recovery and lower regenerative abilities observed in the injured FAP transgenic mice. 
Moreover, nerve deposition of toxic TTR aggregates in uninjured conditions most probably 
impairs Schwann cells and their role in regeneration after toxic events, leading to 
disruption in the crosstalk between Schwann cells and axons. Therefore, it would be 
interesting to address at transcriptional and translational levels whether a naïve situation 
recapitulates in some features the injury condition. In this regard, Schwann cells from 
naïve sciatic nerves of FAP transgenic mice, and corresponding controls, might be sorted 
for future microarray analysis, particularly for the search of regenerating and survival-
related genes. Thereafter, studies with primary Schwann cells, stimulated with different 
intermediate TTR species, might give novel insights into new molecular pathways 
underlying FAP pathology or provide information about drugs able to rescue cell 
impairment.  
Based on results from chapter II demonstrating the importance of inflammation in the 
progress of FAP, in chapter III we explored an anti-inflammatory approach to this disorder 
in a mouse model of disease. IL-1 is a major pro-inflammatory cytokine involved in the 
pathogenesis of different neurodegenerative conditions, such as Alzheimer’s disease, 
multiple sclerosis or FAP. Several studies have shown that blocking the IL-1 signaling 
pathway with Anakinra prevents activation of pro-apoptotic molecules or increase pro-
survival signaling transduction pathways, culminating in neuroprotection. Thus, we 
performed daily treatment in early-stage pathology with Anakinra, in the FAP mouse 
model heterozygous for the Hsf-1. Nerve TTR deposition was found significantly 
decreased in treated animals as well as secondary associated neurotoxic cascades, such 
as NF-κB activation, apoptosis, heat-shock response, ER and nitrosative stress, 
highlighting the importance of IL-1 signaling in the pathogenesis of FAP. 
If IL-1 influenced TTR deposition in the PNS of naïve FAP transgenic mice, in chapter IV 
we questioned whether blocking this cytokine could also inhibit TTR expression after 
nerve injury, rescuing the observed phenotype. By treating FAP animals with Anakinra, 48 
h before sciatic nerve ligation, we were able to prevent TTR deposition and decrease TTR 
nerve expression after damage (Figure 1). In addition, apoptotic cascades were 
diminished accompanied by an improved regenerative response. Furthermore, our data 
suggest that CREB is probably associated with TTR expression/deposition and highlight 
new possible disease biomarker molecules, such as cathepsins B/D, synapsin and 
persephin. After treatment with Anakinra, no differences were found regarding immune 
cell infiltration, so future studies should address how to improve chemotaxis 
pharmacologically. These will probably encompass the development of more suitable 
animals models, with amyloid deposits in peripheral nerves, closely resembling human 
pathology. Application of heparan sulfate proteoglycans into the sciatic nerve of an FAP 
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mouse model failed in triggering fibrillar deposition, possibly due to different ECM 
environments between mouse and human patients. Therefore, future studies in transgenic 
mice should address the modulation of ECM remodeling in FAP nerves through 
stimulation with different types of proteoglycans. In this regard, comparative analyses of 
human and rodent nerve proteoglycan composition should be addressed. 
Schwann cells are the immunocompetent cells of the PNS. After peripheral nerve injury, 
Schwann cells dedifferentiate and are able to phagocyte myelin debris for regeneration to 
occur. TTR aggregates deposition lead to activation of pro-inflammatory cytokines in 
nerves from FAP patients thus possibly functioning as an injury stimulus. TTR expression 
by Schwann cells was previously suggested (Murakami et al., 2010) and corroborated in 
our FAP mouse models; we questioned whether these cells might also be able to 
internalize TTR. In chapter V of the present work, we show in vivo colocalization between 
TTR/EEA1 and TTR/Lamp-1 in nerve Schwann cells and glial cells from DRG, indicating 
protein internalization and degradation. These results prompt us to proceed and analyse 
Schwann cells from human patients. Surprisingly, TTR punctuate material was found, also 
in Schwann cells from disease control individuals, suggesting that these cells might be 
important for the clearance of TTR reaching the nerve through the blood-stream. ANS is 
also a target for TTR deposition, particularly at the myenteric plexus. Using confocal 
microscopy we show that satellite cells from the myenteric plexus internalize and deliver 
TTR to lysosomes for degradation. Additionally, using RNAi, TTR expression by colon 
was observed and attributed to satellite cells since these were the only TTR positive cells 
after treatment with TTR siRNA. The study of TTR internalization is of outmost importance 
since an imbalance of this system might trigger or accelerate TTR aggregates deposition 
in target tissues. These novel data regarding the physiopathology of FAP might open new 
windows of action in the design of new therapeutics to modulate TTR clearance from 
ECM. However, there are some questions that are certainly worth studying, namely: 1) 
TTR uptake by these cells is neuroprotective or neurotoxic ending in glial and neuronal 
cell death? 2) What are the molecular mechanisms and signaling platforms involved in 
these particular systems? 3) Is internalized TTR recycled to cell surface? Answering these 
questions could help to further understand the intracellular TTR processing steps and the 
mechanisms that participate in TTR internalization, or in the identification of putative 
receptors for TTR binding, in addition to megalin and RAGE. 
In summary, this project reinforces the importance of inflammation on TTR amyloidosis 
and further demonstrates the key role of IL-1 in the pathogenesis of FAP. Overall, we 
propose to counteract toxicity in this neurodegenerative disorder by modulating 
inflammation, ECM remodeling and cellular uptake of TTR, possible through combinatorial 
approaches, paving the way for future clinical trials.  
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Figure 1 – Schematic representation of crosstalk events studied in this thesis. Nerve injury 
triggered local TTR expression and non-fibrillar deposition, possibly due to low pH or ECM 
remodeling, characterized by increased levels of heparan sulfate GAGs. Schwann cells are able to 
express and internalize TTR species and are impaired in their normal functions, with compromised 
production of growth factors, pro-inflammatory cytokines and chemokines, ultimately affecting 
nerve regeneration. In fact, despite disruption of the blood-nerve barrier with entrance of systemic 
TTR into nerve tissue, lower frequency of macrophages and neutrophils was found in injured 
nerves from FAP transgenic mice, contributing for the lower production of pro-inflammatory 
cytokines and factors driven regeneration. Blocking IL-1 with Anakinra partially rescue this 
phenotype and prevents TTR non-fibrillar deposition as well as neurotoxic cascades. 
With ageing, a similar scenario in naïve FAP mice might occur with toxic TTR aggregates leading 
to impairment of Schwann cells and threshold of pro or anti-inflammatory intermediaries. 
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Table 1 – Primer sequences used for qPCR. 
